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iABSTRACT
PI3K has been described as a key regulator of signalling cascades in T and B 
lymphocytes. Particularly, PI3K has been proposed as an essential component of the 
CD28 mediated costimulatory signal which, in the presence of antigen specific 
signals delivered by the TCR, drives IL-2 production, T cell proliferation and 
survival. However, as PI3K deficient mice display impaired B cell responses with 
no T cell signalling defects, some reports have questioned the significance of PI3K in 
CD28 mediated T cell activation.
This study presents novel data which further examines the relationship between PI3K 
and CD28: A further level of PI3K regulation is mediated by CD28 via the 
differential recruitment of pi 106 and pi 10p PI3K catalytic subunits. CD28 activates 
the unique serine kinase capacity of pi 105 that results in the down regulation of 
pi 108 lipid kinase activity. Furthermore the CD28 mediated tyrosine 
phosphorylation of SHIP, which catalyses the degradation of PI(3,4,5)P3, is 
described. Evidence is presented which demonstrates that basally high levels of 3’- 
phosphoinositides exist in the Jurkat T cell line that are not subject to regulation by 
lipid phosphatases. Evidence presented here may explain previous data that disputed 
the role of CD28 mediated PI3K activation in Jurkats.
This study has also investigated the mechanisms by which PI3K is regulated in B 
cells: In addition to the enzymatic activity of SHIP, PI3K activity in B cells may be 
negatively regulated via sequestration of p85 by the adaptor protein Gab2. In 
addition this study presents the first report of a potential role for SHP2 in coupling 
the BCR to MAPK activation, and indicates that the SHP2 PTPase mediated release 
of SHP2 from the Gab2/PI3K complex may play a role in inhibitory signalling. The 
examination of Gab2 and SHP2’s relationship to PI3K in CD28 stimulated T cells 
would be of future interest.
ACKNOWLEDGEMENTS
I would, firstly like to acknowledge the Medical Research Council for funding this 
study. Secondly, I must acknowledge my supervisor Stephen Ward, for giving me the 
opportunity to undertake this research, and for directing my work during the last three 
years. Other Wardoids past and present should also be spoken of here: Yannis, it was an 
interesting pleasure, and Richard, thanks for the POR principal (Don’t check the 
abbreviations section, its not there!). The current Wardists should not go unmentioned, 
Marisa, Budgie, and Gill (and ex- Wardist Jane, wherever you are) and honorary 
members (Helen), cheers for the laughs and organised coffee breaks, its been 
emotional!
I would also like to thank the Welham group for their help, advice and reagents, and the 
labs of Bart Vanhaesebroeck, Carl June, Chris Rudd, and Mark Coggeshall, for 
antibodies and cell lines.
On a more personal note I especially want to say thankyou to Mr and Mrs Raven, and of 
course their more senior offspring Maria: I am grateful for the support you have always 
given me, and for your humour which is a continual source of inspiration! Also, and 
probably unconventionally, I would like to thank my in-laws who have ‘been there’ on 
countless occasions for Nick and I, and have made me feel welcome in their family. 
Other people who have made me laugh in the past three years (!) should also have their 
input to this thesis acknowledged, Andy-Fat man trapped in a thin mans body-Collin, 
and the Bentley’s especially!!
Finally, but most importantly, I thank my husband Nick (what about me?!!), whom I 
would never have met had I not ‘done’ this PhD. I can’t express enough appreciation for 
you being in my life, you’re my best friend and I love you. For better for worse, team 
Edmunds!!!!!
TABLE OF CONTENTS
TABLE OF CONTENTS PAGE
1 INTRODUCTION 1
1.1 PHOSPHATIDYLINOSITOL 3’-KINASE 1




1.1.2 MEASUREMENT OF PI3K ACTIVITY 4
1.1.3 REGULATION OF CLASS 1A PI3KS 4





1.2 PI3K EFFECTORS 9
1.2.1 CLASSIFICATION OF PH DOMAINS 9
1.2.2 THE PI3K/TEC FAMILY KINASE PATHWAY 11
1.2.3 THE PI3K/PKB PATHWAY 11
1.2.4 PH CONTAINING ADAPTOR PROTEINS 13
p62 DOK-1 13
GAB FAMILY ADAPTOR PROTEINS 13
1.3 T AND B LYMPHOCYTES 15
1.3.1 THE IMMUNE SYSTEM 15
1.3.2 T LYMPHOCYTES 16
1.3.3 BLYMPHOCYTES
1.4 T LYMPHOCYTE ACTIVATION 16
1.4.1 THE 2 SIGNAL MODEL 16
1.5 TCR/CD3 AND THE ANTIGEN DEPENDENT SIGNAL 17
1.5.1 TCR/CD3 STRUCTURE 17
1.5.2 TCR ACTIVATED PTKS 18
1.5.3 TCR MEDIATED EFFECTOR PATHWAYS 19
REGULATION OF RAS 19
TCR ACTIVATION OF PI3K AND ITS EFFECTORS
TABLE OF CONTENTS 
19




1.6.4 ' B7 F a m ily  l i g a n d s  ‘ • *• ' '  22
1.7 THE COSTIMULATORY SIGNAL 23
1.7.1 THE CD28 SIGNAL-IMMEDIATE UPSTREAM EVENTS 23
1.7.2 CD28 MEDIATED ACTIVATIONOF PI3K AND ITS EFFECTORS 24
CD28/PI3K7TEC KINASE ACTIVATION 25
CD28 / PI3K / PKB PATHWAY 26
CD28/PI3K/VAVGTP EXCHANGE ACTIVITY 26
CD28 / PI3K / CYTOSKELETON AND SMACS 28
1.7.3 TRANSCRIPTIONAL REGULATIONOF I.L-2 BY CD28 28
THE CD28 RESPONSE ELEMENT 28
CD28 AND NFKB 29
1.8 THE T CELL INHIBITORY SIGNAL - CTLA4 30
1.8.1 CTLA4 DEFICIENT MICE 30
1.8.2 IMMUNOTHERAPEUTIC STRATEGIES 31
1.9 B LYMPHOCYTE ACTIVATION 31
1.9.1 BCR STRUCTURE 31
1.9.2 CD 19 32
1.9.3 BCR LIGATION VERSUS BCR/CD 19 COSTIMULATION 33
1.10 BCR EFFECTOR PATHWAYS 33
1.10.1 BCR MEDIATED MAP KINASE ACTIVATION 33
1.10.2 BCR MEDIATED ACTIVATION OF PI3K EFFECTORS 34
BCR / PI3K / BTK ACTIVATION 35
BCR /PI3K / PKB PATHWAY 36
1.11 FCyRIIB MEDIATED INHIBITION OF B LYMPHOCYTE ACTIVATION 37
1.11.1 STRUCTURE / FUNCTION OF THE FCyRIIB ITIM 37





1.12 FCyRIIB INDUCED NEGATIVE REGULATION OF PI3K ACTIVITY 39
1.12.1 FCyRIIB AND SHIP MEDIATED INHIBITION OF PIP3 ACCUMULATION 39
1.12.2 FCyRIIB MODULATION OF BCR / PI3K / PKB PATHWAYS 41
1.12.3 FCyRIIB MODULATION OF PI3K / BTK AND PLCy 41
1.13 FCyRIIB INHIBITION OF MAPK CASCADE 42
1.13.1 FCyRIIB / SHIP / SHC 42
1.13.2 FCyRIIB / P62 DOK / RAS GAP 42
1.14 AIMS AND OBJECTIVES 43
2 MATERIALS AND METHODS 45
2.1 MATERIALS 45
2.1.1 PLASMIDS AND PROTEINS 45
2.1.2 ANTIBODIES 46
2.1.3 GENERAL REAGENTS 48
2.1.4 GENERAL SOLUTIONS 51
2.2 METHODS 54
2.2.1 MOLECULAR BIOLOGY 54
2.2.2 CELL CULTURE 56
JURKAT T CELL LYMPHOMA J6 56
DC27.1 CTLA4+HYBRIDOMA 57
DC27.1 CD28+ HYBRIDOMA 57
B 7.1+CHO CELLS 57
A20 B CELL LYMPHOMA 58
ANALYSIS OF SURFACE ANTIGENS 58
INTRACELLULAR FACS STAINING 58
FREEZING AND THAWING CELLS 59
2.2.3 CELL STIMULATIONS 60
PREPARATION OF CELLS 60
T CELL STIMULATIONS 60
A20 CELL STIMULATIONS 61
PREPARATIONOF WHOLE CELL EXTRACTS 61
MEMBRANE CYTOSOL FRACTIONATION 61
IMMUNOPRECIPITATION FROM WHOLE CELL EXTRACTS 62
ACETONE PRECIPITATION OF PROTEINS 62
GST-FUSION PROTEIN PRECIPITATES 62




FAR WESTERN BLOTTING 64
STRIPPING AND REPROBING 64
2.2.5 IN VITRO LIPID KINASE ASSAY 65
2.2.6 IN VITRO PROTEIN KINASE ASSAY 65
2.2.7 IMMUNOFLUORESCENCE STAINING • > » 66
2.2.8 CELL TRANSFECTION ‘ 66
2.2.9 CONFOCAL VISUALISATION OF GFP TAGGED PROTEINS 67
2.2.10 INOSITOL (POLY)PHOSPHATE 5 PHOSPHATASE ASSAY 67
2.2.11 MEASUREMENT OF D3 PHOSPHOINOSITIDE LIPIDS 68
2.2.12 LYMPHOCYTE PREPARATION AND PURIFICATION 69
2.2.13 PROLIFERATION ASSAY 70
2.2.14 MEASUREMENT OF INTRACELLULAR [Ca2+] 71
CALIBRATION OF THE FLUORIMETER 71
LOADING CELLS WITH FURA-2/AM 72
[Ca2+]I MEASUREMENT 72
3 RESULTS AND DISCUSSION 73
3.1 RESULTS - CD28 AND PI3K 73
DEMONSTRATION OF THE RAPID ACCUMULATION OF PI(3,4,5)P3 IN 
RESPONSE TO B7.1 LIGATION OF CD28 73
DETECTION OF PI3K REGULATORY AND CATALYTIC SUBUNITS IN 
JURKAT T CELLS 73
DETECTION OF pi 106 EXPRESSION IN CULTURED T LYMPHOBLASTS 
AND FRESHLY ISOLATED T LYMPHOCYTES. 75
COASSOCIATION OF p 110 ISOFORMS WITH CD28. 75
DETECTION OF PHOSPHO SERINE pi 106 IN CD28 IMMUNO-PRECIPITATES 78 
DETECTION OF PHOSPHO-pl 105 IN pi 105IMMUNOPRECIPITATES IN 
RESPONSE TO B7.1 STIMULATION. 81
IN VITRO LIPID KINASE ACTIVITY OF CD28 ASSOCIATED pi 10 ISOFORMS. 81
EFFECTS OF OKADAIC ACID AND WORTMANNIN TREATMENT ON pi 105 
PHOSPHORYLATION IN VITRO 84
SUMMARY 86
3.1 DISCUSSION- CD28 AND PI3K 88
CD28 MEDIATED PI(3,4,5)/>3 ACCUMULATION 88
p 1105 - PROTEIN KINASE ACTIVITY 89
p 1105 - LIPID KINASE ACTIVITY 90
CONCLUSIONS 94
TABLE OF CONTENTS vii
3.2 RESULTS - SHIP 96
3.2.1 SHIP AND CD28 96
CD28 SPECIFICALLY MEDIATES TYROSINE PHOSPHORYLATION OF SHIP. 96 
CO-STIMULATORY SIGNALS FURTHER ENHANCE PHOSPHORYLATION 
OF SHIP 98
TYROSINE PHOPSHORYLATION AND ACTIVATION OF SHIP CORRELATE 
WITH SUB-CELLULAR RE-DISTRIBUTION UPON CD28 LIGATION 98
CD28 COUPLING TO PI3K IS NOT REQUIRED FOR SHIP TYROSINE 
PHOSPHORYLATION. 102
SUMMARY 104
3.2.2 SHIP AND CTLA4 104
INTRACELLULAR AND SURFACE STAINING OF CTLA4. 106
PROLIFERATION IN RESPONSE TO ANTI CTLA4 MABs. 106
ACCUMULATION OF D3 INOSITOL LIPIDS IN RESPONSE TO CTLA4 
STIMULATION 109
ACTIVATION OF SHIP IN RESPONSE TO STIMULATION THROUGH CTLA4 109
TYROSINE PHOSPHORYLATION OF SHIP IS A SPECIFIC CTLA4 
MEDIATED EVENT 112
SUMMARY 113
3.2.3 REGULATION OF BASAL LEVELS OF 3’PHOSPHOINOSITIDES 114
3’-PHOSPHOINOSITIDE IN RESTING JURKAT T CELLS VERSUS A20 B CELLS. 114 
DETECTION OF SHIP IN VARIOUS T CELL LINES 114
DETECTION OF PTEN PROTEIN IN A20 CELLS AND CTLA4 EXPRESSING 
HYBRIDOMA CELL LINE DC27.1. 116
CELLULAR LOCALISATION OF GFP-PKB-PH IN JURKAT T CELLS 116
LY249002 INHIBITION OF PI-3K INDUCES CELLULAR REDISTRIBUTION 
OF GFP-PKB-PH 119
CHARACTERISATION AND EXPRESSION OF CD2-SHIP CONSTRUCTS 119
CELLULAR RE-LOCALISATION OF GFP-PKB-PH IN JURKAT T CELLS VIA THE 
CO-EXPRESSION OF CD2-SHIP 123
SUMMARY 124
3.2 DISCUSSION -  SHIP 125
3.2.1 CD28 AND SHIP 125
3.2.2 CTLA4 AND SHIP 130
TABLE OF CONTENTS viii
3.2.3 3’- PHOSPHOINOSITIDE REGULATION IN THE LEUKAEMIC CELL LINE 
JURKAT 134
CONCLUSIONS 137
3.3 REGULATION OF PI3K DEPENDENT SIGNALLING CASCADES IN B 
LYMPHOCYTES 139
3.3.1 FCyRIIB MODULATION OF BCR MEDIATED SIGNALLING CASCADES IN
A20 CELLS. 139
FCyRIIB MODULATION OF BCR INDUCED CALCIUM FLUX. i 39
FCyRIIB MODULATION OF BCR INDUCED ERK1/2 PHOSPHORYLATION 141
FCyRIIB MEDIATED MODULATION OF PI3K ACTIVITY.
ASSOCIATION OF p85 WITH CD 19 141
ACCUMULATION OF 3’ PHOSPHOINOSITIDE LIPIDS IN RESPONSE TO 
BCR LIGATION AND BCR/FCyRIIB COLIGATION 144
TYROSINE PHOSPHORYLATION OF SHIP IN RESPONSE TO BCR LIGATION AND 
BCR FCyRIIB CO-LIGATION. 146
SUMMARY 146
3.3.2 FCyRIIB MODULATION OF P13K RECRUITMENT TO TYROSINE PHOSPHO- 
RYLATED PROTEIN COMPLEXES 148
TYROSINE PHOSPHORYLATION OF WHOLE CELL EXTRACTS FOLLOWING 
BCR LIGATION AND BCR/FCyRIIB COLIGATION 148
DIFFERENTIAL TYROSINE PHOSPHORYLATION OF GAB 2 FOLLOWING 
LIGATION OF THE BCR OR COLIGATION OF THE BCR/FCyRIIB. 150
BCR LIGATION AND BCR/FCyRIIB CO-LIGATION STIMULATES THE 
PRESENCE OF GAB2 IN ANTI p85 PRECIPITATES 153
THE N AND C TERMINAL SH2 DOMAINS OF p85 CAN ASSOCIATE WITH GAB2. 155 
THE C- AND N- TERMINAL SH2 DOMAINS OF p85 DIRECTLY INTERACT WITH 
GAB2 FOLLOWING BCR LIGATION AND BCR/FCyRIIB CO-LIGATION IN GAB2 
IMMUNOPRECIPITATES. 157
BCR AND BCR/FCyRIIB LIGATION INDUCE TYROSINE PHOSPHORYLATION OF 
SHP2 AND ASSOCIATION WITH MULTIPLE TYROSINE PHOSPHORYLATED 
PROTEINS.. 157
SHP2 GAB2 AND p85 CAN BE DETECTED IN THE SAME COMPLEX IN ANTI-SHP2 
PRECIPITATES IN RESPONSE TO BCR/FCyRIIB CO-LIGATION. 159
ASSOCIATION OF GAB 2 WITH GST FUSION PROTEINS REPRESENTING N 





3.3.1 FCyRIIB MODULATION OF THE FUNCTIONAL READOUTS OF BCR MEDIATED 
SIGNALLING CASCADES IN A20 CELLS. 165
3.3.2 REGULATION OF PI(3,4f5)/>3 ACCUMULATION BY SHIP 166
3.3.3 REGULATION OF PI3K BY ITS RECRUITMENT TO TYROSINE PHOSPHORYLATED 
PROTEIN COMPLEXES 169









FIG 1 ACCUMULATION OF D3 GLYCERO-PHOSPHOINOSITIDES IN 
RESPONSE TO B7 LIGATION.
FIG 2 PRESENCE OF p85A AND p 110 ISOFORMS IN JURKAT T CELL 
LYSATES.
FIG 3 PRESENCE OF p ! 105 IN PURIFIED T CELLS AND T LYMPHOBLASTS
FIG 4 ASSOCIATION OF P85A AND P 110 ISOFORMS WITH CD28 AFTER LIGATION 
BY B7.1.
FIG 5 ASSOCIATION OF PI 10A AND PHOSPHO PI 105 WITH CD28 AFTER 
LIGATION BY B7.1.
FIG 6 APPEARANCE OF PHOSPHO-P11 OSIN P 1105IMMUNOPRECIPITATES 
AFTER CD28 LIGATION BY B7.1.
FIG 7 COMPARISON OF P 110a, P 11 OP P 1105 AND CD28 ASSOCIATED 
VITRO LIPID KINASE ACTIVITY.
FIG 8 EFFECT OF WORTMANNIN AND OKADAIC ACID TREATMENT 
ON CD28 MEDIATED PHOSPHORYLATION OF PI 105
SECTION 3.2
FIG 9 TYROSINE PHOSPHORYLATION OF SHIP FOLLOWING CD28 LIGATION 
WITH ANTI-CD28 ANTIBODY 9.3.
FIG 10 FIGURE 10: TYROSINE PHOSPHORYLATION OF SHIP IN RESPONSE 
TO CD28 STIMULATION, IN THE PRESENCE OF FCyRIII/II BLOCKING 
ANTIBODY, 2.4G2.
FIG 11 B7.1 LIGATION OF CD28 STIMULATES 145 KDA SHIP PHOSPHORYLATION.
FIG 12 TYROSINE PHOSPHORYLATION OF SHIP IN RESPONSE TO CD28 
LIGATION, CD3 LIGATION, AND CO-LIGATION OF CD3 AND CD28.
FIG 13 CELLULAR RE-DISTRIBUTION OF SHIP IN RESPONSE TO CD28 
LIGATION
FIG 14 TYROSINE PHOSPHORYLATION OF 145 KDA SHIP FOLLOWING CD28 
LIGATION, IN DC27.1 WILD TYPE CD28+ AND MUTANT CD28+ T CELL 
HYBRIDOMA CELLS
FIG 15 INTRACELLULAR AND SURFACE FACS STAINING FOR CTLA4 
EXPRESSION
FIG 16 PROLIFERATION OF PRIMARY T CELLS IN RESPONSE TO CTLA4 CD3 
AND CD28 STIMULATION



















TABLE OF CONTENTS 
FIG 18 TYROSINE PHOSPHORYLATION OF SHIP IN RESPONSE TO CTLA4
LIGATION. I l l
FIG 19 F(AB’)2 CT29 INDUCED TYROSINE PHOSPHORYLATION OF SHIP
IN THE CTLA-4 EXPRESSING T CELL HYBRIDOMA DC. 113
FIG 20 EXPRESSION OF 145 KDA SHIP IN A20 B CELLS, JURKAT T CELLS, AND
CULTURED T LYMPHOBLASTS 117
FIG 21 DIFFERENTIAL EXPRESSION OF PTEN IN CTLA4 HYBRIDOMA AND A20
CELLS. 118
FIG 22 CELLULAR RE-LOCALISATION OF GFP- PKB-PH BY CO-EXPRESSION
OF rCD2-SHIP AND RCD2-SHIP-C701/A. 120
FIG 23 EFFECT OF LY249002 TREATMENT ON GFP-PKB-PH 121
FIG 24 ANALYSIS OF 5’-POLYPHOSPHATASE ACTIVITY OF CD2-SHIP
AND CD2- ASHIP CONSTRUCTS 122
SECTION 3.3
FIG 25 FCyRIIB AND WORTMANNIN MEDIATED IMPAIRMENT OF BCR ELICITED
CALCIUM RESPONSES IN FURA 2-AM LOADED A20 CELLS 140
FIG 26 FCyRIIB MODULATION OF BCR INDUCED ERK1/2 PHOSPHORYLATION IN
A20 CELLS 142
FIG 27 BCR LIGATION VERSUS BCR/FCyRIIB 1 CO-LIGATION INDUCED CO­
ASSOCIATION OF p85 WITH CD 19 143
FIG 28 FCyRIIB MODULATION OF BCR MEDIATED PIP3 PRODUCTION 145
FIG 29 BCR LIGATION VERSUS BCR/FCyRIIB 1 CO-LIGATION STIMULATED
TYROSINE PHOSPHORYLATION OF ANTI-SHIP IMMUNOPRECIPITATES 147
FIG 30 F(AB’)2 AND RAMIG INDUCED IN VITRO LIPID KINASE
ACTIVITY ASSOCIATED WITH ANTI-PHOSPHO TYROSINE IMMUNO­
PRECIPITATES 149
FIG 31 MODULATION OF BCR INDUCED TYROSINE PHOS-PHORYLATION OF
CELLULAR PROTEINS, FOLLOWING BCR/FCyRIIB CO-LIGATION 151
FIG 32 RAMIG AND F(AB’)2 INDUCED TYROSINE PHOSPHO-RYLATION
OF GAB2 IMMUNOPRECIPITATES 152
FIG 33 TYROSINE PHOSPHORYLATION OF ANTI-p85 IMMUNO­
PRECIPITATES FOLLOWING BCR LIGATION OR BCR/FCyRIIB 1 
CO-LIGATION. 154
FIG34 BCR LIGATION VERSUS BCR/FCyRIIB CO-LIGATION INDUCED 
TYROSINE PHOSPHORYLATION OF N-SH2-p85-GST
IMMUNO-PRECIPITATED PROTEINS 156
FIG35 BCR LIGATION AND FCyRIIB CO-LIGATION INDUCED ASSOCIATION OF 
A GST PROTEIN REPRESENTING THE p85 C TERMINAL SH2 DOMAIN 
WITH A 100 KDA PROTEIN GAB2IMMUNO-PRECIPITATES 158
TABLE OF CONTENTS 
FIG 36 BCR LIGATION, AND FCyRIIB CO-LIGATION, INDUCED TYROSINE
PHOSPHORYLATION OF ANTI-SHP2 IMMUNOPRECIPITATED PROTEINS. 160
FIG 37 BCR LIGATION VERSUS BCR/FCyRIIB 1 CO-LIGATION INDUCED ASSO­
CIATION OF GAB2 AND p85 WITH ANTI-SHP2 PRECIPITATED PROTEINS 162 
FIG 38 BCR LIGATION VERSUS BCR/FCyRIIB 1 CO-LIGATION STIMULATED
ASSOCIATION OF GAB2 WITH SHP2 N-TERMINAL SH2 DOMAIN, C-TERMINAL 
SH2 DOMAIN, AND FULL LENGTH (FL) GST FUSION PROTEINS. 163
LIST OF DIAGRAMS 
SECTION ONE
1 MODULAR STRUCTURE OF 145 kDa SHIP 6
2 STRUCTURE OF TEC FAMILY KINASES 11
3 PKB TARGETS 12
4 STRUCTURAL COMPONENTS OF GAB 1, GAB2 AND DOS 14
5 INVOLVEMENT OF GAB2 IN MAPK SIGNALLING CASCADE 15
6 CD28, ICOS AND CTLA4 21
7 CD28, P56 LCK ITK 25
8 IL-2 TRANSCRIPTIONAL ACTIVATION 27
9 BCR CD 19 COMPLEX 32
10BLNK 35
11 BCR CD 19 COLIGATION WITH THE FCyRIIB 38
12 ENZYMATIC FUNCTION OF SHIP 40
SECTION TWO
13 ANALYSIS OF CELL SURFACE ANTIGENS 59
14 SAMPLE HPLC ELUTION TRACE 69
SECTION THREE
15 p 1106/p85 AND p 1100/p85 CO ASSOCIATION WITH CD28 95
16 SCHEMATIC DEPICTION OF CD28 MEDIATED TYROSINE PHOSPHORLYATION
OF SHIP 138
17 SCHEMATIC REPRESENTATION OF DIFFERENTIAL RECRUITMENT OF p85
TO CD 19 AND GAB2 FOLLOWING BCR AND BCR FCyRIIB CO-LIGATION. 176
18 SCHEMATIC REPRESENTATION OF THE BCR AND FCyRIIB INDUCED CO­
ASSOCIATIONS BETWEEN SHP2, p85 AND GAB2 176
LIST OF TABLES 
SECTION ONE
1 CLASSIFICATION OF PI3K FAMILY MEMBERS 2
TABLE OF CONTENTS xiii
2 CHARACTERISTICS OF PI3K KNOCKOUT MICE 3
3 INOSITOL POLYPHOSPHATE 5’ PHOSPHATASE FAMILY 5
4 PREDICTED 3’-PHOSPHOINOSITIDE BINDING PREFERENCES OF PH DOMAIN 10
SECTION 3.2
5 BASAL AND STIMULATED LEVELS OF 3’-PHOSPHOINOSITIDE LIPIDS IN JURKAT 
AND A20 CELLS 115
ABBREVIATIONS
ARF adenosine ribosylation factor
BCR B cell receptor
Ca2+ calcium
CD cluster of differentiation
CD28RE CD28 response element
CTLA4 cytotoxic T lymphocyte associated antigen 4
DAG di-acyl glycerol
GAB2 Grb 2 associated binding protein 2
GEFs guanine nucleotide exchange factor




IRS-1 Insulin receptor substrate -1
IT AM Immunoglobulin tyrosine based
activation motif
ITIM Immunoglobulin tyrosine based inhibition
motif
ITK Inducible T cell kinase
JNK C-Jun N terminal kinase
kDa kilodalton




mlg Membrane bound immunoglobulin
NFkB nuclear factor k B
PH pleckstrin homology
PIF PDK-1 Interacting fragment
PKB protein kinase B
XV
PKC protein kinase C
PLCy phospholipase C gamma
PRK-2 PKC related kinase 2
PTEN phosphatase and tensin homologue
ten
PTK protein tyrosine kinase
Ras GAP Ras-GTPase activating protein
SEM standard error of the mean
SH3 src homology 3 domain
SHIP SH2 containing inositol
polyphosphatase
SHP2 SH2 containing protein tyrosine
phosphatase 2
SOC store operated calcium channel
SOS son of sevenless
Th T helper
ZAP zeta associated protein






















SECTION I - INTRODUCTION 1
1 - INTRODUCTION
The fundamental aim of this study was to investigate the mechanisms which regulate 
phosphatidylinositol 3’- kinase (PI3K) activation within the context of T and B lymphocyte 
intra-cellular signalling pathways. In this section I shall firstly introduce the extensive 
family of PI3Ks and describe the biochemistry and regulation of these proteins. Secondly, 
I shall discuss the role of T and B lymphocytes within the immune system. I shall describe 
their cell surface receptors and intracellular proteins, and then summarise the biochemical 
pathways by which these proteins regulate lymphocyte activation.
1.1 PHOSPHATIDYINOSITOL 3’ KINASE
The PI3K family comprises a group of ubiquitously expressed proteins which were 
primarily identified through their ability to phosphorylate the D3-OH position on the 
inositol ring of phosphoinositide lipids (Stephens et al 1991). This lipid kinase activity 
regulates intracellular levels of 3’-phosphoinositides, which act as signal transducing 
second messengers (Arcaro et al 1993). The first PI3Ks to be purified and cloned were 
heterodimers of what is now considered the class 1A subfamily, consisting of a p i 10 
catalytic subunit and a regulatory 85 kDa subunit (Otsu et al 1991). Different PI3K 
family members are now classified on the basis of their structural features, preferred lipid 
substrates, and coupled adaptor proteins. They are described in outline below in table 1 
and in the following text:
1.1.1 PHOSPHATIDYLINOSITOL 3’-KINASE CLASSIFICATION 
CLASS I
Class I PI3Ks utilise PI, PI(4) P and PI(4,5)P 2 as lipid substrates in vitro, whilst in vivo, 
the latter acts as the preferred substrate (reviewed by Vanhaesebroeck et al 1997a, 
Vanhaesebroeck et al 1999). All Class I PI3Ks can coassociate with GTP bound Ras. The 
PI3Ks of class I occur as heterodimers comprising an enzymatic domain and an adaptor 
domain, the characteristics of which further divide the class into sub families: Class 1A 
PI3Ks comprise a 110 kDa catalytic domain (pi 10), within which the Ras binding domain, 
lipid kinase domain and carboxy terminal protein kinase domain are featured, p i 10 
associates with an SH2 containing adaptor protein of 85 kDa, through which the catalytic 
domain is coupled to phosphotyrosine regulated signalling pathways. The unique 
phosphotyrosine containing motif with which the SH2 domains of the p85 regulatory 
subunit preferentially associate is YXXM. The presence of this sequence within the 
intracytoplasmic tail of cell surface receptors and adaptor proteins, has indicated the 
involvement of this class of PI3Ks in multiple signal transduction pathways. The p85
SECTION 1 - INTRODUCTION 2 
subunit also contains an SH3 region, which binds proline rich motifs, a proline rich region 
and a break point cluster (BCR) homology domain (BH) of unknown function. Multiple 




























PI-3 K C2a(m) ? 
PI-3 K C2p(m) 
PI-3 K 68D(Dm) 




Table 1: Classification of PI-3 K Family members
Key: (Structural motifs) Black circle =adaptor binding region, white box=Ras binding domain, grey 
box=PIK homology domain, patterned oval=kinase domain white box= C2 domain (species) 
m=mammalian, Ce= Caenorhabditis elegans, Dm=Drosophila melanogaster, Dd=Dicosteleum 
discoideum, Sc=Saccharomyces cerevisiae.
The p i 10 isoforms of class 1A all share the class I PI3Ks characteristic broad substrate 
specificity and the ability to interact with Ras. PI 105 is unusual in that it displays 
leukocyte restricted tissue distribution (Chantry et al 1997 and Vanhaesebroeck et al 
1997b).
Class 1A PI3Ks also possess protein kinase activity. PI 10a has been demonstrated to 
phosphorylate a serine residue in the inter-SH2 domain region of p85a and p85p. In 
contrast p i 105 harbours intrinsic autophosphorylation capacity so that it is phosphorylated 
on 1039 Ser. This autophosphorylation event is associated with a negative regulation of the 
lipid kinase activity (Vanhaesebroeck et al 1997b). Other structural features unique to 
p i 105 include a leucine zipper and a proline rich region.
Class IB PI3Ks associate via larger adaptor proteins to G protein coupled receptors and 
are stimulated by G protein p and y subunits. To date a 101 kDa adaptor has been 
identified. Additional reports have described that p llO y is responsive to activation via G a
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subunits (Murga et al 1998). Recently the activation of class 1A PI3Ks by heterodimeric 
G proteins has been described (Kowalski et al 1996), and, although Gpy activation of class 
1A catalytic subunits may occur via GPy upstream activation of PI3Ks. It appears that Got 
may directly activate p llO p  (Roche et al 1998). Knockout mice of various class I PI3Ks 
have been made and the phenotypic effects of these are summarised in table 2.
CLASS II
The Class II PI3Ks preferentially phosphorylate PI(4) P and are incapable of 
phosphorylating PI(4 ,5)P2 in vitro. These PI3Ks are predominantly membrane located in 
contrast to class I and class II PI3Ks which are cytoplasmically located. Class II PI3Ks 
contain a C2 domain at their carboxyl terminus, which is lacking critical Asp residues that 
are usually needed within this structural motif for Ca2+ binding. However this class of 
PI3Ks exhibit Ca 2+ independent anionic lipid binding properties. Pathways to which these 




Altered insulin responsiveness 
Severe B cell immunodeficiency
P50a and p55a still made.





In Rag 2 chimaeras: B cell maturation 
Impaired, No T cell defects
Cause of lethality not established. 




No apparent defects. Unclear (Not-published)
PI 10a Embryonic lethal Complex changes in PI3K expression and 




Impaired neutrophil and macrophage 
function.
Impaired T cell survival and function.
Neutrophils and macrophages display 
impaired migration by chemotaxis, 
impairment respiratory burst in 
macrophages (Condliffe et al 1999). 
Impaired T cell survival and CD8+ 
responses, (NB. Un-published data (M. 
Wymann) brings into question initial 
observations of this phenotype)
Table 2: Characteristics of PI3K knockout mice.
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CLASS III
Class ID PI3Ks can be characterised by their restricted substrate specificity as they only 
catalyse the phosphorylation of Ptdlns, producing PI(3)P. They seem to be involved in 
housekeeping roles including membrane trafficking and vesicle morphogenesis, and have a 
functional and structural homologue in the yeast PI3K, Vps34p (Volinia et al 1995).
1.1.2 MEASUREMENT OF PI3K ACTIVITY
The development of methodologies by which PI3K activity can be measured has aided 
research into the pathways leading to PI3K biochemical activation. A widely used 
technique has been applied by many studies (Hawkins et al 1992, Ward et al 1993) which 
involves the labelling of cells with [32P]-orthophosphoric acid. Labelled 
phosphatidylinositol lipids can be separated via HPLC by an ammonium phosphate 
gradient, and determination of the accumulation of distinct lipids species can be made. A 
further technique was developed which measured the accumulation of PI(3,4 ,5)P3 via the 
use of an alkali enzyme treatment which releases IP( 1,3,4,5)7*4 from PI(3,4 ,5)/*3. The 
accumulated IP(1,3,4 ,5)P4 which can then be measured by an IP( 1,3,4,5)7*4 binding assay 
(Van der Kaay et al 1997). Techniques which allow the measurement of intracellular 
changes in cellular levels of 3’-phosphoinositide lipids have been developed, which 
employ green fluorescent protein tagged pleckstrin homology domains. The PKB PH 
domain has been exploited in this way to monitor PI(3,4)P2 and PI(3,4 ,5)P3 accumulation 
(Franke et al 1997, Watton et al 1999). Pleckstrin homology domains will be discussed 
later in this Introduction. Finally the use of antibodies which recognise the phosphorylated 
form of the PI3K effector molecule PKB are becoming a more widespread tool for the 
detection of PI3K activation in biological systems (Astoul et al 1999)
1.1.3 REGULATION OF CLASS 1A PI3Ks
This study will concentrate on the class 1A PI3K family members and use of the term 
PI3K should be taken to mean class 1A p85/pll0 heterodimeric PI3K from hereon in this 
study. Recent models for PI3K activation describe the binding of the p85 regulatory 
subunit to adaptor proteins which recruit the enzyme to the plasma membrane where it is 
activated (Reif et al 1996). This model was proposed following the observation that 
constitutive membrane targeting of the p i 10 catalytic subunits of PI3K creates a 
constitutively active enzyme that generates PI(3,4,5)P3 and PI(3,4)P2 when expressed in 
cells (Reif et al 1996).
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Upon membrane localisation, upregulation of class 1A PI3Ks may occur via direct 
association with Ras-GTP. Reports have shown that Ras can activate class 1A PI3Ks in 
vitro, in a GTP dependent manner (Rodriguez Viciana et al 1996), and in vivo, co­
expression of PI3K p ll0 a-p 8 5 a  heterodimers, with active mutants of Ras, has been 
shown to upregulate PI 10 catalytic activity (Rodriguez-viciana et al 1994, Marte et al 
1997). Interestingly, data also exists which places Ras downstream of PI3K (Kurz et al 
2000). Additionally, in some cell types, regulation of p85 and p i 10 by serine / threonine 
phosphorylation has been observed (Reif et al 1993), and reports that p59fyn PTK can act as 
an activator of PI3K exist (Pleiman et al 1994). P59fyn has been demonstrated to interact 
with p85, via an association between the SH3 domains of p59fyn and a proline rich motif 
within the p85 subunit, which leads to tyrosine phosphorylation of p85 at Y688 and 
correlates with enhanced PI3K activity (Pleiman et al 1994).
1.1.4 NEGATIVE REGULATION OF PI3K DEPENDENT PATHWAYS
The lipid products of PI3K are not hydrolysed by PLC-yl, and as PI(3,4,5)P3 has been 
demonstrated to be a potent activator of downstream signalling proteins (Toker et al
1997), and many PH domain containing molecules have been demonstrated to bind 
PI(3,4,5)P3 and PI(3,4)P2 (Lietzke et al 2000), the regulation of intracellular levels of 
these lipids by inositol phosphatases is of major interest. Consequently much research has 
focused on the physiological and biochemical roles of the inositol polyphosphatases SHIP 
and PTEN, which have been implicated as major regulators of PI3K lipid product 
accumulation.
SHIP
The modulation of PI3K signalling pathways by SHIP is the focus of much of the work
G RO U P SUBSTRATES IN OSITO L-5 PHOSPHATASE R O LE
TYPE I Ins(l,4,5)P3
Ins(l,3,4,5)P4
e.g. platelet 5’phosphatase enzyme Ca + regulation 










(Ross et al 1991, 
McPherson et al 
1996,)
t y p e  m Ins(l,3,4,5)P4
PI(3,4,5)P3
SHIP and SHIP II EGFR, PDGFR, 
TCR, FCyRIIB 
(Damen et al 1996, 
Pessesse et al 1998)
Table 3: Inositol polyphosphate 5’phosphatase family
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described in this study. SHIP is a 145 kDa SH2 containing type III member of the inositol 
polyphosphate 5’ phosphatase family (See table 3), which include enzymes that selectively 
de-phosphorylate the 5’ position of the inositol ring on 5’ phosphorylated 
phosphoinositide- and inositol- lipids (Drayer et al 1996). Members of this family are 
defined by two signature motifs: (F/I)WXGDXN (F/Y)R and (R/N)XP(S/A)
(W/Y)(C/T)DR(I/V)(L/I) (Majerus et al 1999).
SHIP has a unique substrate specificity for lipids phosphorylated at the 3’ position of the 
inositol ring, namely Inositol 1,3,4,5-tetra-kis phosphate (Ins(l,3,4 ,5)P4), and PI(3,4 ,5)P3, 
the D-3 phosphoinositide PI3K metabolic product (Damen et al 1996). Removal of the 5’ 
phosphatase from these lipids produces Ins(l,3,4) tris phosphate (Ins(l,3,4 )P3) and 
PI(3,4)P2 which results in the down regulation of the effects of PI3K on mitogenesis, 
cellular transformation and immune cell function (Chacko et al 1997, Ono et al 1997, 
Tridandapani et al 1997b).
Structurally, SHIP possesses an N-terminal SH2 domain, a phosphatase domain, bearing 
the phosphatase core consensus motifs, two NPxY concensus sequences that are targeted
1st NPXPY 2nd NPxPy
Inositol 5’Phosphatase
PxxP motifs
Diagram 1: Modular structure of 145 kDa SHIP
SHIP comprises an SH2 domain which mediates protein - protein interaction with tyrosine 
phosphorylated proteins. Asterisks above the phosphatase domain mark regions of homology shared 
all 5’ - phosphatases. The C terminal NPXPY motifs, when phosphorylated have phosphotyrosine 
binding domain (PTB) binding potential. Also depicted above are several PXXP, poly- proline rich, 
motifs, three of which have good homology for SH3 domain binding (Thicker grey boxes), whilst the 
others show weaker SH3 binding homology, represented by thinner bands.
for phosphotyrosine binding (PTB) domains and several proline rich domains (Damen et al 
1996, Rohrschneider et al 2000) (See Diagram 1). The minimum catalytic core of SHIP 
has recently been identified to lies between amino acids 400-866 (Aman et al 2000). The 
SH2 domain of SHIP has specificity for the phosphotyrosine recognition sequence YSNL
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which is present within the FCyRIIB in B cells (D’Ambrosio et al 1995), and c-kit in 
haemopoietic cells (Yarden et al 1987).
SHIP is subject to phosphorylation in a variety of haemopoietic cell lines and lymphocytes. 
Phosphorylation of SHIP has been described to occur in haemopoietic cell lines in 
response to cytokine receptor stimulation with IL-2, IL-3 (Liu et al 1997b) and IL-4 
(G iallourakis et al 2000). Growth factor receptor stimulation, following treatment of 
cells with erythropoietin (Damen et al 1993, Verdier et al 1997), Insulin, EGF, PDGF, 
IGF-1 and NGF (Habib et al 1998), have also been reported to mediate the tyrosine 
phosphorylation of SHIP. Studies in T and B lymphocytes have shown that SHIP is 
phosphorylated following TCR engagement and IL-4 stimulation (Lamkin et al 1996), and 
ligation of the FCyRIIB was demonstrated to mediate SHIP phosphorylation in B 
lymphocytes and mast cells (Chacko et al 1996). Various studies have sought to identify 
the PTKS which phosphorylate SHIP. In T cells, recombinant Lck has been demonstrated 
to phosphorylate SHIP (Lamkin et al 1997). Meanwhile studies, studies using PTK 
deficient B cell lines suggest that Lyn may be more important for the tyrosine 
phosphorylation of SHIP than Syk in B lymphocytes (Nagai et al 1995), and more recent 
work further supports a role for Lyn as the predominant mediator of SHIP phosphorylation 
in B lymphocytes (Phee et al 2000).
Conflicting evidence exists as to the importance of tyrosine phosphorylation in the 
catalytic activation of SHIP. In platelets tyrosine phosphorylation of SHIP following 
thrombin stimulation does not correlate with its up-regulation, but is correlated with its 
relocalisation to the actin cytoskeleton (Giuriato et al 1997). Thus SHIP may not be 
responsible for the observed accumulation of PI(3,4)P2 upon thrombin stimulation and 
aggregation of platelets. However previous studies by this group have observed that 
tyrosine phosphorylation and enzymatic degradation of Ins(l,3,4,5)P4 are closely 
correlated in T lymphocytes (Edmunds et al 1999). Moreover, recent studies have 
identified key C-terminal tyrosine residues which appear to be essential for SHIP’S 
enzymatic activity (Aman et al 2000). These data, along with those described by another 
study (Phee et al 2000) imply that the enzymatic activation of SHIP may be mediated via 
membrane localisation, which is directed by phosphorylation of this C-terminal motif.
SHIP has been implicated in negative signalling pathways initiated by IL-3 and GMCSF 
(Liu et al 1999), and in B cells following co-ligation of the BCR and FC7RIIB (Liu et al
1998), via its enzymatic degradation of PI(3,4,5)P3. Moreover, through its non catalytic 
domains, SHIP has been proposed to mediate inhibitory signalling independently of its
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enzymatic function. SHIP is implicated in the inhibition of Ras activation, through the 
sequestration of She, via an association between the SH2 domain of SHIP and tyrosine 
phosphorylated She (Liu et al 1997). A further interaction between these two proteins 
occurs through the SHIP NPxPY and the PTB binding domain of She, which may serve to 
stabilise the interaction between She and SHIP (Harmer et al 1999).
Further evidence as to SHIP’S functional role has been gained from the analysis of SHIP 
knockout mice. Whilst these mice are viable and fertile, homozygotes have a reduced 
lifespan which is due to myeloid cell infiltration of vital organs (Liu et al 1999). 
Haemopoietic lineages from these mice display increased colony formation in response to 
IL-3 GM-CSF and G-CSF, which may reflect a role for SHIP in regulating either survival 
or proliferation in response to these cytokines. SHIP-/- myeloid and B cells also exhibit 
elevated resting levels of PI(3,4,5)P3, which correlate with increased PKB activity, and are 
sensitive to the PI3K inhibitor wortmannin (Helgason et al 1998). SHIP null animals show 
a hyperplasia of macrophage and granulocyte lineages, at the expense of B cell production. 
The reduced pool of SHIP deficient B cells demonstrate a marked elevation of resting 
calcium flux which is further elevated above wild type levels upon stimulation, and 
correlates with increased proliferation in vitro (Liu 1998).
PTEN
The human tumour suppressor gene phosphatase and tensin homologue 10 (PTEN) 
encodes a dual specificity serine/threonine and tyrosine phosphatase which has been 
demonstrated to de-phosphorylate a limited array of acidic substrates eg: poly-Glu- 
phospho-Tyr (Myers et al 1997). PTEN has since been demonstrated to dephosphorylate 
3’-phosphoinositides, and can direct the in vitro degradation of PI(3)P, PI(3,4)7*2 and 
PI(3,4,5)P3 .to PI, PI(4)P and PI(4,5)P2 (Myers et al 1998).
Structurally PTEN bears sequence homology to other dual specificity phosphatases, and to 
the cytoskeletal protein, tensin (Liaw et al 1997). Homologous mutation in the PTEN 
gene, which is situated on human chromosome region 10q23, has been identified in many 
tumours including prostate cancer and gliomas. Mutation in a single copy of the gene 
results in Cowden disease and Bannayan zonana syndrome, which lead to a predisposition 
to certain tumours (Celebi et all999). Recent evidence suggests that the ability to 
dephosphorylate PI(3,4,5)P3 may contribute to PTEN’s tumour suppressor activity 
(Stambolic et al 1998). Indeed, PTEN knockout mice exhibit elevated levels of 
PI(3,4,5)P3 and enhanced PKB activity, and whilst biochemical analysis of tumours from
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PTEN  mutants could not detect any 3’-phosphatase activity, some protein phosphatase 
activity towards poly-Glu-phospho-Tyr was retained (Fumari et al 1998).
MYOTUBULARIN
A further regulator of the accumulation of PI3K products is Myotubularin which has been 
recently demonstrated to possess 3-phosphatase activity. Myotubularin was previously 
identified as a tyrosine phosphatase involved in muscle cell differentiation. Mutations in 
the MTM1 gene, which encodes this protein, have been demonstrated as the causative 
factor in X-linked myotubular myopathy (Wallgren et al 1995). Studies have implicated 
myotubularin in the regulation of PI(3)P accumulation, a crucial lipid which plays a role 
in intracellular membrane trafficking (Taylor et al 2000). Overexpression of a substrate 
trapping mutant of myotubularin led to the accumulation of elevated levels of PI(3)P in 
mammalian cells (Taylor et al 2000).
RUK
The novel cytosolic adaptor protein Ruk has recently been identified to negatively regulate 
pathways mediated via PI3K (Gout et al 2000). Ruk was first identified as an SH3 domain 
binding protein (Akopian et al 1996), and has been more recently shown to bind the p85 
regulatory subunit of PI3K. This interaction is mediated via a proline rich region within the 
Ruk protein which associates with the SH3 domain of p85 (Gout et al 2000). Studies in 
which Ruk was overexpressed demonstrated that p85 and RUK co-association upregulated 
apoptosis, and that this could be reversed via the overexpression of catalytically active 
PI3K (pi 10a) or constitutively active PKB (Gout et al 2000).
1.2 PI3K EFFECTORS
The 3’ -phosphatidylinositol lipid products of class 1A PI3Ks specifically target distinct 
classes of proteins which possess lipid binding motifs. One such motif is the FYVE 
domain which binds PI(3)P. A further class of PI lipid binding domains that shall be 
discussed here are pleckstrin homology domains.
1.2.1 CLASSIFICATION OF PH DOMAINS
PH domains are globular protein domains of about 100 amino acids that can bind 
phospholipids (Lemmon et al 1997). About 110 PH domain containing proteins have been 
described to date all of which, despite displaying divergent amino acid sequence, contain a 
conserved core fold consisting of a seven stranded P-barrel capped on one end by a C 
terminal a-helix (Rebecchi et al 1998). 10% of the PH domains that have been identified
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are able to bind phosphoinositides with sufficient affinity to mediate the receptor driven 
membrane translocation of their host proteins, which elicits their activation (Kavran et al 
1998, Lemmon et al 2000). PH domains that bind phosphoinositides with high affinity 
have been identified to have a conserved N terminal KX713R/K X R ■> motif, (where x is 
any amino acid and <■ is a hydrophobic amino acid) the basic residues of which 
specifically interact with phosphorylated inositol head groups (Bottomley et al 1998). Of 
these a subset have been predicted to show preferential binding for the rare 3’- 
phosphoinositide products of PI3K (Isakoff et al 1998), which even after maximal receptor 
stimulation are still present at levels well below those of their abundant phospholipid 
precursors PI(4)P, and PI(4,5)P2 (Auger et al 1990). To date, the PH domain containing 
Tec Kinase BTK (Fukuda et al 1997) and the ARF exchange factor Grpl(K larlund et al 
1997) have been shown to exclusively bind PI(3,4 ,5)P3, whilst in vitro PKB has been 
shown to have affinity for PI(3,4 ,5)P3 and PI(3,4)P2 (James et al 1996). More recently










SIGNATURE MOTIF FOR 3’PHOSPHOINOSITIDE BINDING  
[LVIMF]-X-K-X-[GASP]-Xm-(K/R)-X-R-X-[FL]-X-[LM]-Xn-[LIF]-X-Y
Table 4: predicted 3’ phosphoinositide binding preferences of PH domain containing proteins 
(Ferguson et al 2000), showing the signature motif for 3’-phosphoinositide binding that has been 
recently defined,(x= any amino acid, m=l-5, n=6-10) (Lietzke et al 2000).
predictions for the preferential binding of PI(3,4,5)P3 alone or PI(3,4 ,5)P3 and PI(3,4)P2, 
have been made for other PH domain containing proteins (Lietzke 2000, Ferguson et al
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2000) (see table 4). A more detailed description of PI3K effector pathways that are 
mediated by PH domain containing proteins which possess either enzymatic function, or 
act as adaptor molecules, is described below:
1.2.2 THE PI3K/ TEC FAMILY KINASE PATHWAY
Important structural components of the Tec family kinases are summarised in diagram 2. 
The Tec family kinases target PLCy (Sommer et al 1999, Schaeffer 1999) and are thus 
essential components of the intracellular signalling pathways leading to calcium 
mobilisation (Scharenberg et al 1998). Receptor stimulated calcium mobilisation is a 
product of PLCy activation which in turn catalyses phosphatidylinositol (4,5)- 
bisphosphate (PIP2) breakdown to yield di-acyl glycerol (DAG) and inositol (l,4,5)-tris 
phosphate ( IP3). IP3 stimulates release from intra-cellular calcium stores in the ER which 
rapidly opens IP3 sensitive store operated calcium (SOC) channels on the cell surface 
allowing calcium influx from the extra-cellular space (Putney et al 1993). Recent work 
has shown that Tec kinases can physically associate with components of the 
transmembrane adaptor protein LAT which also recruits PLCy (Bunnell et al 2000) and 
SLP-76 (Su et al 1998), which complexes with LAT via Gads (Fluckiger et al 1998, Liu et 
al 1999).
IPH Pr SH3 SH2 Kinase Tec,Btk,
Itk
CCCPr SH3 SH2 Kinase Rlk/TXK
DIAGRAM 2: Structurally, the Tec family kinases comprise a single SH2 and SH3 domain and an 
upstream conserved region which has been denoted as the Tec homology region (TH). The TH region 
is characterised by a GTPase activating protein (GAP)-BTK homology (BH) region, and a proline rich 
sequence implicated in SH3 domain binding and kinase activity (Andreotti et al 1997). ITK, Tec, and 
BTK each exhibit a PH domain (Lemmon et al 1996), which is substituted in Rlk/Txk by an 
alternative cysteine rich region that acts as a site for palmitoylation and determines Rlk/TxK 
subcellular location at membrane vesicles (Debnath et al 1999). Activation of Tec kinases occurs upon 
association of 3’-phosphoinositides with the PH domain (August et al 1997), which allows the 
subsequent phosphorylation of tyrosine Y551 (Heyeck et al 1997).
1.2.3 THE PI3K/PKB PATHWAY
Protein kinase B (PKB) was first identified in 1991 as a PH domain containing serine 
threonine kinase which bore considerable homology within its kinase domain to PKCe and
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PKA (Coffer et al 1991, Jones et al 1991, Bellacossa et al 1991). PKB’s PH domain can 
preferentially bind PI(3,4)P2 and PI(3,4,5)P3 (James et al 1996, Stephens et al 1998), and 
has been shown to mediate PKB’s rapid and transient membrane relocalisation upon the 
activation of PI3K (Andjelkovic et al 1997). In accordance with this observation, 
membrane localised PI3K constitutively upregulates PKB (Klippel et al 1997) and PKB 
activation is sensitive to the PI3K inhibitor wortmannin (Burgering et al 1995, Reif et al 
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DIAGRAM 3: PKB Targets
conformational change, allowing it to become fully activated by phosphorylation of two 
conserved residues, threonine308 and serine473 (Alessi et al 1997). Phosphorylation of
308Thr is elicited by the activity of a further PH containing protein kinase, 
3’phosphoinositide dependent kinase (PDK1), and is entirely dependent on the presence of 
PI(3,4)/>2 or PI(3,4,5)P3 in vitro (Alessi et al 1997). The kinase which elicits Ser473 
phosphorylation of PKB is as yet unidentified, and was putatively termed PDK2 (Alessi et 
al 1997). Integrin linked kinase (ILK) has been implicated in the phosphorylation of 
Ser473, (Delcommenne et al 1998), but this is possibly via an indirect mechanism (Lynch et 
al 1999). Recent observations indicate that PDK2 may in fact be PDK1: PDK1 has been 
demonstrated to associate with what has been termed the PDK1 interacting fragment (PIF) 
of PKC related kinase 2 (PRK2), and this interaction allows PDK1 to phosphorylate 
Ser473 and Thr308 (Balendran 1999). Interestingly, this PRK2-PIF modified form of PDK1
SECTION 1 - INTRODUCTION 13 
demonstrates a 3 fold enhanced activity in the presence of PI(3,4 ,5)P3 or PI(3,4)P2 
(Balendran 1999).
PKB plays an important role in the maintenance of cell survival in fibroblasts and 
epithelial cells (Coffer et al 1998, Bellacossa et al 1998). PKB targets proteins containing 
the amino acid sequence RXRXXS/T ■fr where X s any amino acid and ■> is a bulky 
hydrophobic amino acid) (Alessi et al 1996). PKB’s role in enhancing cell survival may 
be mediated via multiple pro-apoptotic proteins targets. PKB phosphorylates BAD, a 
member of the BCL2 family causing its dissociation from Bcl-2 and Bcl-Xj (Datta et al 
1997, Yang et al 1999). PKB also targets forkhead transcription factors, resulting in their 
translocation from the nucleus (Brunet et al 1999, Kops et al 1999). PKB mediates the 
transcriptional regulation of anti-apoptotic factors, through the PKB elicited 
phosphorylation of I- kB kinase-a (IKKa) (Ozes et al 1999). IkB kinases phopshorylate 
IkB which causes its degradation and dissociation from NFkB, allowing NFkB 
translocation into the nucleus where it upregulates transcription. Further targets of PKB are 
summarised in the diagram above (Diagram 3).
1.2.4 PH CONTAINING ADAPTOR PROTEINS
The identification of novel cytosolic proteins which lack enzymatic function and have p85 
binding capacity has led to the proposal that PI3K may be regulated via recruitment to 
different protein complexes by these ‘adaptor’ proteins. A few of these proteins relevant to 
this study are described below: 
p62 DOK-1
The adaptor protein P62-Dok-l has been described to associate with p85 and IRS-1 in the 
context of insulin mediated signalling pathways (Noguchi et al 1999). P62-Dok-l was 
first identified as a cytosolic adaptor protein which sequestered the GTPase activating 
proteins (GAP’s), Ras-Gap away from Ras. GAPs activate the intrinsic GTPase activity of 
Ras, and thus enhance GTP hydrolysis, reverting Ras to its inactive GDP bound 
conformation (McCormick 1993). Thus sequestration of Ras GAP by adaptors such as 
p62-Dok-l, inhibit the activation of Ras GTPase activity, and allow its accumulation in an 
active state (Yamanashi et al 1997).
GAB FAMILY ADAPTOR PROTEINS
Gabl and Gab2 are cytosolic docking protein which have been demonstrated to associate 
with Grb2, She and the regulatory PI3K subunit p85 (Craddock and Welham 1997, Gadina 
1999, Nishida et al 1999). Gabl is the mammalian homologue of the drosophila protein 
Dos, that is coupled to sevenless and torso signalling via corkscrew (Herbst et al 1996).
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G abl, Gab2 and Dos each have PH domains, but elsewhere Gab2 displays only 37% 
homology to G abl. Of functional note G abl and Gab2 share conserved tyrosine based 
motifs, which can bind the SH2 domains of PI3K, Crk, and SHP2. Gabl and Gab2 also 
possess a conserved proline rich region which can associate with the grb2 SH3 binding 
motif. Additionally both G abl and Gab2 display a c-met binding domain (MBD (see 
diagram 4).
A  A  A
DOS 1 1 1
V  V  V  I
45%
Not significant —




1 II ' 1
o  o  o
□  = C-Met binding 
region
= PH domain
^  = conserved
tyrosine residue
= proline rich 
region
Diagram 4: Schematic representation of structural components of G abl, Gab2 and Dos.
Dos, Gabl and Gab2 each display a PH domain and several proline rich regions. Gabl and Gab2 share a c- 
Met binding domain, and share 30 % amino acid identity outside of the PH domain. Amino acid identity 
is marked between each protein, conserved phosphotyrosine residues indicated are each within rec­
ognised SH2 binding motifs.
The PH domains of Gabl and DOS have been predicted to preferentially bind PI(3,4,5)P3 
(Ferguson et al 2000). The structural similarity shared by the PH domains of this protein 
family might predict that Gab2 may also display a preference for binding PI(3,4,5)P3 
which would have implications in the kinetics of membrane recruitment of this protein. It 
has been demonstrated that overexpression of Gabl and Gab2 can enhance Erk2 activation 
(Nishida et al 1999). Gab2 has been proposed to act as a substrate for SHP2 PTPase 
activity and this is supported by its reported hyper phosphorylation in the presence of 
enzymatically inactive SHP2 (Gu et al 1997) and reduced phosphorylation in SHP2 
immuno-precipitates from stimulated cells (Craddock and Welham 1997). Furthermore, 
Gab2 is proposed to link SHP2 to the MAP kinase pathway (see diagram 5) and studies 
have demonstrated that disrupting Gab2 binding sites for SHP2 SH2 domains inhibits 
immediate early gene expresssion (Gu et al 1998), whilst enhancing MAP kinase 
activation (Zhao et al 1999, Gu et al 1998). In a more recent study, Gab2’s coassociation 
with p85 has been shown to be essential for IL-3 dependent activation of the PI3K /AKT 
pathway (Gu et al 2000). In the same study She was implicated in mediating tyrosine 
phosphorylation of Gab2 and initiating a shc/grb2/Gab2/PI3K/AKT pathway in response to
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EL-2 receptor signalling (Gu et al 2000). A role for Gab2 in mediating positive signals in T 
cells has also been described by studies which have shown that IL-2 and IL-15 receptor 
stimulation can couple to MAPK activation via Jak3 elicited tyrosine phosphorylation of 





= proline rich 
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Diagram 5: Involvement of Gab2 in MAPK activation downstream of IL-3. Ligation of IL-3 receptor 
leads to activation of Jak s and tyrosine phosphorylation of SHP2 and Gab2. Gab2 may couple SHP2 
and PI3K to MAPK activation but may enhance early gene expression via a parallel pathway through 
SHP2 as abolition of SHP2/ Gab2 interaction site inhibits Elk-1.
1.3 T AND B LYMPHOCYTES
1.3.1 THE IMMUNE SYSTEM
Cells of the T and B Lymphocyte lineages convey the specificity of the immune response. 
This specficity is attributable to the expression of a diverse repertoire of high affinity 
receptors for antigen on the surface of all but the most immature of the T and B 
lymphocyte population. T and B lymphocyte lineages arise via haemopoiesis, and develop 
from common lymphoid progenitor stem cells in the bone marrow, which differentiate into 
immature T and B Lymphocytes (Hsu et al 1983)
1.3.2 T LYMPHOCYTES
Immature T lymphocytes migrate to the thymus where they are ‘educated’ to discriminate 
between self and non-self via a process termed positive and negative selection. 
Furthermore, the expression of the CD4 or CD8 T lymphocyte surface antigens occurs in 
the thymus, culminating in the release of two distinct T cell subsets, CD4+ and CD8+, from
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the thymus into the peripherary (Fowlkes et al 1989), resulting in a population of mature T 
cells that are non-responsive to antigens derived from self-expressed tissues,. Autoimmune 
diseases arise in individuals where incomplete negative selection results in circulating T 
cells that have the capacity to respond to self antigens (Blackman et al 1990).
1.3.3 B LYMPHOCYTES
Divergence of pre-B cells from the lymphoid progenitor cell population, and commitment 
to the B cell lineage, correlates with upregulation of the expression of the B cell surface 
receptor CD 19. Expression of surface immunoglobulin (mlgM), otherwise known as the B 
cell antigen receptor (BCR), marks the emergence of the immature B cell from the bone 
marrow. At this stage the expression of the B220 surface antigen at low levels can be 
measured, and later in this stage CD21, the CD3dg complement receptor, is detected on 
human cells (Sato et al 1997). The mature B cell population is non -  reactive to self 
expressed antigens. This is achieved in part by the clonal deletion of immature B cells 
which express B cell receptors which have high affinity for host proteins (Goodknow et al
1992).
1.4 T LYMPHOCYTE ACTIVATION
1.4.1 THE 2 SIGNAL MODEL
Naive T cells require two signals to become fully activated and elicit a productive immune 
response: The first (signal 1) is delivered by the antigen specific T cell receptor (TCR)/ 
CD3 complex, upon encounter with foreign antigen bound by self major histocompatibility 
complexes (self MHC) on antigen presenting cells (APCs) (Bretscher et al 1992). Signal 2 
is generated via costimulatory molecules that bind counter receptors expressed on the 
surface of antigen presenting cells (Schwartz et al 1990). An important and well 
characterised costimulatory molecule is CD28, a homodimeric glycoprotein, whose 
activation is triggered upon ligation with the APC expressed family of molecules, B7 
(namely B7.1 (CD80) and B7.2 (CD86) (Guinan et al 1994).
The association of the TCR with antigen and CD28 with B7.1/B7.2 allows synergistic 
activation of pathways which control progression of the cell cycle from GO to G l, up­
regulation of the IL-2 receptor and secretion of IL-2 (Ward et al 1996). In addition, CD28 
also promotes cell survival by up-regulation of Bel X L, and regulates expression of a 
number of other cytokines, chemokines, and chemokine receptors (Boise et al 1995, 
Labuda et al 1998). In the absence of a costimulatory signal, TCR stimulation is 
insufficient for proliferation of the cell to occur. Instead the T cell becomes anergic, 
characterised by non-responsiveness to further antigenic encounter, and may undergo
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programmed cell death. If costimulation is provided in the absence of TCR engagement, 
drastically reduced cytokine production can occur. Optimal levels of cytokine production 
can be restored in this situation when phorbol esters are used in place of a TCR/CD3 signal 
(Bretscher et al 1992). Furthermore, CD28 engagement enhances the expression of other 
T cell expressed costimulatory molecules, such as CD40L which has been shown to be 
necessary to provide the full complement of signals that are able to activate naive CD8+ T 
cells and effector functions (Bennett et al 1998).
Thus, it is proposed that CD28 can provide the primary costimulatory signal. Evidence 
which supports this hypothesis can be drawn from the following studies:
i) Blocking B7/CD28 interaction by the use of F(Ab) fragments of CD28 antibodies 
causes cells to enter a state of hyporesponsiveness, strongly suggesting that it is 
through this interaction that T cell reactivity is initiated and maintained (Damle et 
al 1988).
ii) T cells from mice deficient in CD28 show decreased cytokine production and 
proliferation in response to mitogenie stimuli, again highlighting the importance of 
this molecule in T cell costimulatory pathways (Shanhinian et al 1993).
In the following section I shall expand on the key components which characterise the 
downstream biochemical events mediated firstly by the TCR and then the costimulatory 
receptor CD28
1.5 TCR/CD3 AND TH E ANTIGEN DEPENDENT SIGNAL
1.5.1 TCR/CD3 STRU CTU RE
Signal 1, the antigen dependent signal for T cell activation, is mediated via the TCR/CD3 
complex. The TCR comprises the hyper-variable dimeric a  and (3 chains, which provide 
the basis for antigen specificity, which are non covalently associated to the TCR ^ chain 
dimers. This multimeric complex is further coupled to the invariant CD3 y, 5, and e, 
chains (Izquierdo et al 1992, Bolen et al 1995). The initiation of antigen receptor 
signalling is also accompanied by the clustering of other T cell surface molecules, which 
include CD4, CD8, CD2 and LFA1. These proteins form non covalent associations with 
the CD3 e and TCR £ chains in the cytoplasm (Bolen et al 1995).
The intracytoplasmic tail of the TCR £ chains contain three copies of an immunoglobulin 
tyrosine activation motifs (ITAM) sequence (D/E)XXYXX(I/L)6-8YXX(I/L), which is 
singly represented in each of the CD3 e y and 8 chains (Reth et al 1989). IT AMs are 
specific targets for antigen receptor activated protein tyrosine kinases (PTKs), and provide
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phosphotyrosine docking sites for Src homology (SH2) domain containing proteins (Chan 
e ta l  1994).
1.5.2 TCR ACTIVATED PTKS
The most proximal event to occur following ligation of the TCR by antigen is the 
activation of the src family PTKs, p59fyn and p56lck. These PTKs elicit phosphorylation of 
the TCR/CD3 ITAMs, which in turn allows the recruitment, and activation, of Zap-70 
(Osman et al 1995, Sunder-Plasman et al 1997, Weiss et al 1995) and Syk tyrosine kinases 
(Chu e ta l  1999).
p56lck has been described to associate via its SH3 domains with the proline rich region of 
the PI3K regulatory subunit p85 (Kapeller et al 1994, and Pleiman et al 1993) and, more 
recently, with SLP-76 (Sanzenbacher et al 1999). Studies in p S b ^  deficient cell lines 
have demonstrated that TCR induced phosphoinositide hydrolysis, calcium mobilisation, 
and phosphorylation of PLCyl are p56Ick dependent. Mutation of the SH3 domain of p56,ck 
inhibited Ras/Map kinase activation, elevation of Erk or Mek phosphorylation or ERK 
induced CD69 surface expression (Sanzenbacher et al 1999). In adddition to its SH3 
domain binding partners, p56,ck can also bind to Zap70 via its SH2 domain (Neumeister et 
al 1998). An essential role for p59fyn in T Lymphocyte signalling has been described 
following studies in p59fyn knock out mice which show a similar phenotype to p56 ,ck 
deficient mice and are blocked at the double negative (CD4\ CD8 ) stage of thymocyte 
development (Zhang et al 1999). Previous studies have examined p56fyn’s role in TCR 
signalling and have demonstrated a weak association between the TCR £ chains and an N 
terminal region of p56fyn (Gauen et al 1992), which correlates with a 2-4 fold increase in 
p56fyn activity (Tsygankov et al 1992).
In response to TCR ligation, Zap-70 is phosphorylated in the interdomain B region, 
situated between the kinase domain and the C- terminal SH2 domain, on Y319. (Di Bartolo 
et al 1999, and Williams et al 1999). Activation of Zap 70 is crucial for CD69 elevation, 
PLCy phosphorylation (Williams et al 1999), NFAT transcription and IL-2 production (Di 
Bartolo et al 1999). Zap-70 mutant T cells are unable to mediate Ca2+ mobilisation and 
MAPK activation (Shan et al 1999).
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1.5.3 TCR MEDIATED EFFECTOR PATHWAYS.
REGULATION OF RAS
TCR ligation induces the accumulation of the monomeric guanine nucleotide binding 
proto-oncogene product, Ras (Downward et al 1990), in its active GTP bound 
conformation. Ras activation is critical during thymocyte and B cell development (Gartner 
et al 1999), whilst in mature lymphocytes Ras is essential for proliferation and cytokine 
gene transcription (Turner et al 1998). Ras activity is positively regulated in T cells by the 
guanine nucleotide exchange factor SOS (GEF’s), which elicit accumulation of Ras in its 
active GTP bound form. SOS is activated upon membrane recruitment by formation of 
Shc/Grb2 complexes (Holsinger et al 1995). The SH2 domains of Grb2 associate with 
tyrosine phosphorylated She, whilst Grb2s’ SH3 domain can bind a proline rich region on 
SOS (McCormick et al 1993).
The recent identification of the transmembrane adaptor protein LAT which recruits TCR 
regulated signalling complexes, has further characterised the events which couple TCR 
ligation to Ras activation. The TCR stimulated accumulation of GTP-bound Ras leads to 
the activation of Ras effectors, namely PI3K, (Rodriguez-viciana et al 1997), Raf , Rac 
and Ral GDS (Marshall et al 1996 and 1999), and activates downstream targets such as 
the transcription factors of the NFAT (Nuclear factor of activated T cells) family, (Angel 
et al 1991, Genot et al 1996), and AP-1, Elk-1 and serum response factor-1 (Turner et al
1997), via Mitogen activated protein kinase cascades (MAPK) (Blenis et al 1993). 
Interestingly, data also exists which places Ras downstream of PI3K (Hu et al 1995). TCR 
initiated signals are insufficient to activate the Rac effector, c-Jun N terminal kinase (JNK) 
that enhances transcriptional activity of c-jun and thus assembles AP-1 transcription factor 
complexes (Jain et al 1995). Signal 2 CD28 costimulatory signals are required for 
transcriptional activation via this pathway (Su et al 1994) and are discussed later (see 
diagram 8).
TCR ACTIVATION OF PI3K AND ITS EFFECTORS
In T cells, TCR stimulation by antigen ligation activates class 1A PI3Ks. The candidate 
adaptors for recruiting PI3K to the membrane in T cells include the TCR associated 
adaptor protein TRIM (Bruyns et al 1998) and LAT (Zhang et al 1998). Membrane 
recruitment of PI3K may elicit its activation via protein kinase activity, and previous 
studies have shown that in T cells serine/threonine kinases mediate phosphorylation of 
PDK downstream of the TCR (Reif et al 1993, Ward et al 1992). Alternatively, 
approximation of PDK with Ras could be the predominant route for PDK activation in T
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cells (Zhang et al 1998). However, PDK dependent pathways leading to PKB activation 
can be activated independently of Ras in T cells (Genot et al 1998).
Targets of TCR activated PDK include the PH domain containing proteins ITK 
(Scharenberg et al 1998, Bolland et al 1998) and Akt/PKB (Reif et al 1997). ITK has 
been firmly implicated in PLCyl phosphorylation and calcium signalling downstream of 
antigen receptor signals (Schaeffer et al 1999, Sommers et al 1999). However one report 
which examined ITK activation following TCR stimulation suggests that this is not a PDK 
dependent event (Heyeck et al 1997). PKB may promote cell cycle progression in T cells, 
through the stimulation of E2F and its subsequent promotion of Cyclin D3 expression 
which drives G1 to S transition (Brennan et al 1997).
1.6 CD28 AND B7 FAMILIES
1.6.1 CD28
CD28 is a 44 kDa homodimeric glycoprotein which is constitutively expressed on 95% of 
CD4+ T cells and 50% of the CD8 compartment. It contains a single disulphide linked 
IgV like domain making it a member of the Ig superfamily. The mature CD28 polypeptide 
contains 202 amino acids resulting in a protein of 23 kDa which is then glycosylated to 
44kDa. A single transmembrane pass links the extracellular region to a 41 amino acid 
cytoplasmic tail which exhibits no catalytic activity (June et al 1994). The intracytoplasmic 
tail of CD28 exhibits four highly conserved tyrosine residues (see diagram 6), one of 
which, at 173Y, is situated in a conserved motif YXMN (where X is any amino acid) and 
which in its phosphorylated state has specificity for the SH2 domains of the 
phosphoinositide 3-OH kinase (PDK) regulatory sub-unit, p85 (Ward et al 1993, Pages 
et al 1994). Further studies have identified two proline rich motifs, which have been shown 
to be essential for costimulation (Pages et al 1994, Truitt et al 1996).
CD28 co-ligation with the TCR results in IL-2 receptor expression and IL-2 secretion. 
Costimulatory signals through CD28 initiate the production of cytokines IL-4, IL-8, IL-13 
and GMCSF (Weschler et al 1994). CD28 also leads to the activation of transcriptional 
transactivators NFkB and AP-1, and messenger RNA stabilisation of cytokine transcripts. 
Chemokine expression is also thought to be upregulated by CD28 via NFkB (Shapiro et al 
1997, Moriuchi et al 1997, Edmead et al 1996).
1.6.2 ICOS
ICOS is another member of the CD28/CTLA-4 family which plays an important role in 
production of IL-2, IL-4, IL-5, and 1FN y from recently activated T cells (Coyle et al
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2000). ICOS displays structural similarity to CD28 and CTLA4, but lacks the HYQPY 
motif SH3 domain binding motif, which indicates that it recruits alternative 
proteins. Recent reports have shown that, rather than binding B7-1 or 
B7-2, ICOS binds a new B7 related molecule of previously unknown function called
CD28
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Diagram 6: Schematic showing CD28, ICOS and CTLA4 amino acid sequences and structural motifs.
LICOS (lig an d  of ICOS) or B7.h (Brodie et al 2000). Crosslinking ICOS has been 
demonstrated to enhance T cell proliferation and cytokine production particularly of TH2 T 
cell responses leading to IL-10 production(Hutloff et al 1999).
1.6.3 CTLA4
Cytotoxic T Lymphocyte antigen 4 (CTLA4) shares an overall 31% amino acid homology 
with CD28, with 36% homology displayed by their respective intracytoplamic tails 
(Freeman et al 1993). Although initially thought to deliver supplementary costimulatory 
signals, CTLA4 provides a natural ‘braking’ mechanism which inhibits T cell activation 
(Krummel et al 1995, Walanus et al 1996). CTLA4 is expressed as a homodimer of a 
20kDa protein at low levels on the surface of CD4+ T cells, whilst slightly higher levels 
are detected on CD8+ T cells (Walunas et al 1999). CD28 ligation of CD3 activated cells
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transcriptionally upregulates CTLA4, with surface protein expression appearing at 48 hrs 
post activation (Blair et al 1998). CTLA4 shares specificity with CD28 for the B7 family 
of ligands, with which CTLA4 can associate at a 10 fold higher affinity, and a 100 fold
greater avidity than CD28 (Van der Merwe et al 1997).
CTLA4 contains a core internalisation motif of 9 amino acids which is a tyrosine based 
consensus motif (TGVYVKM) to which a number of proteins are recruited e.g. PDK 
(Schneider et al 1995) SHP1, SHP2 (Myers et al 1996, Marengere et al 1996). 
Internalisation is mediated by AP-1, 2, and 3 adaptor proteins, which initiate endocytosis 
of CTLA4 in clathrin coated pits (Ohno et al 1998, Shiratori et al 1997, Pearce et al 1990) 
Internalisation is negatively regulated by tyrosine phosphorylation at Y 165 by p56lck 
(Bradshaw et al 1997). Consequently, the majority of CTLA4 protein is intra-cellularly 
expressed, co-localising with the peri nuclear golgi apparatus, and upon activation 
trafficking to the plasma membrane at the site of TCR-APC ligation (Linsley et al 1996, 
and Leung et al 1995).
1.6.4 B7 FAMILY LIGANDS
Members of the B7 family of proteins were identified as physiological ligands for CD28 
and CTLA4 (Linsley et al 1991a), and were demonstrated to bind CTLA4 with 20-100  
fold higher affinity than the extracellular domain of CD28 (Linsley et al 1991b). B7.1 the 
first identified family member which was shown to provide co-stimulatory signals for 
antigen activated T cells (Linsley et al 1991a, Gimmi et al 1991) and B7.2 and B7.h have 
since been identified (Boussiotis et al 1993, Freeman et al 1993). B7.1 and B7.2 are Ig 
family members and share just 25% sequence homology (Linsley et al 1991,Guinan et al 
1994). B7.1 is a 60 kDa glycoprotein (30 kDa polypeptide) which consists of the two 
extracellular disulphide linked Ig - like domains, a transmembrane region and a short 
cytoplasmic domain of 19 amino acids (June et al 1994). In contrast, B7.2 is a 70 kDa 
molecule, (34 kDa polypeptide glycosylated) with an extended cytoplasmic domain 
containing phosphorylation sites for protein kinase C (PKC), which may indicate a 
signalling role in APCs (Freeman et al 1993).
B7.2 expression has been detected on resting monocytes whilst expression of both B7 
molecules is found on activated cells of the monocyte, B and T lymphocyte and natural 
killer cell lineages (Guinan et al 1994, Azuma et al 1993, Freeman et al 1993). Differing 
temporal regulation of B7.2 and B7.1 exists, with up-regulation of B7.2 surface
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expression at 72 hours (Azuma et al 1993), whilst B7.1 is detected on the cell surface 3 
days later (Freeman et al 1993). B7.h is a more recently identified member of the B7 
family which is constitutively expressed and may mediate costimulation of ICOS leading 
to IL-10 secretion (Brodie et al 2000).
Multiple reports indicate that their may be different functional consequences of engaging 
CD28 by B7.1 as compared to B7.2. Whilst a role for B7.1 in mediating Th2 T cell 
responses is described, B7.2 may mediate Thl T cell responses (Lenschow et al 1996, 
Matulonis et al 1996). B7.1 and B7.2, co-stimulate equivalent CD3/CD28 dependent 
NFAT mediated transcription, and each can induce phosphorylation of a similar array of 
proteins, including Vav and Cbl (Slavik et al 1999). However, B7.1 mediates more potent 
phosphorylation o f CD28 and PLGyl and induces greater co-association between 
CD28/PI3K, than that observed following liugation by B7.2 (Slavik et al 1999).
1.7 THE COSTIMULATORY SIGNAL
The identity of the biochemical components of the costimulatory signal mediated by CD28 
has been the focus of much research. Evidence exists which suggests that the pathway 
downstream of CD28, is distinct to TCR/CD3 triggered pathways. This notion is evidenced 
by the fact that the CD28 triggered signalling pathway is resistant to the 
immunosuppressant Cyclosporin A (CspA), but sensitive to rapamycin, whilst the 
TCR/CD3 pathway is blocked by CspA (June et al 1987). Further research has 
demonstrated that TCR and CD28 signals may activate unique biochemical targets e.g. the 
CD28 mediated phosphorylation of P62 DOK cannot be detected following TCR ligation 
(Klasen et al 1998). However the identification of common downstream targets of the 
CD28 and TCR signalling cascades may suggest that these signals are similar and that 
they act in an additive fashion. For example signal 1 and signal 2 both mediate the 
phosphorylation of Vav (Tusto et al 1996, Klasen et al 1998).
1.7.1 THE CD28 SIGNAL- IMMEDIATE UPSTREAM EVENTS
CD28 ligation results in the phosphorylation of four tyrosine residues within its 
cytoplasmic tail, mutation of which significantly impairs costimulation (Teng et al 1996). 
The identity of the PTK which mediate CD28 tyrosine phosphorylation is controversial. A 
recent study has shown that a p56Lck SH3 domain mediated association with the proline 
residues in the CD28 tail is essential for activation of p56Lck and costimulation, and that 
costimulation cannot occur in p56Lck deficient cells (Holdorf et al 1999). However previous 
studies which were carried out in p56Lck deficient cells showed that activation of PDK
SECTION 1 - INTRODUCTION 24 
along with elevation of intracellular calcium levels ([Ca ] i) could still be achieved and it 
was suggested that proximal events in the CD28 pathway are independent of src kinases 
and are therefore distinct from those mediated by the TCR (Lu et al 1994).
Other studies supported a role for src family PTKs in CD28 phosporylation as treatment of 
cells with herbimycin A, a src family tyrosine kinase inhibitor, caused the inhibition of of 
IL-2 production, PDK association and the tyrosine phosphorylation of cellular proteins 
after TCR and CD28 stimulation (June et al 1994).
1.7.2 CD28 MEDIATED ACTIVATION OF PDK AND ITS EFFECTORS
The first strong evidence which implicated a role for PDK in T cell costimulatory 
pathways was the rapid and massive accumulation of D3 phospoinositides, in particular of 
PI(3,4,5,) P3, upon CD28 stimulation (Ward et al 1996). Furthermore, pre-treatment of 
primary human T lymphoblasts with nanomolar concentrations of wortmannin, a fungal 
metabolite which irreversibly blocks PDK activity, can inhibit CD28 dependent 
costimulation, resulting in decreased proliferation and IL2 production (Ward et al 1995). 
Further evidence from molecular studies supports the role of PDK in mediating the 
costimulatory signal: disruption of the PDK binding site within the CD28 cytoplasmic tail 
led to abrogated IL-2 production following TCR/CD28 costimulation of a T cell 
hybridoma cell line (Pages et al 1994).
However, several studies have disputed the importance of PDK in CD28 mediated 
signalling pathways. One study suggested that PDKs major role was to mediate receptor 
endocytosis, as mutations that disrupt PDK binding and co-stimulation prevented the 
internalisation of CD28 (Cefai et al 1998). Another group demonstrated that mutation of 
the PDK phosphotyrosine binding site Y 173 failed to block costimulation, whilst mutation 
of an alternative residue Y 188, abrogated IL-2 production (Sadra et al 1999). Furthermore, 
p85a deficient mice which demonstrate multiple B cell defects, exhibit no defects in T cell 
costimulatory repsonses (Suzuki et al 1999). Studies which have employed the acute 
lymphoblastic T cell line Jurkat, also demonstrated that wortmannin treatment failed to 
block IL-2 production (Crooks et al 1995) upon CD28 co-ligation with the TCR. The use 
of the Jurkat T cell line for functional studies is however questionable, as recent work has 
shown that this cell line lacks important regulatory lipid phosphatases (Edmunds et al 
1999, Shan et al 2000).
CD28 /PI3K/TEC KINASE ACTIVATION
CD28 ligation stimulates the tyrosine phosphorylation of ITK and Tec and a physical 
interaction between TEC and ITK through an interaction between the proline rich motif of
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the CD28 intracytoplasmic tail, and the SH3 domain of Tec or ITK has been detected (Lu 
et al 1998) Previous work has demonstrated that ITK has the capacity to elicit tyrosine 
phosphorylation of all four tyrosine residues in the CD28 cytoplasmic tail (King et al
1997). CD28 induced activation of p S b ^  (Marengere et al 1997, and Yang et al 1999), 
and studies indicate that in response to CD28 ligation p56Lck phosphorylates ITK within 
the activation loop of ITK at Y511 (Heyeck et al 1997). Furthermore, p56Lck has been 
demonstrated to phosphorylate the PI3K interaction motif, Y 173 within the CD28 
cytoplasmic tail (King et al 1997). CD28, but not CD3 mediated, ITK activation is PI3K 
dependent (Lu et al 1998). Taken together these reports suggest that the recruitment of ITK 
to the CD28 receptor and its phosphorylation and activation by p56 is dependent on the 
association of PDK D-3 lipid products with the PH domain of ITK (Lu et al 1998). Indeed 
a physical association between ITK and p85 has been detected which appears to be 
mediated through the SH2 domain of ITK (Lu et al 1998). A proposed summary of the 
interplay between PDK p56lck and ITK is depicted in diagram 7.
CD28
PK3A5) P. ITK
Diagram 7: Proposed sequence of events leading to phosphorylation of CD28 by ITK and p56LCK 
1. p561>ck phosphorylates Y 173 of the Cd28 cytoplasmic tail. 2. PDK is recruited to Y173 and is 
activated. 3. PI(3,4,5)P3 association with the PH domain of ITK recruits ITK to the membrane where it 
is activated by p56 and can phosphorylate Y173, Y 188, Y 191, and Y 200.
In strong support of differential regulation of ITK by CD3 and CD28 stimuli, a negative 
regulatory role for ITK in costimulatory signalling has been proposed, which contrasts 
with its role in augmenting phosphorylation of PLCy following TCR ligation, (Liao et al 
al 1997). This suggestion is supported by the fact that ITK deficient T cells exhibit 
elevated In vitro proliferative responses following CD28 ligation (Liao et al 1995, Holdorf
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et al 1998). However further data has shown that Tec kinases are involved in IL-2 and IL- 
4 transcriptional activaty in the CD28 pathway (Yang et al 2000)
CD28 /  PI3K /  PKB PATHWAY
Recent evidence has suggested that CD28 ligation leads to the PDK dependent activation 
of PKB (Parry et al 1997). This, in addition to CD28 up-regulation of Bcl-Xi expression 
further illustrates CD28’s role in enhancing resistance to apoptosis induced by irradiation, 
and CD3 or Fas Ab treatment. PKB has been implicated in the activation of E2F 
transcription factors (Brennan et al 1997), and CD28 has been implicated in cell cycle 
progression. CD28 co-ligation with CD3 upregulates Gi cell cycle kinases (Nagasawa et al
1997), and the degradation of the cell cycle inhibitor p27Kip (Firpo et al 1994) which leads 
to transition from G0 to S phases of the cell cycle.
CD28 /  PD K  /  VAV GTP EXCHANGE ACTIVITY
The Rho family Guanine nucleotide exchange factor Vav is tyrosine phosphorylated upon 
CD28 ligation by p56lck. Phosphorylated Vav couples to the C terminal SH2 domain of 
Grb 2 CD28 can mediate an association with Grb2 through the co-operative binding of the 
Grb2 SH2 and SH3 domains (Kim et al 1998) to the CD28 tail. Interestingly the Grb2 
SH2 domain shares specificity with p85 for binding to the CD28YXXM motif, however 
Grb2 has been reported to interact with CD28 at extremely low stoichiometry (Ramos- 
Morales et al 1994). Accordingly, phosphorylated Vav is detected in association with Grb2 
and CD28 following CD28 ligation (Kim et al 1998) and disruption of the Grb2 SH2 
binding site (Gin193) attenuates this complex (Kim et al 1998), which again correlates with 
a reduction in IL-2 production. CD28 can mediate phosphorylation of Vav at Y 174 which 
enhances its GEF activity, and this is further promoted by the binding of PI(3,4,5)P? 
phosphoinositides to Vav’s PH domain (Han et al 1998). Vav may therefore explain the 
PDK dependency of CD28 mediated DL-2 production (Han et al 1998). Vav is also known 
to complex to the adaptor protein SLP 76 after TCR/CD3 and CD28 ligation, and thus it is 
thought that Vav can couple both of these receptors to Rac signalling in T cells (Han et al
1998).
In summary CD28 induced accumulation of GTP bound Rac can stimulate IL-2 
transcriptional activation via JNK mediated assembly of AP-1 transcription factor 
complexes (See Diagram 8) (Su et al 1994). JNK is the anchor kinase of the Rac/ 
PAK/MEKK1/SEK/JNK signalling cascade.
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Diagram 8: IL-2 transcriptional activation.
TCR mediated signals couple to IL-2 transcription via the Rafl/MEK/ERK cascade MAPK cascade. ERK 
MAPK phosphorylates the ELK-1 transcription factor (a ternary complex factor, tcf) which activates serum 
response factor transcription (SRF), and together tcf and SRF stimulate c-fos transcription. CD28 mediated 
signals activate Rac GTP exchange factor Vav which leads to GTP Rac and GTP CDC42accumulation. In 
turn the recruitment of PAK and MEKK1 protein kinases leads to the activation of the 
PAK/MEKK1/SEK/JNK MAPK cascade. As CD3 mediated signals can also contribute to Rac activation, 
via Ras, the Rac/PAK/MEKKl/SEK/JNK cascade is a point of intersection between signal 1 and signal 2.
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CD28 / PDK / CYTOSKELETON AND SMACS
CD28 has been implicated in the cytoskeletal reorganisation which occurs upon T cell 
APC interaction. Upon initial T cell APC interaction weak associations between a ring of 
TCR and MHC, and CD28 and B7 complexes are stabilised by a high concentration of 
centrally located integrin molecules. Subsequent formation of strong affinity CD28 and 
B7, and MHC/TCR associations inverts the synapse structure such that integrin molecules 
encircle a centrally located group of tightly bound TCR/MHC complexes, which is 
accompanied by the initiation of intracellular signals (Shaw et al 1997, Dustin et al 1999). 
This complex has been termed SMAC (for supramolecular activation cluster). Glycolipid 
enriched motifs exist within this region to which the TCR and CD28 relocalise upon 
receptor ligation (James et al 1999). CD28 can induce major relocalisation of TCR 
complexes to the actin cytoskeleton in a PDK and ATP dependent fashion and may 
potentiate the formation of SMACS (Viola et al 1999). Interestingly the only PKC 
isoform to translocate to SMACS is PKC0 which has been heavily implicated in 
CD28/CD3 costimulation, and interestingly may have a conserved docking site for the 3’ 
phosphoinositide dependent kinase PDK-1 (Brennan et al 2000, Kane et al 2000). In 
addition to PKC0, ZAP-70 and LAT (Lin et al 1999) re-localise to SMACS upon 
TCR/CD28 triggering (Wulfing et al 1998). LAT and Zap 70 have been implicated in 
CD28/CD3 costimulation: co-ligation of CD28 and the TCR results in increased tyrosine 
phosphorylation of LAT, whilst CD28 ligation leads to phosphorylation of LAT in a ZAP- 
70 and Syk independent manner, implicating LAT as a target, and most probably a 
mediator of costimulatory signals (Tsuchida et al 1999).
1.7.3 TRANSCRIPTIONAL REGULATION OF IL-2 BY CD28 
THE CD28 RESPONSE ELEMENT
CD28 ligation via monoclonal abs or physiological ligand, in the presence of phorbol 
esters, can lead to cyclosporin A resistant IL-2 production (June et al 1994) (see diagram
8). The upstream regulatory sequences of the IL-2 gene contain elements which confer 
CD28 responsiveness on IL-2 transcription (Civil et al 1992). These elements, located 
between -160 and -152 bp relative to the transcriptional start site (Fraser et al 1991), have 
been characterised and have been individually designated as the CD28 response element 
(CD28RE) and the NF-IL-2 and AP-1 sites (Civil et al 1992, Shapiro et al 1997).
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The CD28 RE has been demonstrated to bind members of the NFkB family including c- 
Rel, NFkBI, and relA, (Ghosh et al 1993, Shapiro et al 1997). NFkB proteins enter the 
nucleus following CD28 stimulation. Furthermore, in response to costimulation, the 
binding of the transcriptional activator NFAT to this region can co-operate, with NFkB 
family DNA binding factors, in mediating transcriptional up-regulation of the IL-2 
promoter, (Rooney et al 1995, Good et al 1996). Cytokine and chemokine genes encoding, 
IL-8 (Weschler et al 1994), RANTES (Nelson et al 1993) IL-3, granulocyte macrophage 
colony stimulating factor (GM-CSF) and gamma-interferon (IFNy) (Fraser et al 1991) 
contain similar sequences to the CD28RE within their promoter regions, however these are 
less stringently CD28 dependent.
In addition to the factors that bind the CD28RE, CD28 mediated costimulation stimulates 
transcription of c-Jun, via the JNK cascade, which forms the AP-1 heterodimer with c- 
fos, and binds NF-IL2 sites within the IL-2 promotor (Rincon et al 1994). CD28 signals 
are alone insufficient to activate c-jun, and the integration of CD3 and CD28 signals, 
which can be replaced by phorbol ester and calcium ionophore treatment, is required (Su et 
al 1994). AP-1 binds the IL-2 promoter alone, at the NF-IL-2B site, in association with 
NFAT, at the NF-IL2E site, or with octamer proteins, at the NF-IL-2A site proteins 
(Shapiro et al 1997). Together, the CD28RE and the NF-IL-2B sites, which are separated 
by only 2bp, have been shown to synergistically regulate the CD28 mediated component of 
transcriptional activation of the IL-2 gene through the coordinated binding of c-Rel and 
AP-1 proteins, c-fos and c-jun (Shapiro et al 1997).
CD28 AND NFkB
CD28 also activates IkB kinase (IKK), which elicits the phosphorylation and degradation 
of the IkBcl and IkBP proteins that allows the release of NFkB proteins to the nucleus 
(Zandi et al 1997). It was demonstrated that CD28 regulates IKK via MEKK1 which 
colocalises with the IKK, IkB complex (Kempiak et al 1999). MEKK1, is a regulator of 
the Rac and p21 activated kinases/Mekkl/SEK/JNK p38 MAPK cascade, which converges 
on JNK (Kaga et al 1998). Thus, MEKK plays a dual role in regulating IL-2 transcription, 
in eliciting transcriptional activation of c-jun via JNK, and of c-Rel via IKK (Kempiak et 
al 1999). More recently studies have described further routes to IKK activation one of 
which is mediated via Cot Kinase which can activate IKKa, and NIK which in turn 
activates IKKP (Lin et al 1999). Another pathway to IKKp activation is via PKC0 (Lin et 
2000), and a further pathway has been proposed which is PI3K/PKB dependent. It is
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unclear as yet whether the latter pathway lies upstream o f PKC0 and/or Cot kinase (Kane 
et al 2000, Brennan et al 2000).
1.8 THE T CELL INHIBITORY SIGNAL- CTLA4
CTLA4 has been clearly demonstrated in vitro to inhibit murine (Chambers et al 1997) and 
human (Blair et al 1998) T cell proliferation. CTLA4 engagement inhibits induction of 
DL-2 a  receptor chain, CD69 expression and secretion of EL-2 (Chambers et al 1997). 
Characterisation of the inhibitory signal mediated by CTLA4 has been the focus of much 
research. The identification of SHP1 and SHP2 association with CTLA4 suggested a role 
for PTPases in CTLA4 function (Marengere et al 1996, Chambers and Allison 1996), 
which correlated with the observed hyperphosphorylation of TCR/CD3 signalling proteins: 
ZAP-70, CD3£ chain, She, fyn and Lck, in T cells from CTLA4 deficient T cells. Further 
studies have demonstrated that CTLA4 ligation prevents the accumulation of IL-2 mRNA 
via the inhibition of NFAT translocation to the nucleus (Brunner et al 1999). CTLA4 has 
been shown to impair progression of the cell cycle through the inhibiton of the cyclin 
dependent kinases, cdk4 and cyclin D3, (Brunner et al 1996). Furthermore, TGFP has 
been implicated in CTLA4 signalling through the observation that TGFp and 
CTLA4 deficient mice exhibit similar proliferative disorder (Chen et al 1998). Recently, it 
has been demonstrated that CTLA4 can mediate inhibitory signalling independently of 
tyrosine phosphorylation (Cinek et al 2000, Baroja et al 2000). In a further study CTLA4 
has been described to inhibit T cell signalling via two distinct mechanisms: In the presence 
of B7 costimulation, high levels of CTLA4 surface expression antagonise B7/CD28 
interactions independently of the CTLA4 cytoplasmic domain; In the absence of B7 co­
stimulation, low levels of CTLA4 expression mediate inhibitory signals which are 
dependent on the CTLA4 cytoplasmic tail (Baroja et al 2000).
1.8.1 CTLA4 DEFICIENT MICE
CTLA4 deficient mice exhibit a dramatic lymphoproliferative disease, which is lethal at 3- 
4 weeks of age (Tivol et al 1995). These mice exhibit a huge expansion of CD4+ and, in 
particular the generally smaller CD8+, T cell compartments (Waterhouse et al 1995) whilst 
thymocyte development is normal (Chambers et al 1997). The majority of peripheral T 
cells in these mice have an activated phenotype (Chambers et al 1996).
Further reports demonstrated that B7/CD28 interaction is necessary to induce the 
lymphoproliferative phenotype in these mice (Tivol et al 1997, Chambers et al 1997).
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Antibody depletion of CD4+ T cells in CTLA4-/- mice was shown to inhibit the 
lymphoproliferative effect observed and remaining CD8+ cells displayed a normal 
phenotype, whilst CD8 + depletion had no effect on the severity of the disease (Chambers 
et al 1997), which suggested that the lymphoproliferation was strongly CD4 dependent.
1.8.2 CTLA4-IMMUNOTHERAPEUTIC STRATEGIES
Immunotherapeutic strategies have been devised which exploit the regulatory role of CD28 
in the immune system. The blockade of CTLA4 engagement in vivo exacerbates 
autoimmune disease, including autoimmune diabetes (Luhder et al 1998), graft versus host 
disease in CD28'7' mice (Saito et al 1998) and leads to allograft rejection (Lin et al 1998). 
Strategies, which disrupt CTLA4 inhibitory signals, and thus enhance tumour rejection in 
normal mice (Leach 1996), have been utilised, and the successful treatment of prostate 
tumours (Kwon et al 1997) and experimental mammary carcinoma (Hurwitz et al 1998) 
have been reported. CTLA4 blockade has also been shown to result in protective 
immunity to nematode infection (McCoy et al 1997), and Leishmania donovani (Murphy 
et al 1998), whilst CTLA4 has been shown to be necessary for tolerance induction to 
allogeneic skin grafts (Perez et al 1997).
1.9 B LYMPHOCYTE ACTIVATION
Activated B cells produce antibodies, which contribute to the ‘humoral’ immune response. 
Antibodies neutralise and eliminate the specific antigen which elicited their formation. 
The elimination of antigen relies on the combined efforts of the effector mechanisms 
which are elicited by the distinct isotypes of antibody. Mature B cells express antigen 
specific surface bound IgM and IgD immunoglobulin, or B cell receptors (BCR) (Le Bien 
et al 1998). The binding of specific antigen to the BCR activates the B cell leading to the 
proliferation and differentiation of a clonotypic population of antigen secreting B 
lymphocytes. These progeny cells produce antibodies of an array of heavy chain isotypes, 
with the specificity of the progenitor cell BCR, and thus mediate B cell effector function. 
This section describes the intracellular events that follow antigen ligation of the BCR, and 
couple to pathways which lead to B cell proliferation and antibody secretion (Le Bien et al
1998).
1.9.1 BCR STRUCTURE
The B cell receptor consists o f an antigen binding membrane bound immunoglobulin 
component which is non covalently associated with a signal transducing/transporting, 
cytoplasmic substructure composed of disulfide linked dimers of immunoglobulin a  (Iga)
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and immunoglobulin p (Ig-p) (Campbell et al 1991). The Iga  and Igp chains of the BCR 
contain immunoglobulin tyrosine activation motifs which become phosphorylated upoon 
BCR ligation by the constitutively associated Src PTKs Fyn, Blk, lck and Lyn (Gold et al 
1990) which leads to the recruitment of the PTK Syk (Lankester et al 1996). Evidence 
from co-capping and co-modulation studies identified a constitutive association between 
the BCR and a complex containing the CD 19 receptor which is in turn complexed with the 
tetraspan web proteins Leul3/CD21/CD81 (Pesandot et al 1989). Thus, a role for CD 19 in 
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Diagram 9: BCR/CD19 Complex. Antigen ligation induces PTK activation and phosphorylation of the 
ITAMs of the BCR by Syk. CD 19 becomes phosphorylated by constitutively associated PTKs, Lyn and Fyn, 
allowing the association of PLCy, Vav, and p85. Association of She with the BCR Iga chain allows its 
phosphorylation, and association with the SH2 domain of Grb2, which recruits SOS to the membrane via its 
association with the SH3 domain of Grb2. The assembly of these protein complexes results in the 
mobilisation of intracellular calcium, activation of PKC, activation of Ras and Rac effector pathways and the 
recruitment of PH domain containing proteins to the membrane.
1.9.2 CD19
CD 19 is a 95 kDa membrane bound glycoprotein that belongs to the Ig superfamily. It is 
expressed on B cells, at gradually increasing levels with maturation. Structurally CD 19 
has two immunoglobulin domains and an extensive cytoplasmic tail which comprises nine 
tyrosine motifs (Tedder et al 1989). CD 19 is expressed prior to BCR expression and 
transmits signals throughout the different stages of B cell ontogeny. CD 19 is 
phosphorylated in a ligation dependent manner by constitutively associated PTKs, lyn and
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fyn  (Uckun et al 1993). Tyrosine phosphorylated motifs within the CD 19 intra- 
cytoplasmic tail act as docking sites for SH2 bearing molecules. The SH2 domain of Vav 
proto-oncogene product binds the Y393 EEP motif in the CD 19 tail (Songyang et al 1994), 
and is thought to contribute to the phosphorylation of M ekl and activation of the MAPK 
pathway in B cell pre-cursors (Weng et al 1994). CD 19 bears two YXXM motifs 
(Tyr484Gln - Asp-Met and Tyr5,5-Glu-Asn-Met) (Zhou et al 1991), which have specificity 
for the SH2 domains of PI3K, and the presence of CD19/Vav/ PI3K complexes have been 
detected in B cell pre-cursors (Shanafelt et al 1995).
1.9.3 BCR LIGATION VERSUS BCR/CD19 COSTIMULATION
CD 19 has been heavily implicated in the costimulation of BCR mediated signalling 
pathways (see diagram 9). Whilst BCR stimulation alone leads to elevated calcium 
mobilisation (Buhl et al 1998), and activation of ERK/MAPKs (Li et al 1997, Li et al
1998). Co-ligation of CD 19 and the BCR synergistically enhances Map kinase activation 
(Li et al 1998) association and activation of PI3K (Tuveson et al 1993) and calcium 
mobilisation (Carter et al 1991). Co-ligation of the BCR and CD 19 is thought to lower the 
threshold for B cell activation by two orders of magnitude (Dempsey et al 1996).
The in vivo significance of CD 19/BCR co-stimulation has been illustrated in knock-out 
studies where it appears that CD 19 is essential for germinal centre development, and 
maintenance of the B1 peritoneal subset of the B cell population. CD 19 knockout mice 
exhibit normal B cell development, but impaired responses to antigens and reduced levels 
of circulating immunoglobulins (Ricket et al 1995, Engel et al 1995).
1.10 BCR EFFECTOR PATHWAYS
1.10.1 BCR MEDIATED MAP KINASE ACTIVATION
BCR ligation has been described to induce MAPK activation via several routes:
Firstly, BCR ligation results in the assembly of Grb2/ Shc/SOS complexes (see diagram
9) following the phosphorylation and recruitment of She to the Iga and Igp chains of the 
BCR. This leads to the accumulation of active GTP-bound Ras (Saxton et al 1994, 
Harwood et al 1993) which can mediate the Raf /MEK /ERK MAPK pathway (Tordai et al 
1994, and Li et al 1998). The existence of additional or more significant pathways 
coupling the BCR to MAPK activation was suggested following the observation that there 
is no great decrease in BCR induced MAPK activation in Grb2 deficient B cells (Harmer et 
al 1999). Thus a second pathway, is suggested to lead to MAPK activation downstream of
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the BCR in which PKCa mediates Grb2 independent phosphorylation of Raf (Kolch et 
1993).
A third route by which MAPK activation could be achieved following BCR ligation 
involves Vav (Gulbins et al 1997). VAV acts as a GTP exchange factor for Rac /CDC42 
family GTP binding proteins which can augment the activity of PAK and MEK1 kinase 
(MEKK). PAK and MEKK elicit phosphorylation of MEK 1, which synergises with Raf 
mediated activation of MEK1 to upregulate ERK activity (Yan et al 1994, Lange-Carer et 
al 1993).
The exact pathway/s by which the enhanced phosphorylation of ERK arises following 
simultaneous CD 19 and BCR ligation are unclear, however it is not accompanied by 
enhanced Ras or Raf activation, and is calcium independent and insensitive to PKC 
inhibition. Additionally, although reports have described Vav elicits synergistic activation 
of the MAPK cascade following BCR and CD 19 co-ligation (Li et 1997), this has been 
disputed by studies performed in Vav mutant mice (O’Rourke et al 1998).
1.10.2 BCR MEDIATED ACTIVATION OF PI3K EFFECTORS
BCR ligation results in the accumulation of the PI3K D3 phosphoinositide products 
PI(3,4)P2 and PI(3,4 ,5)P3 (Gold et al 1994). PI3K activation is considered to occur upon 
co-association with the conserved tyrosine residues within the YXXM motif of CD 19 
which is phosphorylated in response to BCR ligation (Carter et al 1997, Tuveson et al
1993). Mutational studies have demonstrated that disruption of Y482 of the CD19 tail 
abrogates the PI3K/CD19 co-association and abrogates PI3K activity (Carter et al 1997). 
It has been reported that p85 may also interact with the BCR Ig a and IgP chains (Clark 
1992), and that PI3K can be activated in vitro by Fyn and Lyn binding via their SH3 
domains to proline rich regions of p85 (Chalupny et al 1995). Evidence suggests however 
that PI3K is activated predominantly via CD19, as CD19 -/- B cells display a similar 
deficiency in BCR mediated signalling to that observed following wortmannin treatment of 
wild type B cells (Buhl et al 1997).
Studies in which the p85a adaptor subunit of PI3K is disrupted, further implicate PI3K in 
pathways leading to B cell development, survival, and proliferation. Lymphocytes from 
p85-/- deficient mice display severely impaired B cell development and have a reduced 
number of mature B cells in the peripherary, reduced serum Ig levels and a complete
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absence of the CD5+ B1 sub-population of B cells (Suzuki et al 1999 and Fruman et al
1999).
BCR/PI3K/BTK/ ACTIVATION
The B cell Tec family kinase (See diagram 2) BTK has been implicated as a BCR activated 
PI3K target that mediates calcium mobilisation in B cells through the phosphorylation of 
PLCy2 (Fluckiger et al 1998, Buhl et al 1999). The membrane localisation of BTK is 
directed, in response to BCR ligation, by the association of PI(3,4,5)P3 with the BTK PH 
domain. This mediates the approximation of BTK with membrane localised Src and Syk 
PTK activity (Vamai et al 1999).
Evidence that BTK activation lies downstream of CD 19 activated PI3K, may be drawn 
from studies in which BTK activation was abrogated in cells carrying a targeted disruption 
of the CD19-PI3K SH2 binding motif (Buhl et al 1999). Accordingly, in a CD 19 deficient 





Diagram 10: BLNK the B cell homologue of SLP76. In B cells Blnk is a structural homolog of SLP76. It 
shares the capacity of SLP76 to associate withGrb2 Vav and PLCy. Blnk/Slp65 is an additional target for 
Syk PTK activity, and following its phosphorylation, Blnk can act as a cytosolic adaptor protein, recruiting 
PLCy. BCR ligation also leads the phosphorylation of Btk by Blk. Btk is recruited to the membrane and into 
the vicinity of Blk via the association of PI(3,4,5)/>3 with its PH domain.
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in response to BCR ligation (Buhl et al 1999). Further, the similarity between impaired 
BCR triggered calcium responses, observed in cells from Xid mice, CD 19-/- deficient cell 
lines, Y484 Y515CD19 mutant cell lines (Buhl et al 1999) and p85a-/- mice (Suzuki et al 
1999, Fruman et al 1999) supports the CD 19 and PI3K dependency of BTK activation. 
BTK has been shown to bind the BLNK protein (see diagram 10), which is the B cell 
homologue of SLP-76, via the BTK SH2 domain and mutation of BTK SH2 domains has 
been shown to inhibit calcium mobilisation (Takata et al 1996). Additionally mutation of 
BLNK has been demonstrated to prevent PLCy activation, calcium mobilisation and 
MAPK activation (Ishiai et al 1999). Thus it has been proposed that upon BCR ligation 
BLNK is phosphorylated by Syk, whereupon it is able to mediate an interaction between 
the SH2 domain of BTK, and PLCy (Ishiai et al 1999).
The physiological importance of BTK in B cells is emphasised by B cells from Xid mice 
which carry a Cys-Arg mutation within the PH domain of BTK (Fukuda et al 1996) which 
causes impaired B cell development, high levels of BCR expression, and low serum Ig 
levels (Lindsberg et al 1991). In humans, a more expansive mutation, is the causative 
factor of the severe immunodeficieny, X-linked agamma-globulinaemia (XLA), and is 
characterised genetically by deletions and insertions in various BTK regions, including the 
SH3 domain (Zhu et al 1994). The aetiology of this deficiency is defined by arrest at 
early stages of B cell development, drastically reduced numbers of peripheral B cells 
which express high levels of surface IgM, and decreased circulating serum Ig levels 
(Vihinen et al 1997).
BCR/PI3K/PKB PATHWAY
PKB has been shown to be activated following BCR ligation in murine and human B cells 
(Gold et al 1999). PKB activation mediated via the BCR was shown, as in other systems 
(Cross et al 1995), to lead to the phosphorylation of GSK3 Astoul et al 1999) which 
correlated with the inactivation of GSK-3 enzymatic activity demonstrated in a further 
study (Gold et al 1999). Furthermore, using DT40 PTK deficient cell lines, it was shown 
that both lyn and syk kinase activity are required for PKB activation in B cells (Gold et al
1999). Furthermore it was demonstrated that BCR ligation, mediates the rapid and transient 
tranclocation of PKB to the membrane, whilst the activation of PKB kinase activity and 
PKB mediated phosphorylation of its downstream effector GSK3, are sustained for over 
one hour (Astoul et al 1999). Interestingly, constitutively active PI3K was shown to be 
sufficient to induce the transient recruitment of PKB from the nucleus and cytosol to the 
membrane, and sustain PKBs’ enzymatic activation (Astoul et al 1999).
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1.11 FCyRIIB M EDIATED IN HIBITIO N  O F B LY M PH O CYTE A CTIV ATIO N
1.11.1 STRUCTURE / FUNCTION OF THE FCyRIIB ITIM
The FCyRIIB receptor is the low affinity inhibitory receptor for the immunoglobulin G 
constant region. The FCyRIIB bears a single immunoglobulin inhibitory tyrosine based 
motif (ITIM). This is a conserved 13 amino acid motif which is necessary and sufficient 
for inhibitory signalling in B cells. Within the ITIM the amino acid sequence: tyrosine- 
serine-leucine -leucine (Y309SLL) is phosphorylated upon BCR / FCyRIIBco-ligation 
(Muta et al 1994, Kiener et al 1997). Although only one form o f FCyRIIB receptor has 
been identified in mice, humans express two isforms, the FCyRIIB 1 and the FCyRIIB2 
which has a deletion of 19 amino acids between the ITIM and the trans-membrane region 
(Sarmay et al 1997).
Under physiological conditions the FCyRIIB mediates low affinity association with IgG 
FC regions. At high serum Ig levels a single IgG molecule can co-ligate the FCyRIIB and 
the BCR, via the IgG FC region and antigenic epitopes respectively (Morgan et al 1978). 
In this manner signalling through a variety of receptors including the BCR, and TCR, 
FCRI and FCRIII is inhibited (Daeron et al 1995). Targeted disruption of the FCyRIIB 
receptor showed its essential function in controlling anaphylactic responses in mice, and 
preventing autoimmunity and hyperglobulinaemia (Takai et al 1996). Co-crosslinking the 
BCR with the FCyRIIB generates an inhibitory signal which abrogates proliferation and 
differentiation of B lymphocytes. The underlying mechanisms which lead to the inhibition 
of B cell signalling are not fully understood. A summary of the biochemical events that 
follow BCR/FCyRIIB co-ligation are outlined in the following sections:
1.11.2 ASSOCIATION OF SH2 CONTAINING MOLECULES WITH THE FCyRIIB 
ITIM
In murine B cells co-ligation o f the FCyRIIB with the BCR leads to the co-association 
and and activation of the lipid and protein phosphatases SHIP, SHP1 and SHP2 with the 
phosphorylated ITIM (Sarmay et al 1997) (see diagram 11). The avidity of their 
interactions decreases thus: SHIP> SHP2> SHP1 (D’Ambrosio et al 1995). Assembly of 
these proteins at the membrane brings them into proximity with the activating receptor and 
its associated signalling complexes, upon which the ITIM binding molecules presumably 
exert their effects. In other murine cell types the FCyRIIB ITIM has different specificities,
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eg; in bone marrow derived mast cells FCyRIIB receptors co-aggregated with FCsRl 
selectively binds to SHIP (Fong et al 1996).
SHP1


















Diagram 11: BCR/CD19 Coligation with the FCyRIIB. Simultaneous ligation of the BCR with antigen 
and the FCyRIIB ligation with antibody leads to the phosphorylation of the FCyRIIB ITIM, and the 
subsequent recruitment of SHIP SHPI and SHP2 to the ITIM. SHIP is implicated in the abrogation of MAPK 
signalling pathways and calcium mobilisation whilst SHPI is thought to mediate de-phosphorylataion of 
CD 19. A role for SHP2 in inhibitory signalling cascades still remains to be defined.
phosphatase domain and C terminal tyrosine phosphorylation sites (Shen et al 1991). SHPI 
phosphatase activity is upregulated upon its association with the phosphorylated ITIM 
(D’Ambrosio et al 1995). Indeed the de-phosphorylation of CD 19 was thought to be 
attributable to the phosphatase activty of SHPI (Kiener et al 1997). Mutations in the SHPI 
gene, carried by motheaten lead to aberrant FCyRIIB inhibiton of BCR signalling 
(D’Ambrosio et al 1995, Olcese et al 1996). Conflicting evidence is presented by studies 
which showed that SHPI was dispensable for FCyRIIB mediated signalling, as in SHPI 
deficient DT40 cells normal calcium mobilisation and NFAT translocation to the nucleus 
was observed (Ono et al 1997).
SHP2
SHP2 is an SH2 domain containing phospho-tyrosine phosphatase (PTPase) which 
displays two N terminal SH2 domains, and a C terminal catalytic domain. SHP2 is
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ubiquitously expressed (Feng et al 1993, Freeman et al 1992), and multiple studies in 
haemopoietic cells have shown that SHP2 is subject to tyrosine phosphorylation in 
response to multiple growth factors and cytokines (Gadina et al 1998, Welham et al 1994). 
SHP2 can physically associate, via its SH2 domains with growth factor and cytokine 
receptors (Yamauchi et al 1995, Lechleider et al 1993, Tauchi et al 1996, Bone et al 1997), 
IRS-1 (Kuhne et al 1993), CrkL (Chin et al 1997), the PI3K p85 adaptor sub-unit (Welham 
et al 1994, Craddock and Welham 1997, Zhang et al 1999) and Gab2 (Gu et al 1998). 
Tyrosine phosphorylated SHP2 has also been reported to associate with Grb-2 and SHIP 
(Bennett et al 1994, Welham et al 1994, Liu et al 1996).
Efforts to identify PTPase substrates for SHP2 have putatively indicated that Gab2 
(Craddock and Welham 1997, Zhang et al 1998, Gadina et al 1999, Frearson et al 1998) 
G abl (Holgado Madruga et al 1996, Nakamura et al 1998), and SIRP (Stofega et al 1998, 
Kharitonenkov et al 1997) may be subject to PTPase activity directed by SHP2. SHP2 has 
been implicated in immediate early, and late signal transduction which elicits progression 
of the cell cycle (Bennett et al 1996), in cell survival (Pazdrak et al 1997) and in 
mitogenesis (Xiao et al 1994). SHP2 is thought to mediate enhanced Ras activation 
leading to MAPK activation via its interactions with Grb2, and Gab2 (Noguchi et al 1994, 
Bennett et al 1996, Li et al 1994, Gu et al 1998, Nishida et al 1999).
Relatively little is understood o f SHP2 function in mediating FCyRIIB inhibitory signals. 
SHP2’s stimulatory role in other systems, suggested that it may mediate a positive role in 
B cells (Tamir et al 2000). However studies which used decoy proteins to block SHP2s 
association with the ITIM demonstrated an inhibitory role for SHP2 in ERK 
phosphorylation and calcium mobilisation (Nakamura et al 2000). Efforts to identify 
proteins with which SHP2 may associate in B cells have indicated an association between 
SHP2 and Gabl which is enhanced following BCR ligation (Nakamura et al 1998, 
Nishida et al 1999).
1.12 FCyRIIB INDUCED NEGATIVE REGULATION OF PI3K ACTIVITY
1.12.1 FCyRIIB AND SHIP- INHIBITION OF PIP3 ACCUMULATION
Upon FCyRIIB co-ligation SHIP is recruited via its SH2 domain to the phosphorylated
TOO
tyrosine residue in the ITIM (Muta et al 1994). This association leads to the rapid and 
substantial tyrosine phosphorylation of the lipid polyphosphate 5 ’-phosphatase, SHIP 
(Chacko et al 1996). SHIP phosphorylation correlates with an upregulation of SHIPs’ 
catalytic activity (Sarmay et al 1997) and its subsequent recruitment of tyrosine
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phosphorylated She (Liu et al 1997). SHIP has been implicated in negative signalling 
following BCR /FCyRIIB co-ligation through its enzymatic degradation of PI(3,4,5)P3, the 
PI3K metabolic product to PI(3,4)P2 (see diagram 12) and therefore SHIP could be 
responsible for the reduced accumulation of this lipid under negative signalling conditions 
(Scharenberg et al 1998).
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Diagram 12: Enzymatic function of SHIP in calcium signalling.
Co-ligation of the BCR with the FCyRIIB, via simultaneous occupancy by antigen and antibody 
respectively, allows the phosphorylation of the FCyRIIB ITIM, which subsequently recruits, and elicits 
the phosphorylation of SHIP. SHIP catalytic activity acts to reverse the accumulation of PI (3,4,5)P3, 
leading to the production of PI(3,4)2. The lack of PI(3,4,5)P3 at the cell membrane prevents the 
recruitment of Btk and significantly attenuates calcium mobilisation.
Multiple reports argue that SHIP is the predominant inhibitory effector molecule that 
mediates FCyRIIB’s modulation of BCR signalling. One such study blocked SHIP binding
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to the ITIM using SHIP decoy proteins and demonstrated the abrogation of SHIP’S 
recruitment of She, and inhibition of PI(3,4 ,5)P3 accumulation, calcium mobilisation, and 
Erk activation (Nakamura et 2000). Furthermore, in a SHIP deficient DT40 chicken B cell 
line it was shown that SHIP is an absolute requirement for FCyRIIB mediated inhibition of 
calcium signalling (Ono et al 1996 and Hashimoto et al 1999), and the calcium dependent 
re-localisation of NFAT to the nucleus. In addition mutation of the SH2 binding tyrosine 
residue of the ITIM or mutation of SHIP’S catalytic activity can also prevent inhibition of 
BCR mediated pathways (Aman et al 2000). SHIP has also been implicated in apoptosis: 
SHIP recruitment attenuates a proapoptotic signal initiated by FCyRIIB BCR coligation 
(Ono et al 1996). A later study demonstrated that FCyRIIB can signal independently of 
BCR coligation to directly mediate an apoptotic response, requiring only an intact 
transmembrane domain. Failure to recruit SHIP, either by deletion of SHIP or mutation of 
FCyRIIB, results in enhanced FCyRIIB-triggered apoptosis (Pearse et al 1999).
1.12.2 FCyRIIB MODULATION OF BCR / PI3K / PKB PATHWAYS
FCyRIIB co-ligation with the BCR negatively regulates PKB activation, and this is thought 
to be mediated through SHIP by the hydrolysis of PI(3,4 ,5)P3 (Astoul et al 1999). 
Accordingly, FCyRIIB co-ligation inhibits the membrane localisation and enzymatic 
activity of PKB (Astoul et al 1999).
Studies in SHIP deficient Avian B cells showed that SHIP is essential for FCyRIIB co­
ligation induced inhibition of PKB activation, and GSK3 inhibition (Jacob et al 1999). 
Similarly in FCyRIIB deficient cells, which could not activate SHIP, impaired negative 
regulation of PKB was evident (Aman et al 1998), further indicating that SHIP is an 
essential component in the negative regulation of PKB.
1.12.3 FCyRIIB MODULATION OF PI3K / BTK AND PLCy
Co-ligation o f the BCR and FCyRIIB abrogates PLCy phosphorylation which in turn leads 
to the inhibition of IP3 production (Bijsterbosch et al 1985, Sarkar et al 1996) and the 
sustained extracellular influx of calcium that occurs in response to BCR ligation (Diegel et 
al 1994). The degradation of PI(3,4 ,5)P3 by SHIP in response to FCyRIIB ligation is 
thought to prevent recruitment of the PH domain containing protein BTK to the membrane 
where it is further activated by PTK activity (Scharenberg et al 1998). The abrogation of 
BTK phosphorylation o f PLCy (See diagram 12) (Scharenberg et al 1998), and the 
subsequent inhibition of PI(4,5)P2 hydrolysis mediated by PLCy, may be responsible for 
the diminished calcium responses observed following BCR/FCyRIIB co-ligation (Falasca
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et al and Scharenberg et al 1998, Ono et al 1996). Accordingly, overexpression of a BTK 
membrane associated chimaera can reverse the inhibitory effects of FCyRIIB co-ligation; 
membrane expression of SHIP, or wortmannin inhibition of PI3K on BCR triggered 
calcium signalling (Bolland et al 1998). In further support of a role for BTK in calcium 
mobilisation it was shown that deletion of SHIP increased the membrane localisation of 
BTK, via elevated PI(3,4,5)P3 accumulation (Bolland et al 1998).
1.13 FCyRIIB INHIBITION OF MAPK CASCADE
1.13.1 FCyRIIB / SHIP / SHC
FCyRIIB results in the inhibition o f Ras (Sarmay et al 1996), Raf-1 induction (Moodie et 
al 1994) and Erk activity (Campbell et al 1995). SHIP is thought to compete with Grb2 for 
binding to She and thus could be responsible for the decrease in GTP bound Ras observed 
on FCyRIIB co-aggregation. (Tridandipani et al 1997). The recruitment of She by SHIP is 
mediated by a bidentate interaction which occurs between i) the NpxY motif of SHIP and 
the PTB domain of tyrosine phosphorylated She, and ii) the SHIP SH2 domain binding 
the doubly phosphorylated residues Y239 and Y240 of She ((Harmer et al 1999, Liu et al 
1997, Pradhan et al 1997). SHIP knockout mice lend support to a role for SHIP in the 
abrogation of MAPK as in the absence of SHIP, FCyRIIB co-aggregation does not inhibit 
ERK phosphorylation (Liu et al 1998).
1.13.2 FCyRIIB / P62 DOK / RAS GAP
A further route has been proposed to inhibit MAPK activation upon BCR/FCyRIIB co­
ligation. In addition to regulation by GEF’s the inactivation of the intrinsic GTPase activity 
of Ras is thought to be essential for its full activation and maintenance of a GTP bound 
state. Ras GAP is a Ras GTPase which has been shown to enhances the GTPase activity 
of Ras causing the hydrolysis of GTP to GDP (Lazarus et al 1998). Upon BCR ligation 
Ras Gap is thought to bind the tyrosine phosphorylated adaptor protein p62-Dok-l via a 
PTB domain mediated interaction (Yamanashi et al 1997). FCyRIIB co-ligation further 
enhances the phosphorylation of p62 which enhances its interaction with Ras Gap via aa 
260-482 in the p62 Dok-1 tyrosine rich motif. In addition p62 Dok-1 and SHIP co­
associate via the p62 Dok-1 PTB domain (aa 1-259) which presumably binds one of 
SHIP’S NPXY motifs (Tamir et al 2000). Phosphorylation of p62 Dok-1 is dependent upon 
both SHIP and an intact ITIM, suggesting that SHIP mediates p62 Dok-1 association with 
the ITIM and thus proximity with FCyRIIB activated PTKs. The inhibition o f Erk activity 
correlates with Ras Gap p62 association but not SHIP p62. This is thought to occur 
independently of She as She and SHIP are thought to exist in distinct complex to p62 Dok-
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1 and Ship (Tamir et al 2000). B cells from p62 Knock out mice show impaired FCyRIIB 
mediated inhibition of ERK activation which further supports a role for p62 Dok-1 in 
regulating Ras activity via Ras Gap.
1.14 A IM S A N D  O B JE C T IV E S
The delineation of mechanisms, which regulate signal transduction pathways in T and B 
lymphocytes, is essential in order that immunotherapeutic strategies leading to 
manipulation of the immune system can be designed. PI3K has been widely implicated in 
the biochemical events which characterise T and B lymphocyte activation(Reif et al 1996, 
Klippel et al 1997, Tuveson et al 1993). However, data that has questioned the 
significance of PI3K in T lymphocytes has arisen from studies in which p85 deficient mice 
were generated. Whilst p85 deficient B cells exhibit profoundly heightened immune 
responses and basal levels of activation, T cells from these mice were shown to be 
phenotypically normal (Suzuki et al 1999, Fruhman et al 1999). Similarly, further studies 
which examined the regulation of PI3K lipid product accumulation in SHIP deficient mice 
again identified a normal signalling phenotype in T cells, whilst B cell responses were 
perturbed (Liu et al 1999, Helgason et al 1998).
The primary objective of this study was to further investigate the intracellular pathways that 
regulate PI3K activity in T and B lymphocytes downstream of CD28 and the BCR.
The aims of this study were four fold:
1) To examine the differential recruitment of PI3K catalytic isoforms p i 10a, p i 10p, 
and p i 105 to the T cell costimulatory receptor CD28. The identification of p i 105, 
a novel isoform of PI3K which displays a restricted tissue distribution, in 
haemopoietic cell lineages, poses many questions as to the role of this isoform in 
Lymphocytes.
2) To investigate the regulation of the SH2 containing inositol 5’-(poly)phosphatase 
(SHIP) mediated by CD28 and CTLA4 initiated signalling cascades in T 
lymphocytes.
3) In an effort to explain the data from studies which have claimed that PI3K does not 
play a significant role in the leukaemic T cell model, Jurkat, this study will 
examine the regulation of 3’-phosphoinositdes accumulation in this cell line.
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Using the A20 B cell lymphoma cell line this study will examine the nature of the 
FCyRIIB signalling cascade with regard to its inhibition of BCR mediated PDK  
dependent signalling cascades.
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pGST-SH2-SHIP Generous gift from Mark Coggeshall, Ohio state 
University USA. GST tagged SH2 domain of SHIP 
expressed in pGEX vector.
pGST-NSH2-p85 Generous gift from Dr Melanie Welham, University of 
Bath, UK. GST tagged N terminal SH2 domain of p85 
expressed in pGEX vector.
pGST-CSH2-p85 Generous gift from Dr Melanie Welham, University of 
Bath, UK. GST tagged C terminal SH2 domain of p85 
expressed in pGEX vector.
pGFP-PKB Generous gift from Julian Downward, ICRF, London, 
UK. GFP tagged PKB expressed in pEGFP vector.
pGFP- R25CPKB Generous gift from Julian Downward ICRF, London, 
UK GFP tagged PKB PH R25C mutant expressed in 
pEGFP vector.
pGST-SH2-SHP2 (FL) Generous gift from Dr Helen Wheadon, University of 
Bath, UK. GST tagged SHP2 N and C terminal SH2 
domains expressed in pGEX2T vector .
pGST-SH2-SHP2 (C) Generous gift from Dr Helen Wheadon, University of 
Bath, UK. GST tagged SHP2 C terminal SH2 domain 
expressed in pGEX2T vector.
pGST-SH2-SHP2 (N) Generous gift from Dr Helen Wheadon, Bath 
University, UK. GST tagged SHP2 N terminal SH2 
domain expressed in pGEX2T vector.
prCD2- SHIP Generous gift from Doreen Cantrell, ICRF, London, 
UK. rat CD2 transmembrane domain with SHIP 
catalytic core (364-825aa) expressed in pEF BOS.
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prCD2- C671A SHIP Generous gift from Doreen Cantrell ICRF, London, 
UK., CD2 transmembrane domain with point mutant 
C/A671 SHIP catalytic core (364-825 aa) expressed in 
pEF BOS.




Geneorous gift from Bart Vanhaesebroeck, Ludwig 
institute London. Recombinant proteins comprising 
bovine p85 coupled to human p i 10 subunits. 
Expressed in SF9 cells and purified using Actigel 







Mouse monoclonal Carl June, Naval medical 
research institute, 
Bethesda, USA.
F(ab’)2 anti mouse IgG Rabbit polyclonal Zymed, USA
anti mouse IgG Rabbit polyclonal Zymed, USA.
anti-CTA4 (3D6) Mouse monoclonal Carl June, Naval medical 
research institute, 
Bethesda
anti-CTLA4 (CT29) Mouse monoclonal Carl June Naval medical 
research institute, 
Bethesda
anti-CD28 (9.3) Mouse monoclonal Carl June, Naval medical 
research institute, 
Bethesda
anti-p85a Mouse monoclonal Doreen Cantrell, ICRF, 
London.
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anti-pll05 Rabbit polyclonal Bart vanhaesebroeck, ludwig 
institute, london
anti-pllOp Rabbit polyclonal Santa Cruz
anti-pllOa Goat polyclonal Santa Cruz
anti-SHIP Goat polyclonal Santa Cruz
anti-SHIP 
(aa 874-941)
Rabbit polyclonal Mark Coggeshall, Ohio state 
university, OH.
anti-hCD3 UCHT1 Mouse monoclonal Generous gift from Doreen 
Cantrell, ICRF, London, UK.
anti-mCD3 2C11 Mouse monoclonal Daniel Olive, INSERM, 
Marseille.
anti-mFCYRIII/II mAb Rabbit polyclonal Pharmingen San Diego, USA.
purified mIgG2a Mouse monoclonal Sigma, Poole, Dorset
anti-CTLA4 (CT29) Mouse monoclonal Carl June, Naval medical 
research institute, Bethesda
anti-CTLA4 (3D6) Mouse monoclonal Carl June, Naval medical 
research institute, Bethesda
anti-ratCD2 (0X34) Mouse monoclonal Doreen Cantrell, ICRF, 
London,UK.
anti-phospho ERK 1/2 Rabbit polyclonal NEB, New England, USA.
anti-ERKl/2 Rabbit polyclonal NEB, New England, USA.
anti-phosphotyrosine
(4G10)
Mouse polyclonal Upstate Biochemical Industries, 
NJ, USA.
anti-p62 DOK1 rabbit monoclonal Santa Cruz,
anti-Gab2 Rabbit polyclonal Upstate Biochemical Industries, 
NJ, USA
anti-SHP2 Rabbit polyclonal Santa Cruz,
anti Rabbit-FITC Goat polyclonal Sigma, Poole UK.
anti mouse-FITC Rabbit polyclonal Sigma, Poole, UK.
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anti-GST Mouse monoclonal Upstate Biochemical Industries
anti- CD19 Rat monoclonal Sigma, Poole, Dorset
anti-MHCDR abL243 Rabbit polyclonal Dave Sansom, Bath University 
Bath UK.
anti-mouse HRP Rabbit polyclonal DAKO, Denmark.
anti-Goat HRP Sheep polyclonal DAKO, Denmark.
anti-Rabbit-HRP Sheep polyclonal DAKO, Denmark.
anti-CD14
(UCHM1)
Rabbit polyclonal Dave Sansom, Bath University, 
Bath UK.
anti-mouse IgG coated 
magnetic beads.
Sheep polyclonal Dynal, Merseyside,UK.
2.1.3 GENERAL REAGENTS
REAGENT SOURCE
[32P]-orthophosphoric acid 5 mCi/ml NEN, Stevenage UK.
[32P]y-ATP 5 pCi/ml NEN, Stevenage, UK
[’H]- inositol [1,3,4,5]- tetrakisphosphate NEN, Stevenage UK
2-Mercaptoethanol Sigma,Poole UK.
3MM filter paper Whatmann, UK
Acetone BDH, Poole, UK.
Acrylamide Biorad,
Agarose (Molecular Biology grade) Sigma,Poole UK.




Bovine Foetal calf serum (heat inactivated) Gibco, BRL
BSA (Tissue culture grade) Sigma,Poole UK.
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Butanol BDH, Poole Uk.
Calcium Chloride Fisher, Loughborough, UK.
Chloroform BDH, Poole U.K.
Cryovials NUNC, UK.
Dabco Sigma, Poole, UK.
DMEM with L Glu without Na Pyruvate, 
without Na bicarbonate
Sigma, Poole, UK








Ethidium bromide Sigma, Poole UK.
Ethyl Formate, Fisher scientific, UK
Flo-Scint IV liquid scintillant Canberra Packard, UK.
Folsch lipids Sigma, Poole, UK
Fungizone Gibco BRL
Glacial Acetic Acid BDH, Poole, UK.
Glucose Fisher, Loughborough, Uk
Glutathione Sigma, Poole, UK
Glutathione Sepharose Pharmacia, UK.
Glycerol Sigma,Poole UK.
p-Glycerophosphate Sigma, Poole, UK.
HBSS (without calcium and magnesium) Gibco, Paisley UK.
HC1 BDH, Poole Uk.
Heparin Fisons, loughborough UK
HEPES (1M) Sigma, Poole, Dorset
HPLC column (SAX partisphere) Whatmann, UK.
Iodine Sigma, Poole, UK
Iodoacetamide Sigma, Poole, UK.
Kanamycin Sigma,Poole UK.
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KC1 BDH, Poole, UK
KH2PO4 BDH Poole, UK
LB Agar Sigma, Poole, UK.
LB broth (miller) Sigma, Poole, UK.
Leupeptin Sigma,Poole UK.
Lithium Chloride Sigma,Poole UK.
Magnesium chloride BDH Poole, UK
Manganese Chloride BDH Poole, UK
Marvel Supermarket
Methanol BDH, Poole, UK
Methanol BDH Poole, UK
Methylamine (25%-30% in dH20) Fisher, Loughborough, UK.
Methylamine (25%-30% in dH20) Fisher Loughborough, UK




NaF Sigma, Poole UK.
Nitrocellulose BDH, Poole, UK
NP40 BDH, Poole, UK
Paraformaldehyde Sigma,Poole UK.
Pen/Strep Gibco BRL, Paisley, UK.
Pepstatin Sigma,Poole UK.
Petroleum ether (bp 40-60 °C) BDH, Poole UK.
Phenyl Methyl Sulfonyl Flouride Sigma,Poole UK.
Phosphatidyl inositol Sigma, Poole, UK
Phosphatidyl serine Sigma, Poole, UK
Phosphoric acid Fisher, UK
PMA Calbiochem, Nottingham 
UK.
Poly L lysine coated slides BDH, Poole UK
Ponceau S Sigma, Poole, Dorset
Potassium Acetate Sigma,Poole UK.
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Propan-2-ol BDH Poole, UK
Propan-I-ol BDH Poole, UK
Protein A sepharose Pharmacia, Uk
Protein G sepharose Sigma, Poole, Dorset
M l*
Qiagen endo -free DNA purification kit Qiagen, UK
Restriction enzymes(ECORl, Hindlll) Promega, UK
RPMI1640 Gibco BRL, UK
Rubidium chloride Fisher, UK
SDS Sigma, Poole, UK
SEB Fluka, Dorset, UK
Sodium hydroxide BDH, Poole Uk
Sodium Orthovanadate Sigma,Poole UK.
Sucrose Fisher, UK
TEAS Sigma, Poole, UK.
TEMED Sigma, Poole, UK
Terrific broth Sigma, Poole, Dorset.
TLC plates (linear K Whatmann, Maistone, Kent.
Tris.Hcl Sigma, Poole, UK
Trypan Blue Sigma,Poole UK.
Trypsin EDTA Gibco BRL, Paisley, UK.
Tween Sigma, Poole, Dorset.
Xomat film Kodak, Harrow, UK.
2.1.4 GENERAL SOLUTIONS.
7.5% Gel (mini protean-gels x 1 mm thick) 
(run at 100V for 1 hr)
30 % bis:acrylamide 2.1 mis
1M Tris.HCl pH 7.5 1.8 mis
H20 1.8 mis
10 % APS 15.0 pi
TEMED 3.5 pi
10 % SDS 25.0 pi
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Gradient Gel (15 cm x 15 cm x 1.5 mm thick) 
(run at 75V o/n)
7% 17%
30% bis:acrylamide 3.5 mis 8.5 mis
1M Tris.HCl pH 7.5 7.6 mis 5.6 mis
H20 3.1 mis
Sucrose 1.59 g
10 % APS 50 pi 50 pi
TEMED 10 pi 10 pi
10 % SDS 75 pi 75 pi
Stacking Gel
30% bis:acrylamide 1.6 mis
h 2o 7.6 mis
Upper Buffer 3.1 mis
10 % APS 50 pi
TEMED 10 pi
Upper Buffer
Tris pH 6.8 0.5 M
SDS 0.4%
PBS (IX)- for western blotting
Na2HP04 80 mM
NaH2P 04.12 H20 20 mM
NaCl, 100 mM
pH 7.5
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Tris.HCl pH6.8 62.5 mM
dH20 48.8 mis
SDS 2 %
2- mercaptoethanol. 100 mM
SDS Laemmli sample buffer
Glycerol 10%
SDS 0.4%
Tris HC1 pH 6.8 200 mM
2-Mercaptoethanol 5%
Bromophenol blue To colour
Semi Dry Transfer Buffer
Glycine 39mM
Tris base 48 mM
SDS 0.0375%
Methanol 20%
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2.2 M ETHODS
2.2.1 MOLECULAR BIOLOGY 
PREPARATION OF COMPETENT CELLS
DH5 a  E.Coli were picked from a single colony and streaked onto a pre-dried LB 
agar plate. After incubation at 37 °C overnight a single colony was picked and 
grown in 5 ml LB in an orbital shaking incubator at 37 °C overnight. Subsequently 1 
ml of this culture was diluted in 100 ml of LB and further cultured until the optical 
density at 550 nm read 0.48. The culture was then immersed in ice to cool and then 
pelleted by centrifugation at 6,000 r.p.m in 50 ml tubes, for 5 minutes at 4 °C. Cells 
were then re-suspended in 40 mis of Tfbl (30 mM KC1, 100 mM RbCl, 10 mM 
CaCb, 50 mM MnCb, 15% (v/v) Glycerol, pHd to 5.8 with glacial acetic acid), and 
incubated on ice at 4 °C. Cells were then resuspended in 4 mis of Tfbll (10 mM 
MOPS, 75 mM CaCh, 10 mM RbCl, 15% (v/v) glycerol) and incubated on ice for 
15 minutes. After 15 minutes the competent cells were aliquoted in 200 pi aliquots 
and snap frozen in a dry ice ethanol bath, prior to long term storage at -8 0  °C.
TRANSFORMATION
Plasmid DNA was transformed into competent DH5a via the heat shock method. 1 
pg of stock DNA was mixed via gentle vortexing with 100 pi of competent cells 
which had been thawed on ice, and the mixture incubated on ice for 30 minutes. 
Cells were then placed at 42 °C for 90 seconds, and then diluted 1:10 in pre-warmed 
LB. The cells were placed at 37 °C for 30 minutes, and then spread onto a pre-dried 
agar plate containing ampicillin at 0.1 mg per ml, or, in the case of GFP-PH PKB and 
GFP-PH(618)-PKB, kanamycin at 50 ng per ml. The plate was allowed tor dry 
before inverting and growing at 37 °C overnight.
SMALL SCALE PLASMID PREPARATION
To verify the identity of plasmid DNA prior to large scale preparation a single 
colony was picked and placed in 3mls of LB with the apropriate antibiotic (As 
above) and grown overnight. 1.5 mis of the culture were pelleted and resuspended 
by vortexing in 100 pi solution 1 (200 mM Tris.HCl pH 8 , 50 mM glucose, 10 mM 
EDTA). The remaining culture was stored at 4 0 for further use. Cells were lysed
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through addition o f 200 pi of solution II (0.2 N NaOH and 1 % SDS), and the 
plasmid DNA purified from the cell debris though addition of 150 pi ice cold 
solution HI (60 mis 5M KOAc 11.5 mis glacial acetic acid 28.5 mis H2O). 
Samples were incubated on ice for ten minutes prior to centrifugation. Supernatants 
were harvested and nucleic acids were subsequently precipitated with 0.7 vols room 
temperature' isopropanol. Nucleic acid was pelleted via centrifugation at 13,000 
r.p.m for 15 minutes and pellets were washed with 70 % ethanol, and subsequently 
air dried. Finally the nucleic acids were resuspended in 200-100 pi dH20, and 
stored at -2 0  °C. Concentration of DNA was determined crudely via measurement of 
optical density at 260 nm.
RESTRICTION ENZYME DIGESTION
DNA from small scale plasmid preparations was subject to confirmatory digestion 
using at least two appropriate restriction enzymes. 1 pi of DNA was cleaved using
0.5 Units (0.5 pi) of each restriction enzyme, lpl 10X restriction buffer, lpl 10X 
BSA in a total volume of 10 pi. Where larger volume digests were performed, 
volumes were adjusted accordingly, ensuring that the total volume of enzyme added 
did not exceed more than 10 % of the final digest volume.
LARGE SCALE PLASMID PREPARATION
Following confirmation that the chosen clone contained the correct plasmid, 1.0 ml 
of the retained mini culture was used to innoculate 500 ml of LB supplemented with 
the appropriate antibiotic. After incubation overnight at 37 °C, endotoxin free DNA
HpjLyl
was prepared using Qiagen Endo-Free plasmid preparation kit.
PREPARATION OF GST FUSION PROTIENS
A single bacterial colony was innoculated into 10 mis 2x YT supplemented with 50 
pg per ml ampicillin and grown o/n at 37 °C. The overnight culture was then used to 
innoculate 500 mis 2xYT supplemented with ampicillin as before. The culture was 
grown at 37 °C until O.D = 0.6-0.8 and then induced with lOOmM IPTG and 
incubated at 27 °C o/n.
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Cells were then pelleted and washed in fusion protein lysis buffer and resedimented 
before resuspension in 15 mis of ice cold lysis buffer (10 mg/ml aprotinin, 20 mg/ml 
leupeptin, 2.8 mg/ml pepstatin, 80 mg/ml PMSF, 10 mg/ml Lysozyme, 10 mM 2- 
ME). The resuspended cells were incubated at 25 °C for 10 minutes and lysis was 
achieved by freeze / thawing on dry ice / 37 °C water bath x 3. Nucleic acids were 
then digested by the addition of 20 mM MgCL and 0.14 mg Dnasel and incubation 
for a further 15 minutes, with agitation, at 25 °C. The reaction is stopped with EDTA 
(20 mM) and 630 pi 10% NP40 was added prior to incubation at 25 0 C for 15 
minutes. Lysates were then subject to centrifugation at 30,000g for 30 minutes. The 
supernatant was then aliquoted in 1 ml volumes and stored at -  80 °C.
To prepare GST fusion protein from crude extract, extracts were thawed on ice and 
transferred into 5 ml bijous. 1 ml of glutathione sepharose was added to each ml of 
extract and rotated at 4 °C for 3 hours. Glutathione beads absorbed to fusion 
protein were recovered by centrifugation, and the supemtant was removed and 
stored. Fusion proteins were then eluted from the glutathione beads by rotation with 
3x 1 ml of 20 mM mM glutathione for twenty minutes. Finally recovered protein 
was pooled and the concentration of the protein crudely determined via OD at 280nm 
and more accurately determined by Bradford assay (Biorad). Using 10 pi of protein 
serial dilutions in water were made and added to 50 pi Bradford reagent. Protein 
concentration was determined by optical density readings at 595 nm and comparison 
to a range of known protein standards (2 mg/ml -  0.05 mg ml). Finally purified 
proteins were run on an SDS PAGE gel to check the integrity, and molecular weight 
of the protein.
2.2.2 CELL CULTURE
JURKAT T CELL LYMPHOMA -J6
Jurkat J6 Lymphoma T cells were maintained in RPMI-1640, supplemented with 
10% heat inactivated foetal calf serum, Penicillin (50U/ml), Streptomycin (50pg 
/ml), and fungizone. Cells were grown in suspension in 175cm tissue culture flasks 
at 5% CO2 in a humidified atmosphere at 37°C in 175 cm2 tissue culture flasks. Cells
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were passaged 2-3 times weekly, by splitting each flask 1:4 into the original volume 
of pre-warmed full growth medium (as described above).
CTLA4+T CELL HYBRIDOMA
The murine T cell Hybridoma, DC27.1 which was stably transfecetd with CTLA4, 
was a kind gift from Chris Rudd (Dana Farber institute, USA), and was maintained 
in RPMI-1640 supplemented with 10% heat inactivated foetal calf serum, penicillin 
(50U/ml) streptomycin (50pg/ml), and Fungizone™ (diluted 1:500). Cells were 
grown in 175cm tissue culture flasks, which were incubated in a humidified 
atmosphere at 5% CO2, 37°C. Cells grew in a semi-adherent manner, and adherent 
cells were removed from tissue culture plastic, prior to passageing, via vigorous 
agitation. The resulting suspension was split 1:4 into the original volume of fresh 
pre-warmed full growth medium as described above, 3 times weekly.
DC27.1 CD28+ T CELL HYBRIDOMA
The murine T cell hybridoma DC27.1, stably expressing wild type or site mutated 
CD28 was kindly provided by Daniel Olive (INSERM, Marseille) and maintained in 
DMDM containing 10% FCS, supplemented with sodium pyruvate (ImM) and 2- 
mercaptoethanol (50pM) and penicillin (50U/ml) and streptomycin (50pg/ml) the 
cells were grown in a humidified atmosphere at 37°C, 5% CO2. Cells grew in a 
semi-adherent manner, and adherent cells were removed from tissue culture plastic, 
via to passageing, via vigorous agitation. The resultant suspension was split 1:4, 
three times weekly.
B7+ CHO CELLS
CHO B7 stable transfectants and CHO parentals were a kind gift from Dave Sansom 
(University of Bath, UK), and were maintained in Dulbecco’s modified essentials 
medium (DMEM), without glutamine, with pyridoxine (and supplemented with 10% 
heat inactivated foetal calf serum, nucleosides (GIBCO), and non essential amino 
acids (GIBCO). The cells were grown at 37°C, 5% CO2. Cells were passaged at 
100% confluency. After removing the medium from confluent cells the remaining 
medium was washed from the flask with PBS and cells were overlayed with trypsin-
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EDTA, and placed at 37°C for 2 minutes. Trypsin-EDTA was rapidly neutralised 
with DMEM with 10% foetal calf serum, and cells were dislodged from plastic by 
vigorous agitation, and subsequently pelleted by centrifugation. Pelleted cells were 
resuspended in full growth medium, and ‘split’ 1:5 for subsequent culture.
A20 B CELL LYMPHOMA
The A20 B cell lymphoma was maintained in RPMI 1640, supplemented with 10% 
heat inactivated foetal calf serum, 50U/ml Penicillin, 50pg/ml Streptomycin, and 
50pM 2-mercaptoethanol. The cells were grown at 5% CO2, 37°C. Cells were grown 
until semi-confluent. Cells grew in a semi-adherent manner and aherent cells were 
harvested before passageing by vigorous agitation of the culture flask. The resultant 
suspension was split 1:3, three times a week.
ANALYSIS OF CELL SURFACE ANTIGENS
All cells were routinely analysed for expression of the relevant cell surface antigens 
via FACS analysis (See diagram 13). For each cell line to be analysed, 5x l04 cells 
were aliquoted and washed twice in serum free RPMI 1640, and resuspended in 100 
pi of the appropiate antibody specific for cell surface antigens, at a dilution of 1 
pg/ml in serum free RPMI 1640. Cells were subsequently incubated at 4 °C for 1 
hour and agitated intermittently. As a control for non-specific binding, 5x l04 cells 
were incubated in 100 pi of an antibody which was isotype matched to the primary 
antibody, for 1 hour at a concentration of 1 pg/ml in serum free RPMI 1640.
Control and non-control samples were then washed twice using ice cold PBS, and 
incubated at 4° C for 20 minutes with 100 pi anti-Mouse-FITC, or anti Rabbit-FITC, 
depending on the species in which the primary antibody was raised, diluted to 250 
pg/pl. Finally samples were washed three times in PBS and analysed for surface 
expression of antigenic determinants by flow cytometry.
INTRACELLULAR FACS STAINING
CTLA4+ T cell hybridoma cells were analysed for extracellular CTLA4 expression 
(as described above) and intra-cellular expression of internalised CTLA4 protein.
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5x10 cells were aliquoted and then washed twice in serum free RPMI 1640. Cells 
were subsequently fixed in 100 pi 1% paraformaldehyde for 15 minutes at room
WT / CD28
  =C D 28 + 1X27.1
  = Isotype control
10°  101 102 103 104
B7 L / BB1
=B7.1 + CHO cells 
= Isotype control
DIAGRAM 13 Analysis of cell surface antigens
temperature, before washing three times in PBS. The cells were then permeabilised 
in lOOpl 0.01% saponin, for 15 minutes at room temperature. Subsequently the cells 
were washed three times in PBS and incubated for 1 hour with 100 pi anti-CTLA4 
antibody, 11D4, diluted to a concentration of 1 pg/ml in serum free RPMI 1640. As a 
negative control, cells were treated similarly and incubated with IgG2a, isotype 
matched immunoglobulins. Finally cells were washed three times in PBS and 
incubated for 20 minutes with anti-mouse FITC at a concentration of 250 pg/ml. 
Samples were then analysed for intracelllular CTLA4 expression, by flow cytometry.
FREEZING AND THAWING CELLS
Early passage cells of all cells lines were stored for long term use in liquid nitrogen. 
Prior to freezing cells were grown until semi-confluent and then pelleted by 
centrifugation and counted using a haemocytometer. Viability of cells was 
determined via trypan blue exclusion. Cells were resuspended in freezing mix: 10% 
dimethyl sulfoxide, 90% full growth medium and aliquoted at a cell density of
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5xl06/ml, into cryovials™. Subsequently cells were placed in ‘MR Frosty’™ cooler 
at -80°C, which allowed the vials to cool at a steady rate of 1 °C per minute. After 12 
hours cells were placed onto canes for storage in liquid nitrogen cylinders.
Cells were recovered from liquid nitrogen by removing from canes and placing on 
ice. Cells were then rapidly thawed in a 37 °C waterbath, and immediately diluted 
into pre-warmed full growth medium, and pelleted by centrifugation. The resultant 
pellet was resuspended in 10 mis of warmed full growth medium, and transferred 
into a 20 cm2 flask, for overnight culture. Cells were subject to visual assesment over 
the subsequent days, and when confluent, and recovered, transferred in to 80 cm and 
subsequently 175 c m 2 tissue culture flasks.
2.2.3 CELL STIMULATIONS 
PREPARATION OF CELLS
Prior to stimulating, cells were grown to semi-confluency and harvested from tissue 
culture flasks. Where semi adherent cells were used, vigorous agitation was 
necessary to remove cells from tissue culture plastic. Where adherent CHO cells 
were used to stimulate T cell lines, cells were removed from tissue culture plastic 
using trypsin-EDTA, and incubated at 37 °C, for 2 minutes. Care was taken to 
neutralise the trypsin rapidly, so as to avoid cleavage of cell surface antigens.
All cells lines were then pelleted by centrifugation at 1200 r.p.m. at room 
temperature. Resultant cell pellets were pooled and washed four times in RPMI 
1640, without serum. Finally, after having been assessed for viability via trypan blue 
exclusion and counted using a haemocytometer, cells were then resuspended at a 
density of 40x106 cells per ml in HEPES buffered serum free RPMI 1640, and 
aliquoted in 0.5 ml volumes, into eppendorf tubes. Cells were then allowed to 
quiesce for 30 minutes at 37 °C, before being stimulated.
T CELL STIMULATIONS
T cell antibody stimulations (anti-CD28, anti-CTLA4, and anti CD3) were achieved 
using the appropriate antibody at a concentration of 5pg per 0.5 ml aliquot of cells.
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Cells were immediately mixed and incubated at 37 °C for the time points required. T 
cells were stimulated via the CD28 physiological ligand in the following manner: 
CHO cells expressing B7.1, were prepared as described earlier and resuspended at a 
concentration of 24xl06 per ml, and then incubated at 37 °C prior to stimulation. To 
stimulate T cells, 0.5 mis of the B7.1+ CHO cell suspension was added to 0.5 mis 
of T cells (prepared as above) such that the T cell: CHO cell ratio was 3:1. Cells 
were then mixed and briefly pulsed in a microcentrifuge, to achieve cell-cell contact, 
and then placed at 37 ° C for the required time points.
A20- B CELL STIMULATIONS
The A20 B cell Lymphoma was stimulated with either 40 pg/ml intact rabbit anti­
mouse IgG (RAMIG) or 24 pg/ml F(ab’)2 fragments of rabbit anti-mouse 
IgG(F(ab’)2, for the time points required.
PREPARATION OF WHOLE CELL EXTRACTS
Following stimulation, cells were removed from the waterbath, and pulsed for 5 
seconds in a microcentrifuge, to sediment. The medium was then aspirated from the 
cells, and the cells were then lysed in 500 pi lx  cell lysis buffer [0.5% v/v NP40, 
65mM NaCl, lOmM Tris pH7.5, 1%(3 glycerophosphate, 5 mM iodoacetamide, 5 
mM NaF, ImM phenylmethyl-sulfonylflouride, 1 pg/ml leupeptin, 1 pg/ml 
pepstatinA, lpM sodium ortho vanadate]. All samples were incubated on ice, to 
allow thorough lysis to occur, after which nuclear debris was sedimented via 
centrifugation at 4 °C, 13,000 r.p.m, for 15 minutes. Subsequently, the supernatants, 
containing cellular proteins, were harvested from the samples, and kept on ice.
MEMBRANE CYTOSOL FRACTIONATION
For membrane cytosol fractionation cells were stimulated and lysed in lysis bufer 
minus NP40. Cells were then sonicated ten times for 15 seconds on ice and intact cell 
debris was pelleted by centrifugation for 30 seconds at 13,000rpm in a bench top 
microcentrifuge. Supernatants were harvested and membrane cytosol fractions 
prepared by centrifugation at 300,000g (100,000 r.p.m. using the Beckman T 120 
ultracentrifuge rotor), for 20 minutes at 4 °C. Supernatants containing cytosolic
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fractions were harvested and boiled in Laemmli sample buffer, or subject to 
immunoprecipitation as described below. Pellets, containing membrane fraction, 
were washed using detergent free lysis buffer and then solubilised in lysis bufer plus 
10% NP40. Membrane fractions were then either boiled in Laemmli sample buffer 
or subject to immunoprecipitation as described below.
IMMUNOPRECIPITATION FROM CELL LYSATES
Where immunoprecipitation was to be carried out, samples were first pre-cleared by 
the addition of 20 pi 50 % protein A sepharose slurry and rotated for 20 minutes at 4 
°C. After pre-clearing, protein A sepharose was sedimented by centrifugation at 
13,000 r.p.m. for 1 minute, and the supernatants were harvested. Cell lysates were 
next subject to immunoprecipitation by addition of the relevant antibody at a final 
concentration of 2 ng/ml, and rotation for 2 hours at 4 ° C. Immune complexes 
were precipitated by rotation with 40 pi 50 % protein A sepharose slurry for 1 hour 
at 4 °C. Sepharose beads were then sedimented from cell lysates, by pulsing tubes 
to 13,000 r.p.m in a microcentrifuge. Immunoprecipitates were then washed 5 times 
with lysis buffer, drained with a hamilton syringe, and boiled in 30 pi SDS-Laemmli 
sample buffer for 10 minutes.
ACETONE PRECIPITATION OF PROTEINS
Acetone precipitation of total cell proteins was achieved, following sedimentation of 
nuclear proteins from the lysed cells, through the addition of 0.7 volumes of ice 
cold acetone to the cell lysate. Samples were placed at -2 0  °C for one hour and then 
flocculent protein pellets were sedimented via centrifugation at 13, 000 r.p.m, for 20 
minutes. Pellets were retained and dried in vacuo. Finally acetone precipitated 
proteins were boiled in 200 pi SDS-Laemmli sample buffer, and loaded at a volume 
of 10 pi per gel.
GST-FUSION PROTEIN PRECIPITATES
Where precipitation using a GST fusion protein was required, 20 pg of GST fusion 
protein was added to cell lysates and samples were rotated for 4 hours at 4 °  C.
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Subsequently, protein complexes were adsorbed through the addition of 30 pi GST 
sepharose slurry, and rotation for 1 hour at 4 °C. Adsorbed proteins were recovered 
via sedimentation of the sepharose beads by centrifugation at 13.000 r.p.m., followed 
by 5 washes with lysis buffer. Finally beads were sedemented and drained with a 
hamilton syringe, prior to boiling in 30 pi SDS-Laemmli sample buffer.
2.2.4 WESTERN BLOTTING 
SDS- PAGE
Immunoprecipitated proteins, fusion protein precipitates, and acetone precipitates, 
were separated via 7-17 % gradient SDS PAGE overnight, or 7.5 % SDS-PAGE for 
one hour. All gels were assembled using 1.5 cm spacers.
Proteins were then transferred onto nitro cellulose membranes by semi dry transfer. 
Eight pieces of 3 MM filter paper were cut to the exact size o f the gel, and each 
piece was wetted with in semi dry transfer buffer and placed onto the anode of the 
semi dry transfer apparatus. Between sheets each filter paper was vigorously rolled to 
remove air bubbles. Finally after four sheets had been layered onto the anode in a 
vertical stack, nitrocellulose which had been cut to the exact size of the gel and pre­
soaked in semi-dry transfer buffer, was layered onto the stack, and rollered. The gel 
was briefly pre-soaked in semi dry transfer buffer, placed onto the nitro-cellulose 
membrane and gently rollered. A further four pieces of pre-wetted 3 MM filter paper 
were layered and rollered. Finally the semi-dry transfer cathode was applied and 
proteins were set to transfer for one hour and a half at 1 mA per cm2.
IMMUNOBLOTTING
Following transfer blots were rinsed in dH20 , and proteins were visualised using 
ponceau-S stain, and were subsequently de-stained with dH20 . Nitro-cellulose 
membranes were blocked for 3 hrs with 5 % Marvel in PBS. Primary antibodies 
were diluted in 0.05% Marvel (in PBS) at a final antibody concentration of lng/ml. 
Primary antibodies were applied for three hours at room temperature in the case of 
anti-phospho tyrosine antibody 4G10, or overnight in the case of all other antibodies.
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After removal of the primary antibody, and its storage at 4 °C for re-use, blots were 
washed 3 times for 15 minutes each wash, in PBS.
After washing antibody bound proteins were detected using a secondary antibody 
consisting of horseradish peroxidase-conjugated immunoglobulins, relevant to the 
species in which the primary antibody had been raised. Secondary antibody stocks 
were diluted at 1:20,000 in 0.05% marvel, and applied for 40 minutes. Following 
removal, secondary antibodies were discarded and blots were washed thoroughtly six 
times for 15 minutes each wash, in PBS. Blots were visualised using chemi- 
luminescence reagent (ECL), and autoradiography.
FAR WESTERN BLOTTING
GST fusion proteins were used to far western blot nitro cellulose membranes which 
had been prepared as described above. GST Fusion protein was diluted in 0.05 % 
marvel at a concentration of 100 ng per ml, and incubated at room temperature with 
the blocked membrane, for three hours. Subsequently blots were washed five times 
with PBS / 0.01 % Tween, for five minutes each wash. Membranes were then 
incubated at room temperature with anti-GST antibody, at a dilution of 1: 10,000, for 
one hour. Blots were then washed three times with PBS / 0.01 % Tween and 
incubated for one hour at room temperature with anti- mouse HRP conjugated 
immunoglobulins, diluted to 1:5000 in 0.05 % marvel. Finally blots were washed 
three times for five minute in PBS / 0.01 % Tween and visualised with ECL by 
autoradiogram.
STRIPPING AND REPROBING
Prior to reprobing, or storage, membranes were stripped at 50 °C for 1 hour in 
stripping buffer with fresh 2- mercaptoethanol. After stripping blots were washed 
10 times, in PBS, each wash for 15 minutes. Where blots were to be stored they 
were air-dried between two sheets of 3 MM paper, and stored at room temperature. 
Where blots were to be re-probed they were blocked in 5% Marvel for 1 hour.
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2.2.5 IN VITRO LIPID KINASE ASSAY
Immunoprecipitated proteins from stimulated whole cell extracts were prepared as 
described above. Following washing in lysis buffer, protein A sepharose beads were 
subject to further washing: once in ice cold PBS, twice in 0.5 mM LiCl, 100 mM 
Tris-HCL(pH 7.6), once in dH20 and finally once in lipid kinase buffer [5 mM 
MgCh, 0.25 mM EDTA, 20 mM HEPES pH 7.4]. Ptd ins activity was determined 
via the method described by Whitman et al (1988). Following washing the sepharose 
beads were resuspended in 30 mis of lipid kinase buffer, and 50 pi of a lipid mixture, 
sonicated in 25mM HEPES buffer pH7.4 and ImM EDTA, containing O.lmg/ml 
phosphatidyl- inositol and 0.1 mg/ml phosphatidyl serine,) was added.
The lipid kinase reaction was initiated by the addition of 20 jxCi of [y-32P] ATP and 
lOOpM ATP and terminated after 15 mins. by the addition of 80 pis 1M HC1 and 
200pl chloroformrmethanol in a 1:1 ratio. After vigorous mixing and centrifugation 
to separate the phases, the organic layer was removed, dried in vacuo and 
resuspended in 50 pi chloroform. The extracted lipids were then analysed by thin 
layer chromatography in propan-l-ol:acetic acid (2N) 65:35 v/v developing solvents, 
and visualised by exposure to iodine vapour and autoradiography.
2.2.6 IN VITRO PROTEIN KINASE ASSAYS
Analysis of protein kinase activity in immunoprecipitated protein complexes 
prepared from stimulated whole cell extracts, as described above, was carried out via 
an in vitro protein kinase assay. After washing sepharose beads in lysis buffer 
following immunoprecipitation, they were further washed in protein kinase assay 
buffer lysis buffer (100 mM NaCl, 25 mM HEPES, pH 7.4, 10 mM MgCL, 5 mM 
MnCL. 100 pM sodium orthovanadate). In vitro kinase activity was initiated by the 
addition of 20 pi kinase assay buffer containing 10 pM ATP and 10 pCi of [y-32P]- 
ATP. Reactions were quenched after 10 minutes by the addition of 1 ml of lysis 
buffer containing 20 mM EDTA. The immuno-precipitates were then washed 8 times 
in this buffer, to remove unincorporated radioisotope and then sepharose beads were 
drained. Samples were boiled in SDS-Laemmli sample buffer and separated via 7-17
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% SDS-PAGE, overnight. Gels were fixed in propan-2-ol:H20:acetic acid 
(50:130:20) for 20 minutes then briefly rinsed in water and dried down at 80 °C 
under Vacuum, for 1 hr. Radiolabelled kinase assay products were visualised by 
autoradiography at -7 0  °C.
2.2.7 IMMUNOFLUORESCENCE STAINING.
To visualise cellular proteins via confocal microscopy, cells were plated at lxlO6 
cells per ml onto poly-L Lysine coated cover slips placed in 24 well plates and left to 
adhere overnight under normal growth conditions. Subsequently cells were 
stimulated as described above, and signalling was quenched via fixation in 1 % 
paraformaldehyde, for 15 minutes at room temperature. Samples were then 
permeabilised in ice cold acetone for 5 minutes and then rinsed with PBS / 0.01 % 
Tween prior to blocking in abdil solution [PBS / 0.01 % BSA /  1 % foetal calf 
serum], for 10 minutes at room temperature. Samples were then washed 3 times 
with PBS / 0.01 % Tween, for five minutes each wash. After the final wash, 
primary antibodies were applied, at a concentration of 1:1000, diluted in Abdil 
buffer, and samples were incubated for 30 minutes at room temperature, using a 
humidified slide chamber, to prevent evaporation.
Subsequently samples were washed 3 times in PBS / 0.01 % Tween, for 5 minutes 
each wash, and incubated with secondary antibody, FTTC conjugated anti- rabbit 
immunoglobulins, for 20 minutes at room temperature, in the dark. Samples were 
then washed a further 3 times with PBS / 0.01 % Tween and then mounted with 50 
% glycerol in PBS containing 2 % Dabco, and dried for one hour. Samples were 
visualised via immunoflourescence microscopy using a ‘Zeiss Axiovert’ 100 M 
inverted epiflourescence microcope attached to a LSM 510 confocal laser scanning 
system equipped with a krypton / argon laser (Karl Zeiss, Oberkochen, Germany).
2.2.8 CELL TRANSFECTIONS
Prior to electroporation, Jurkat T cells were grown to semi confluency and then 
harvested by centrifugation at 1200 r.p.m. Cell pellets were pooled and counted 
using a haemocytometer, assessing viability via Trypan Blue exclusion. Cells were
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then aliquoted in 500 pi volumes at 15 x 10 6 cells per ml, into electroporation 
cuvettes, and electroporated with 30 jig DNA per cuvette, at 960 pF, 310 mV using a 
Biorad ‘gene pulser’ electroporation system. In cases where green flourescent protein 
expressing plasmids were used, 10 pg DNA was added per cuvette. Following 
electroporation, cells were placed directly into culture at 50 x 106 cells per 10 mis 
full growth medium supplemented with 10 % fetal calf serum, and pre-equilibrated to 
37 °C, 5 % FCS.
2.2.9 CONFOCAL VISUALISATION OF GFP TAGGED PROTEINS.
To assess the re-distribution of GFP-PH PKB through co-expression with rCD2 
SHIP, and rCD2 C671/A SHIP throughout the cell, Jurkat cells were electroporated as 
described above, and plated onto poly-L Lysine coated coverslips in 24 well plates. 
After 5 hours in culture cells adhered to cover slips were fixed in 1 % 
paraformaldehyde, and mounted with 50 % glycerol in PBS containing 2 % Dabco, 
prior to visualisation using a Zeiss Axiovert 100M confocal microscope.
2.2.10 INOSITOL (POLY)PHOSPHATE 5-PHOSPHATASE ASSAY
To assess the inositol polyphosphate 5-phosphatase activity of endogenous SHIP 
derived from human CD28- or murine CD3- stimulated DC27.1 cells, cells were 
prepared and stimulated as described above prior to immunoprecipitation with anti- 
SHIP polyclonal antiserum. To assess the inositol polyphosphate 5-phosphatase 
activity of CD2-SHIP and CD2-C671/A SHIP, cells were electroporated as described 
above and immunoprecipitated with anti CD2 antibody, 0X34.
Immunoprecipitates were assayed for 5-phosphatase activity by determining, the in 
vitro hydrolysis {[3H]- Ins(l,3,4,5)P4} to [3H]- inositol [1,3,4]- trisphosphate {[3H]- 
Ins(l,3,4,)P3}. Immunoprecipitates were re-suspended in 25pi containing 16pM 
[3H]- Ins(l,3,4,5)P4 under conditions where the reaction was linear with time (20 
mins, 37°C). Reactions were stopped by the addition of acidified: chloroform: 
methanol and the aqueous phase was harvested and dried under vacuum. Finally the 
samples were resuspended in 100 pi of water. The samples were then analysed by 
anion-exchange HPLC analysis using a Partisphere SAX column (Whatman) and
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levels of [3H]- Ins(l,3,4,5)P4 and [3H]- Ins(l,3,4,)P3 were quantitated using an on­
line radiodetector (Canberra-Packard].
2.2.11 MEASUREMENT OF D3 PHOSPHOINOSITIDE LIPIDS.
To measure D3 inositol lipid accumulation on intact cells, cells were first harvested 
from culture and depleted of phosphate by washing three times in 50 mis of 
phosphate free DMEM, and incubating at 37°C for 15 minutes between washes. 
After phosphate depletion, cells were resuspended at 20x106 cells per ml in RPMI 
1640 supplemented with 5% dialysed FCS and 20 mM HEPES prior to labelling with 
1 m Ci [32P]- phosphoric acid, at 37°C for four hours.
Following incubation cells were washed three times in phosphate free DMEM, to
TOremove unincorporated [ P]-phosphoric acid, and then re suspended at 20x10 cells 
per ml in DMEM and aliquoted into 500pl volumes. Cells were then stimulated in as 
described above. Reactions were quenched with ice cold Methanol:H20:chloroform, 
producing a homogenous primary extraction phase.
Phases were then separated by the addition of 200 |il folsch lpids in trace amounts, 
suspended in chloroform, and 200 p.1 5 mM TBAS / 2.4 M HC1. Tubes were then 
vortexed and phases were separated by centrifugation at 800 r.p.m for 5’. Lower 
phases were harvested into a fresh tube using a gel loading tip, and 400 pi of 0.1 M 
HC1, 5 mM EDTA was added. The samples were then vortexed and centrifuged as 
before. Again the lower phase was harvested into a fresh tube and dried in vacuo. 
Once dried the extracted lipids were deacylated by the addition of 1 ml 25 % w/v 
methylamine / methanol / butan-l-ol (4:4:1) followed by incubation at 53 °C for 40 
mins. Samples were then cooled on ice for 5 mins and dried in vacuo. Samples 
were then resuspended in 0.5 ml H2O followed by addition of 0.6 ml Butan-l-ol / 
petroleum ether (bp 40-60 °C) / ethyl formate (20 / 4 / 1 v/v ) to the dried deacylated 
lipids. Samples were then vortexed and centrifuged 800 r.p.m. before removing the 
as upper organic phase and washing the lower, water soluble phase with a further 0.6 
ml of Butan-l-ol /  petroleum ether (bp 40-60 °C) / ethyl formate mix. After 
vortexing, centrifugation as before the upper phase was discarded and the lower
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phase was dried in vacuo. Finally pellets were redissolved in 100 jil dH20, and 
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Diagram 14: Sample HPLC elution trace of deacylated [32P]-labelled phosphoinostide lipid 
products derived from resting Jurkat T cells.
Samples were eluted from the column using a gradient based on buffers A (H2O) and 
B (1.25 M (NH4) HPO4] ( adjusted to pH 3.8 with H3PO4 at 25 °C) at a flow rate of 
1 ml / min: Omin, 0 % B; 5 min, 0 % B; 45 min, 12 %B; 52 min, 20% B; 64 min, 
100% B; 70 min, 100% B; 71 min, 0 % B 90 mins, 0 % A and B.
2.2.12 LYMPHOCYTE PREPARATION AND PURIFICATION
Blood from healthy donors was taken aseptically in 50 ml syringes containing 
heparin at 10 U per ml of blood, via 19 gauge butterfly needles. The blood was 
diluted immediately 1:1 in RPMI 1640 culture medium and 35 ml aliquots were 
carefully layered onto 15 ml lymphoprep, so as not to disturb the interphase, in 50 
ml centrifuge tubes and spun without brake for 30 minutes at 1200 rpm.
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Lymphocytes were then carefully removed from the interphase and washed x3 in 
RPMI. To prepare cultured lymphoblasts, cells were then resuspended in an equal 
volume to the blood from which they originated and incubated at 37 °C, 95 % 
humidity and 5 % CO2 for 72 hours in 80 cm2 tissue culture flasks with one o f the 
following mitogenic stimuli: 1 |ig/ml Staphylococcal enterotoxin B, 1 pg/ml 
phytohaemagglutinin A (PHA), 1 pg / ml Ionomycin with 5 ng / ml phorbol 
myristate acetate or CD2/CD28 ligation. After 72h and every 48 h for 15 days the 
blasts were supplemented with 20 ng / ml 11-2. T blasts were maintained at a 0.5- 
1.5x 10 6 per ml density. To prepare purified T-lymphocytes the PBMCs were 
resuspended in volumes equal to the volume of blood from which they originated in 
complete RPMI 1640, 10 % FCS, pen.strep. (500 U / ml) and 0.5 jig /  ml 
Amphotericin B. Adherent cells were removed by plastic adherence on tissue 
culture petri dishes or 175 cm2 flasks incubated at 37 °C for 60 mins, 95 % 
humidity and 5 % CO2 .
The non adherent cells were washed gently from the surface of the plate and 
resuspended in 15 ml centrifuge tubes in RPMI (1ml for PBMCs from 100ml of 
blood), and rotated gently for 45’ at 4°C with the following mouse a  human Abs at 
1 pg/ml: anti B Cell mAb against CD 19, anti monocyte and macrophage Ab clone 
UCHM-1 against CD 14, and anti APC Ab L243 against MHC D-R. The tagged 
cells were then washed and resuspended with 2-4 xlO6 /ml magnetic beads M-450, 
coated with sheep anti mouse IgG Abs (in 2mls for lOOmls of blood). After 45’ 
rotation at 4°C the cells were purified over magnetic beads in 12ml RPMI. Cells 
were counted and viability assessed with trypan blue exclusion.
2.2.13 PROLIFERATION ASSAY
Purified T cells were resuspended in RPMI growth medium, and aliquoted, 
150pl/5xl04cell s/well in 96 well plates, and stimulated with varying concentrations 
of aCD3, aCD3, aCD28 or CHO-B7.1, PMA ionomycin or PHA and IL-2 the 
various points were plated in quintiplicate to standardise the assay. Antibodies were 
used soluble with cross linker at 1-10 pg/ml. All other agents were used at the 
concentration stated previously. Inhibitors were used at 0.1 -100 nM concentrations.
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The plates were incubated at 37°C, 95% humidity and 5% CO2 for 48 h and then 
pulsed with 0.5|iCi/well 3H-thymidine. 72h after stimulation the cells were 
harvested using an automated cell harvester on 96 well filter plates (Unifilter™) and 
radioactivity was measured with a Packard instruments p scintillation counter (Top 
Count™) according to manufacturer’s specifications.
2.2.14 MEASUREMENT OF INTRACELLULAR [Ca2+]
Using the calcium-sensitive fluorochrome Fura-2 AM intracellular [Ca2+] can be 
readily measured. Fura-2 is coupled to the acetoxymethylester (AM) which allows 
entry into cells, and is then cleaved by endogenous esterases, preventing the escape 
of fura-2 from the cells. On binding to calcium ions, the fluorescence excitation 
maximum of fura-2 transfers to a lower wavelength without any alteration in the 
emission spectrum, thereby enabling fura-2 to be used as a dual excitation indicator. 
The excitation maximum for free-calcium and bound-calcium can be measured at 
380nm and 340nm respectively.
CALIBRATION OF THE FLUORIMETER
Calibration was obtained by monitoring the fluorescent changes in the cell 
suspensions after the addition of 0.16|ig/ml digitonin (to lyse cell membranes and 
expel intracellular calcium). Fluorescence was monitored using a dual 
excitation/dual emission spectrofluorimeter (Photon Technologies) for 30 seconds 
followed by the addition of 40mM sodium hydroxide (NaOH) and 4mM EGTA. 
Conversion of the fluorescence ratios at two wavelengths into intracellular calcium 
concentration was achieved using the equation developed by Grynkiewicz et al 
(Grynkiewicz et al, 1985):
[Ca2 +]i =  Kd R -R mm Sjg 
Rmax"R Sb2
Where,
•  Kd = effective dissociation constant for fura-2 (2.24 x 10'7 M)
•  R = Ca2+ bound/Ca2+ free fluorescence ratio
• Rmin = fluorescence ratio with zero calcium
• Rmax = fluorescence ratio under saturating conditions
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•  Si2/Sb2 = ratio of fluorescence values for Ca2+/Ca2+ free indicator measured at the 
wavelength used to monitor Ca - free indicator (denominator wavelength of R)
i.e. at 380nm.
LOADING CELLS WITH FURA-2/AM
Cells were pelleted by centrifugation and resuspended in HBSS (without calcium, 
magnesium and phenol) containing 0.1% BSA at lxlO7 cells per ml. Cells were then 
incubated with 5pM fura-2/AM at 37°C for 45 minutes. Following incubation, cells 
were washed twice and resuspended at lxlO6 cells per ml in HBSS/BSA.
[CA2+]i MEASUREMENT
Fura-loaded cells were aliquoted into a 2-ml cuvette at a concentration of lxlO6 - 
2xl06 cells per ml. To the cell suspension ImM of calcium chloride and ImM of 
magnesium chloride were added and allowed to equilibrate at 37°C in the 
spectrofluorimeter for 5 minutes.
Prior to the addition of the agonists, a basal calcium measurement was taken for 30 
seconds. The agonist induce-response was monitored for at least 180 seconds and 
was detected using dual excitation wavelengths of 340nm and 380nm and a single 
emission wavelength of 510nm on the spectrofluorimeter (Photon Technologies).
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3. RESULTS -T LYMPHOCYTES
3.1 CD28 AND PI3K
As outlined by the introduction to this study previous studies have examined the role of 
CD28 in activating PI3K dependent signalling cascades in T cells (Ward et al 1996). 
This study has further examined the regulatory mechanisms by which these pathways 
are governed. Firstly, the potential regulatory role of the multiple catalytic isoforms of 
PI3K, pi 10a, p 11 Op, and the leukocyte expressed pi 108, in the context of CD28 
signalling was considered. Using the acute lymphoblastic T cell line, Jurkat, the 
association of these isoforms with CD28, in response to B7 ligation, is described.
DEMONSTRATION OF THE RAPID ACCUMULATION OF PI(3,4,5)P3 IN 
RESPONSE TO B7.1 LIGATION OF CD28.
For the purposes of this study the Jurkat T cell line, J6, was used to investigate CD28 
driven PI3K dependent signalling cascades. Ligation of CD28, by the physiological 
ligand B7.1 was achieved here using a B7.1 expressing CHO cell line, (CHO-B7.1+). 
Ligation of CD28 by its physiological ligand B7.1 has been previously described (Ward 
et al 1996) to lead to the rapid and sustained accumulation of the PI3K product, 
PI(3,4,5)P3. Thus, to verify that B7.1 stimulated the biochemical coupling of the CD28 
receptor to PI3K activation, the accumulation of D3-phosphoinositide lipids in response 
to stimulation of Jurkat T cells by CHO-B7.1+ cells, was measured.
Firstly, it was noted that considerable levels of PI(3,4,5)P3 could be measured in resting 
Jurkat T cells. Secondly, and in accordance with prior studies (Ward et al 1996), the 
rapid accumulation of PI(3,4,5)P3 was observed in response to B7.1 stimulation of Jurkat 
T cells, which rose by a seven fold increase, above non-stimulated levels, after ten 
minutes following CD28 ligation (figure 1).
DETECTION OF PI3K REGULATORY AND CATALYTIC SUB-UNITS IN 
JURKAT T CELLS.
The different catalytic isoforms of Class 1A PI3Ks, pi 10a, p, and 8 were described 
earlier, in the introduction to this study. In order to investigate the role of these isoforms 
in PI3K regulated signalling pathways in T lymphocytes, the expression of these 
isoforms in the Jurkat T cell line was first confirmed.
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Figure 1: Accumulation of D3 Glycero-phosphoinositides in
response to B7 ligation.
7 322x10 Jurkat T cells were labelled per point with [ “P]Pi in phosphate free 
medium supplemented with 10% dialysed FCS and HEPES, for 3 hrs at 37°C. 
Cells were then stimulated with B7.1 expressing CHO cells at a ratio of 3 
Jurkats:l CHO cell, for the times shown. Reactions were quenched with chloro­
form: methanol, and the phosohatidylinositol lipids were extracted, de-acylated
32and the [ P]-labelled glycerophosphoryl derivatives of D-3 phosphoinositide 
lipids were analysed via anion exchange HPLC. Results are plotted as actual 
peak area. Actual counts = B7.1 0 mins: 3,100 cpm; B7.1 lmin: 4,109cpm; B7.1 
5min:6,087cpm; B7.1 10 minutes: 10,047cpm. Total counts 2,156,OOOcpm.
These data are from single experiment which is representative of three others.
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The regulatory PI3K subunit, p85, and the catalytic isoforms pi 10a, p liop  and pi 105 
were each readily detected in acetone precipitated (A.P) whole cell extracts (WCE) 
derived from Jurkat T cells (figure 2). Furthermore the ability of these catalytic isoforms 
to co-precipitate with p85 in non-stimulated T cells was examined. Coprecipitation of 
pi 10p and pi 105 in p85 immunoprecipitates was observed (figure 2), whilst the pi 10a 
isoform appeared to co-precipitate less readily, and this isoform was observed only once 
to co-associate with p85 in five repetitions of this experiment.
DETECTION OF pll05 EXPRESSION IN CULTURED T LYMPHOBLASTS 
AND FRESHLY ISOLATED T LYMPHOCYTES.
Other groups (Chantry et al 1997, Vanhaesebroeck et al 1997) have previously reported 
the leukocyte restricted tissue distribution of the pi 105 catalytic isoform of PI3K. Thus, 
in addition to the Jurkat cell line, expression of this isoform in primary isolated and 
cultured T cells, would be expected. To confirm whether this was the case, the presence 
of pi 105 protein in WCEs and A.Ps. derived from human T lymphoblasts, which had 
been cultured for 7 days with IL-2, and from freshly isolated T lymphocytes purified 
from peripheral blood mononuclear cells (PBMCs) was examined (figure 3).
pi 105 protein was readily detectable in WCEs and APs derived from both freshly 
purified T cells and cultured T lymphoblasts. Furthermore a p85a-pll05 recombinant 
protein was detected by anti-pll05 immunoblotting, whilst p85a-pll0a was not 
(proteins kindly supplied by B.Vanhaesebroeck, Ludwig institute, London), thus 
confirming the specificity of the anti-pll05 antibody. (N.B. High background signal 
surrounding the p85a/pll0a lane, due to overexposure of blots, slightly impairs 
visualisation of this result (figure 3)).
COASSOCIATION OF pllO ISOFORMS WITH CD28.
The direct co-association of the Class 1A PI3K regulatory subunit, p85 with conserved 
tyrosine phosphorylated motifs, present within the intracytoplasmic tail of CD28, has 
been described in previous studies by this group (Ward et al 1996) to occur in response 
to B7.1 ligation of CD28. Following the detection, by this study, of pi 1 Op and pi 105 
and to a lesser extent pi 10a, catalytic isoforms of PI3K in various T cells, it was 
speculated that p85 may convey the differential recruitment of pi 10 isoforms to the 
CD28 co-receptor in response to ligation by B7.1. To verify whether this might be the
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Figure 2: Presence of p85a and pllO isoforms in Jurkat T cell 
lysates.
Jurkat T cells were aliquoted at the cell numbers indicated and lysed prior to 
acetone precipitation on ice for one hour. Proteins were then pelleted by 
centrifugation at 13,000 rpm, 4°C, for 15 minutes. Resultant protein pellets were 
boiled in Laemmli-SDS sample buffer (A.P.s), and separated by 7.5% SDS- 
PAGE. In addition 2 x l0 7 cells were lysed and immunoprecipitated with 1 pg 
anti-p85a antibody as a control, and the resultant precipitates were electro- 
phoresed in parallel with the A.P.s. Separated proteins were transferred onto 
nitro-cellulose for immunoblotting with anti-p85a (top panel) or anti-pllO  a  
(second panel), p (third panel), and 5 (bottom panel) antibodies, each at a 
concentration of 1 pg per ml in 0.05% marvel/PBS, and proteins were visualised 
via chemiluminescence. These data are from a single experiment which is 
representative of five other experiments.
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Figure 3: Presence of pi 108 in purified T Cells, and T 
Lymphoblasts.
2 x l0 6 cultured T lymphoblasts (T blasts) or freshly isolated purified T cells (1° 
T cell) were lysed and whole cell extracts (WCE) were either boiled in 
Laemlli- SDS sample buffer, or precipitated on ice for one hour with 1.2 
volumes o f acetone, pelleted by centrifugation at 13,000rpm for 15 minutes 
(A.P), before boiling in Laemmli SDS-sample buffer. 0.01 pg p 8 5 a -p ll0 a  and 
p85-pl 105 recombinant proteins were electrophoresed in parallel as a control. 
Samples were separated by 7.5% SDS-PAGE. Proteins were then transferred 
to nitro-cellulose for immuno-blotting with anti p i 105 mAb at a concentration 
o f 1 pg per ml in 0.05% marvel/PBS, and proteins were visualised using 
chemiluminescence. These data are from a single experiment and are 
representative o f three other experiments.
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case, Jurkat T cells were stimulated with CHO-B7.1+ cells, and CD28 was 
immunoprecipitated with the mAb 9.3. Immunoprecipitates were then subjected to 
immunoblot analysis with mAbs specific for each PI3K catalytic isoform.
Anti-pi 105 immunoblot analysis identified the co-precipitation of pi 108 protein with 
anti-CD28 immunoprecipitated proteins at 1 minute following B7.1 ligation (bottom 
panel, figure 4), and this co-precipitation was further enhanced at 5 minutes. Meanwhile 
anti-pllOp immunoblotting failed to detect co-precipitation of pi 1 Op protein with anti- 
CD28 immunoprecipitates until 5 minutes following ligation. Over several experiments, 
the identification of pi 10a protein in anti-CD28 immuno-precipitates was either 
minimal (as shown in figure 4) or undetected, however recognition of a p85a/pll0a  
recombinant peptide confirmed the efficacy of the anti-pllOa antibody {second panel, 
figure 4). Finally the co-precipitation of p85 with anti-CD28 immunoprecipitates at 
1 minute following ligation by B7.1, which was detected by immunoblotting with anti- 
p85a antibody, and was sustained over five minutes, demonstrated the efficient coupling 
of PI3K with CD28 in response to CHO-B7.1+ stimulation of Jurkat T cells.
DETECTION OF PHOSPHO SERINE P1105 IN CD28 IMMUNO­
PRECIPITATES.
The pi 105 isoform of PI3K is known to have intrinsic protein kinase activity which 
serine phosphorylates the pi 108 catalytic domain at Ser 1039 resulting in the down 
regulation of its lipid kinase activity (Vanhaesebroeck et al 1997). To examine the 
effects of CD28 ligation by B7.1 on pi 108 serine phosphorylation, mAbs specific for 
phospho-pllOS (anti-pllOSP) were used to immunoblot anti-CD28 immunoprecipitates 
derived from Jurkat T cells. In this way the comparative association of pi 105 and 
phospho -pi 108 with CD28 was ascertained.
Immunoblot analysis using anti-phospho-pl 108 antibody detected the co-precipitation of 
phospho-pl 108 with anti-CD28 immunoprecipitates from Jurkat T cells, which was 
maximal at 5-10 minutes following with CHO-B7.1+ cells {bottom panel, figure 5), and 
had partially diminished after 15 minutes stimulation {bottom panel, figure 5). 
Immunoblotting of anti-CD28 immunoprecipitates, derived from CHO-B7.1+stimulated 
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Figure 4: Association of p85a and pi 10 isoforms with CD28 after ligation 
by B7.1.
2 x l0 7 Jurkat T cells were either left un-stimulated as a control (C) or stimulated with CHO- 
B7.1+ cells at a ratio of 3:1 respectively. Cells were lysed and subject to precipitation with 
1 pg of either anti-CD28 antibody, 9.3, or anti-p85a antibody. Precipitated proteins were 
separated by 7.5 % SDS-PAGE, along with 0.01 pg of p 8 5a-p ll0a , p, or 8 recombinant 
protein, prior to immunoblotting with anti-p85a (top panel), anti-pllO a (second panel), 
anti-pl 10p (third panel), and anti-pl 106 (bottom panel) each at a concentration o f 1 pg per 
ml in 0.05 % marvel/PBS. Proteins were visualised by chemiluminescence. These data are 
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Figure 5: Association of p i  105 and phospho p i 105 with CD28 
after ligation by B7.1.
2 x l0 7 Jurkat T cells were either stimulated with CHO-B7.1+ cells at a ratio 
of 3:1 respectively, or left unstimulated as a control (C). Cells were lysed 
and subject to immunoprecipitation with 1 pg of anti-CD28 antibody 9.3. 
For control purposes 2 x l0 7 cells were lysed and immunoprecipitated with 
either anti-p85 or anti phospho-pl 105, in addition control peptides 
representing p85a-pl 105 and p85a-p ll05P  were electrophoresed in parallel 
with the described immunoprecipitates. Samples were separated by 7.5 % 
SDS-PAGE and transferred onto nitro-cellulose for immunoblotting with 
anti p i 105 or anti phospho-pl 105P antibody, at a concentration of lpg pre 
ml in 0.05 % marvel/PBS. Proteins were visualised via chemiluminescence. 
These data are from a single experiment which is representative of three 
others.
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{top panel, figure 5) and which was readily detectable at 1 minute and was sustained 
for 15 minutes, following B7.1 stimulation {top panel, figure 5).
DETECTION OF PHOSPHO-pll05 IN pllOS IMMUNOPRECIPITATES IN 
RESPONSE TO B7.1 STIMULATION.
In order to further examine the serine phosphorylation of pi 105 which is brought about 
by B7.1 ligation, immunoblot analysis of anti-pll05 immunoprecipitates derived from 
resting or B7.1 stimulated Jurkat cells, using anti-pll05P and anti-pll05 antibodies, 
was carried out. Anti-pll05P antibodies were a kind gift from Bart Vanhasebroeck, 
(Ludwig Institute, London) and had been raised in rabbits immunised with a synthetic 
peptide (1028KTKVNWLAHNVSPKDNR1044Q, where S p=  phospho-serine). This 
revealed the appearance of phospho-pl 105 in anti-pl 105 immunoprecipitates after B7.1 
stimulation (figure 6). The kinetics of the association mirrored that observed for 
association of phospho-Ser pi 105 with CD28, in that the marked association of 
phospho-pl 105 could be detected at 5 minutes. However, in contrast to the co- 
precipitation of phospho-pl 105 with CD28, phospho-pl 105 could still be detected in 
anti-pl 105 immunoprecipitates 15 minutes following B7.1 stimulation (figure 6). 
Recombinant p85a-pll05 and p85a-phospho-pll05 proteins were immunoblotted in 
parallel and demonstrated Ab specificity. Re-probing with anti-pl 105 Ab demonstrated 
equal loading and transfer of immunoprecipitated protein (figure 6).
IN VITRO LIPID KINASE ACTIVITY OF CD28 ASSOCIATED pllO  
ISOFORMS.
In an attempt to measure the effects of CD28 ligation on different pi 10 isoforms 
enzymatic activity, Jurkat T cells were stimulated using CHO-B7.1+ cells and each 
pi 10 isoform was immunoprecipitated, and their in vitro lipid kinase activity was 
examined. Anti-pl 10a immunoprecipitates exhibited high basal in vitro lipid kinase 
activity which decreased upon B7.1 ligation (figure 7). In contrast anti-pl 1 Op 
immunoprecipitates showed low basal lipid kinase activity which was markedly 
increased upon CD28 ligation by B7.1. This activity was sustained for up to 5 minutes 
post CD28 ligation. Finally anti-pl 105 immunoprecipitates displayed transient lipid 
kinase activity which was basally low but elevated to maximal level at 1-2 minutes post 
activation which had returned to basal levels within 5 minutes. As a positive control the 
lipid kinase activity associated with anti-CD28 immunoprecipitates from CHO-B7.1+
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Figure 6: Appearance of phospho-pl 105 in p i 105 
immunoprecipitates after CD28 ligation by B7.1.
2 x l0 7 Jurkat cells were either stimulated with B7.1 expressing CHO cells 
or left unstimulated as a control (C). Cells were lysed and immuno­
precipitated with 1 pg anti-pl 108 antibody. As a control 2 x l07 Jurkats 
were lysed and immuno-precipitated with 1 pg anti-p85 or anti-pl 108 
antibodies, and electrophoresed with the above precipitates and control 
peptides, representing, p85a-phospho-l 108, and p85a-pll08. Samples 
were separated by 7.5 % SDS-PAGE and transferred onto nitro cellulose 
for immunoblotting with anti-phospho-pl 108 at a concentration of 1 pg 
per ml in 0.05 % marvel/PBS. Blots were then stripped and re-probed 
with anti-pl 108 antibody at 1 pg per ml in 0.05 % marvel/PBS, to verify 
equal loading of immunoprecipitated protein (bottom panel). Proteins 
were visualised via chemiluminescence. These data are from a single 
experiment and are representative of three other experiments.
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Figure 7: Comparison o f p i 10a, p i 10(3 p i 108 and CD28 associated vitro 
lipid kinase activity.
2 x l0 7 Jurkat cells were either left unstimulated as a control (C), or stimulated with CHO-B7.1+ 
cells, at a ratio of 3:1 respectively. Cells were lysed and immunoprecipitated with 1 pg of 
either anti-CD28 mab 9.3, or anti-pl 10 a, (3 and 8. Immunoprecipitates were then incubated 
with [32P]-yATP, and phosphatidylinositol, in lipid kinase buffer, at 37°C for 20 mins (as 
detailed in Materials and Methods. Resultant [32P]-phoshphatidylinositol lipids were separated 
by TLC, and visualised by autoradiography (left hand panels). Autoradiograph data shown are 
from a single experiment and are representative of four experiments. Autoradiographs were 
subject to densitometric analysis, and data values representing lipid kinase activity attributable 
to CD28, p i 10a, p, or 8 immunoprecipitates was expressed as a percentage of lipid kinase 
activity immunoprecipitated from resting cells (% of control). The error bars represent the 
mean ± SEM for four separate experiments (Right hand panels).
2000
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stimulated Jurkats was assessed and revealed an increase in lipid kinase activity after 
ligation of CD28. The lipid kinase activity present in p85 immunoprecipitates and whole 
cell lysates is also indicated (figure 7).
EFFECTS OF OKADAIC ACID AND WORTMANNIN TREATMENT ON pllOS 
PHOSPHORYLATION IN VITRO
One interpretation of the data outlined in the above experiments is that CD28 can 
stimulate the autophosphorylation of pi 105, through activation of pllOS’s intrinsic 
'serine kinase activity which elicits a regulatory auto^hosphorylation of the pi 105 C- 
terminus. In order to verify that the protein kinase activity measured in this assay was 
attributable to PI3K kinase activity and not to a contaminating protein kinase, the 
sensitivity of the phosphorylation of pi 105 to the PI3K inhibitors LY249002 and 
wortmannin and measured. Given that PI3K’s exhibit dual specificity, as both lipid and 
protein kinases, it was necessary to verify that was sensitive to PI3K inhibitors.
Initially, in vitro kinase assays were carried out using immunoprecipitates derived from 
CHO-B7.1 stimulated Jurkat T cells. However as these preliminary assays were 
unsuccessful, immunoprecipitates derived from the hCD28 transfected T cell hybridoma 
DC27.1 were employed. It was observed that the in vitro phosphorylation of a 110 kDa 
protein associated with anti-pl 105 immunoprecipitates was basally elevated in non 
stimulated cells. The phosphorylation of this band was further elevated upon CHO- 
B7.1+ stimulation and was maximal at five minutes (figure 8). In addition to the 110 
kDa band, phosphorylation of further bands of approximately 59 kDa, 56 kDa, and 52 
kDa could be seen in immunoprecipitates from resting cells, which was slightly elevated 
following CHO-B7.1+cell stimulation. Furthermore, it was demonstrated that the in vitro 
kinase activity associated with pi 105 immunoprecipitates from B7.1 stimulated DC27.1 
CD28+ T cells, could be abrogated by the PI3K inhibitor wortmannin. Hence the 100, 
59 56, and 52 kDa phospho proteins described above, were completely absent following 
wortmannin treatment (Figure 8). Cells were also treated in parallel with okadaic acid, a 
Ser/Thr phosphatase protein I and protein phosphatase Ila inhibitor, which demonstrated 
that inhibition of basally active serine phosphatases allowed an increase in levels of 
pi 105 phosphorylation in resting DC27.1 CD28+ T cells (see figure 8). Finally, as a 
positive control, kinase activity associated with anti-p85a immunoprecipitated proteins
a - p i  105 IPs
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Figure 8: Effect of wortmannin and okadaic acid treatment on 
CD28 mediated phosphorylation of p i 105 and In Vitro kinase 
activity associated with p i 105- immunoprecipitated protein 
complexes.
2xl07 DC27.1 CD28+ T cell hybridoma cells were either left untreated (C) or 
stimulated with CHO-B7.1+ cells at a ratio of 3:1 respectively, and then lysed.. 
To analyse the effects of wortmannin and okadaic acid pre-treatment on in vitro 
phosphorylation of pi 105, 2x l07 cells were either treated with 50 nM 
wortmannin (Wm), prior to stimulation, or treated with 10 nM okadaic acid 
(OA) left unstimulated. Samples were immunoprecipitated with 1 pg anti-pl 105, 
or anti-p85a as a positive control and assayed for in vitro kinase activity, by 
incubation with [ 2P]-ATP, and Na2+ATP in kinase buffer. Nascent [32P]- 
labelled proteins were separated via SDS-PAGE on a 12cm, 10% gel, and 
visualised by autoradiography. These data are from a single experiment and are 
representative of two other experiments.
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were examined, and the presence of a 110 kDa band, and a fainter 85 kDa band reflected 
the basal phosphorylation state of p85 and 110 isoforms in this cell line.
SUMMARY
1. High levels of the PI3K product PI(3,4,5)P3 were basally present in unstimulated 
Jurkat T cells.
2. In accordance with previous studies, ligation of the CD28 co-receptor by B7.1 
led to a rapid elevation of PI(3,4,5)P3 levels, which was maximal at ten minutes.
3. Expression of PI3K catalytic isoforms pi 10a, pllOP, and the novel leukocyte 
expressed catalytic isoform, pi 108 can be detected in jurkat T cells, 
pi 108 protein was also detected in freshly isolated human T lymphocytes and 
cultured human T lymphoblasts, consistent with the leukocyte restricted 
distribution of this catalytic isoform.
4. B7.1 stimulation of Jurkats, led to the co-association of pi 10(3 and pi 108 with 
the CD28 coreceptor. The consistent detection of pi 10a in CD28 
immunoprecipitates was not possible.
5. Auto-phosphorylation of pi 108 occurs in response to CD28 ligation by B7.1, 
and is maximal at 10 minutes but diminishes at fifteen minutes post stimulation.
6. B7.1 ligation induces phosphorylation of the total cellular pool of pi 108, which 
occurs rapidly and is sustained at 15 minutes.
7. B7.1 ligation of CD28 regulates the intrinsic lipid kinase activity associated with 
immunoprecipitates of PI3K isoforms, pi 10a p 110(3 and pi 108, measured in 
vitro. Lipid kinase activity associated with anti-pl 10a IPs is abrogated 
following CD28 ligation. Anti-pl 1 Op IPs exhibit elevated lipid kinase activity 
upon B7.1 ligation which is sustained at 5 minutes. Anti-pl 108 IPs exhibit initial 
lipid kinase activity, however this is abrogated after 5 minutes, which correlates 
with the serine phosphorylation of pi 10 8 observed by western blotting.
8. pi 108 exhibits a basal level of phosphorylation which is elevated upon B7.1 
ligation, as detected via an in vitro kinase assay. Phosphorylation of pi 108 is 
abrogated in vitro by pre-treatment of cells with the PI3K inhibitor wortmannin 
prior to B7.1 stimulation. Treatment of cells with okadaic acid dramatically 
enhances basal levels of pi lOd phosphorylation. (Phosphoproteins of 59,56,
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and 52 kDa can also be detected in association with pi 108, and the 
phosphorylation of these proteins in response to CD28 stimulation is observed 
and can be inhibited by wortmannin. Furthermore okadaic acid treatment of cells 
enhances the basal phosphorylation of these unidentified proteins).
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3.1 DISCUSSION - CD28 AND PI3K
The CD28 mediated activation of PI3K, and the concomitant production of D-3 
phosphoinositides, has been extensively described in T cells (Ward et al 1993) and 
occurs at a 5-10 fold greater magnitude than activation of PI3K via the TCR (Ward et al
1992). In particular, the accumulation of the rare phosphoinositide PI(3,4,5)P3 in 
response to receptor ligation, may represent a critical upstream component of a co­
stimulatory signalling pathway that is driven by the CD28 co-receptor. However, the 
role of PI3K in CD28 mediated costimulation is very controversial; Pharmacological and 
genetic studies have presented conflicting evidence as to the importance of PI3K in T 
cell costimulation. Studies in which truncation mutants of the CD28 cytoplasmic tail 
were expressed in T cell hybridoma cells, suggested that PI3K association with tyrosine 
residues within the CD28 tail was not essential for efficient costimulation (Nagel et al 
2000). Earlier studies in Jurkat T cells demonstrated that wortmannin inhibition was not 
sufficient to inhibit IL-2 production and abolition of tyr 170 of the CD28 tail, which 
prevents PI3K association, did not inhibit CD28 mediated costimulatory signals leading 
to IL-2 production (Truitt et al 1995, Lu et al 1995). Furthermore T cells from p85 a  
knockout mice do not exhibit impaired T cell responsiveness, data which further 
contributes to the controversy surrounding PI3K’s relationship to CD28 (Suzuki et al 
1999, Fruhman et al 1999). This study therefore sought to further investigate the nature 
of the interaction between CD28 and PI3K.
CD28 MEDIATED PI(3,4,5)P3 ACCUMULATION
This study has described in vitro data which indicates that the CD28 driven 
accumulation of PI(3,4,5)P3, observed by this and previous studies (Ward et al 1993) to 
occur in Jurkats, may be largely attributable to the pi 1 Op catalytic isoform of PI3K. 
The rapid and sustained stimulation of pi 10 (3 in vitro lipid kinase activity, seen in this 
study upon CD28 ligation, closely correlates with B7.1 induced PI(3,4,5)P3 
accumulation in intact cells. In contrast, CD28 is shown here to mediate the negative 
regulation of pi 10a and pi 105 lipid kinase activity. Thus this study implicates pi 10(3 as 
the major catalytic isoform which acts to couple CD28 to a diverse array of intracellular 
pathways, that culminate in IL-2 production (Ward et al 1995), T cell proliferation 
(Karnitz et al 1995) and cell survival (Parry et al 1997). However, the physiologically
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relevant regulatory mechanisms involved in PI3K activation in vivo may not be wholly 
represented by in vitro analysis of lipid kinase activity, and as such these data can only 
be taken as an indication of the CD28 mediated regulation of different PI3K isoforms. 
For example the existence of 4- and 5- lipid kinases, which may contaminate immuno­
precipitated PI3Ks, could also contribute to the [32]-P labelled PI-P detected by a lipid 
kinase assay.
PI 108 PROTEIN KINASE ACTIVITY
The identification of pi 108, a newly characterised pi 10 isoform specifically expressed 
in leukocytes, has raised questions regarding the physiological role of this isoform, 
which up until now has been predominantly studied in vitro (Vanhaesebroeck et al 
1997). Furthermore, the observation that pi 108 displays auto-serine phosphorylation 
capacity which has been described to occur in vitro and to minimal levels in B cells and 
mast cells (Vanhaesebroeck et al 1997) has led to the use of pi 108 as a working model 
by which the protein kinase activity of PI3Ks can be studied. The catalytic domains of 
all PI3Ks share homology with the kinase domain of protein kinases, and this 
observation led to the identification of lipid and protein kinase activities for class I and 
m  PI3Ks (Hunter et al 1995).
This study has demonstrated that the intrinsic protein kinase activity of pi 108 is 
activated in response to CD28 ligation, and targets serine residue 1039 within the pi 108 
catalytic domain. Not only does this novel observation suggest that CD28 mediates the 
regulation of a set of functionally distinct PI3K catalytic isoforms, but it has also led to 
the suggestion that CD28 may target an as yet unidentified array of protein targets via 
pi 1 OS’s protein kinase activity. The identification of physiological substrates for the 
class I and HI PI3K protein kinase activities has been limited and most PI3K protein 
kinase activities that have been demonstrated either autophosphorylate their catalytic 
subunits (Stoyanova et al 1997) or target the associated adaptor subunits (Carpenter et al
1993). One exception is the classlA PI3K pi 10a which has been putatively described 
to phosphorylate the insulin receptor substrate, IRS-1 (Lam et al 1994, Uddin et al
1997). In addition to the autophosphorylation capacity of pi 108, the class IB PI3K, 
pllOy has intrinsic autophosphorylation capacity. In contrast to pi 108, however, 
pi lOy’s protein kinase activity has not been associated with the negative regulation of its
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lipid kinase activity (Stoyanova et al 1997). However, pi 10a protein kinase activity can 
impart negative regulation of its own lipid kinase activity through the serine 
phosphorylation of p85a (Carpenter et al 1993). Whilst this study did not examine the 
phosphorylation of p85a in p85/pl 10a heterodimers, or conclusively demonstrate a co­
association between p85 and pi 10a, it is interesting to note that CD28 stimulated a 
marked down regulation of the constitutive lipid kinase activity that could be 
immunoprecipitated via pi 10a. Hence, lipid kinase activity attributable to pi 10a may 
also be negatively regulated by CD28 ligation. Conjecture could surmise that the CD28 
driven negative regulation of pi 10a lipid kinase activity is conferred via the serine 
phosphorylation of p85a by pi 10a.
It is therefore unclear whether in addition to autophosphorylation of pi 105, the CD28 
mediated activation of pi 105 protein kinase activity targets unidentified protein 
substrates. The existence of unique biochemical targets for pi 105’s protein kinase 
activity would parallel the accumulating evidence which describes the role of the PI3K 
like kinase domain of the PIK related proteins (mTOR, ATM) in mediating in vivo 
protein phosphorylation of a mounting array of substrates (Brunn et al 1997, Shieh et al 
1997, Canman et al 1998). Further evidence that PI3K protein kinase activity can target 
exogenous protein substrates has arisen from studies in which protein kinase only pi lOy 
mutants were demonstrated to direct the phosphorylation of MEK1 (Bondeva et al
1998).
pllOS - LIPID KINASE ACTIVITY
This study has illustrated pi 105 ’s role in a physiologically relevant signalling cascade. 
The observed serine phosphorylation of pi 105 described above correlates with the CD28 
mediated negative regulation of pllOS’s lipid kinase activity. This observation may 
support previous work which suggests that auto phosphorylation of pi 105 elicits the 
inhibition of pi 105s lipid kinase activity (Vanhaesebroeck et al 1999). Structural 
analysis suggests that the phosphorylation of Serine1039, which would create a negative 
charge in the C-terminal region of pi 105 surrounding this residue, may be sufficient to 
abrogate the binding of lipid substrates as this region has been implicated in binding to 
inositol head groups (Vanhaesebroeck et al 1999). Indeed the artificial creation of a
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negative charge at serine 1039 (D-E) of pi 10 8 correlates with a reduction in lipid 
kinase activity (Vanhaesebroeck et al 1999).
The current study has demonstrated that the lipid kinase activity of pi 105 may be 
negatively regulated following CD28 ligation by pi 1 OS’s intrinsic protein kinase activity 
which mediates phosphorylation of serine 1039:
1) B7.1 stimulation of Jurkat cells mediates the down regulation of anti-pl 106 
immunoprecipitates in vitro lipid kinase activity.
2) Data gained through the immunoblotting of anti-pl 108 immunoprecipitates 
suggests that pi 108 is serine phosphorylated in response to CD28 ligation.
3) In vitro data indicates that pi 108 is subject to protein phosphorylation 
following B7.1 stimulation of CD28 expressing T cell hybridoma stimulation, 
and that this phosphorylation event is mediated in a PI3K dependent fashion.
The role of CD28 mediated negative regulation of the pi 108s lipid kinase activity is not 
obvious.
Perhaps significantly, the co-association of pi 108 with CD28 is sustained over the time 
courses examined in this study, and may even increase nominally. The attenuation of 
pi 1 OS’s briefly elevated lipid kinase activity occurs shortly after the observed co­
association of CD28 and pi 108. Thus, in addition to the speculation that pi 10 8 may 
elicit the CD28 driven serine phosphorylation of as yet unidentified proteins, pi 108 
could be considered to play a role in negatively regulating lipid accumulation following 
CD28 ligation. The sustained association of quiescent p85/pll08 heterodimers with 
CD28 dimeric receptors would preclude the co-association of operational PI3K 
isoforms, namely p85/pll0p, with the p85 SH2 interaction motifs within the CD28 
cytoplasmic tail. Alternatively heterogeneity in the coupling of pi 10 isoforms to a 
single CD28 dimer may exist. Thus pi 108 may play a role in dampening PI(3,4,5)P3 
production, through the competitive inhibition of CD28/pl 1 Op associations.
The physiological significance of a role for pi 105 in down regulating the cell’s potential 
PI(3,4,5)P3 production is not easily determined. In vitro data suggests that pi 10ps co­
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association with CD28 may be sufficient to lead to the D-3 phosphoinositide production 
observed following CD28 ligation in intact cells. Furthermore, at later time points, 
serine phosphorylation of pi 108 associated with CD28 appears to diminish and this may 
correlate with a re-elevation of its lipid kinase activity. Thus, it may be that pi 105 plays 
a minor role in dampening the cells D-3 phosphoinositide production as the considerable 
association of pi 1 Op protein with CD28 has been detected and is shown to be sustained 
for 15-20 mins following receptor ligation. Furthermore, CD28 mediated PI(3,4,5)P3 
production has been described here and in previous studies (Ward et al 1996) to be 
dramatic, and reflects the sustained in vitro lipid kinase activity attributed to pi 10p and 
the co-association of pi 10p with CD28.
Later in this study the high basal activity of PI3K apparent in Jurkat T cells, which may 
be a characteristic feature of leukaemic cell lines, will be discussed. In the light of this 
data it could be considered that the significance of a regulatory mechanism controlled by 
pi 108 may vary between cell lines. This may possibly explain the difficulty 
experienced in detecting the in vitro phosphorylation of pi 108 described in Jurkat T 
cells, and the need to use an alternative cell line for these assays.
The relevance of a role for pi 108 in regulating PI(3,4,5)P3 accumulation following 
CD28 ligation could also be determined through the measurement of phosphoinositide 
production in response to receptor ligation in pi 108 deficient cells. Moreover, if the size 
of the cellular pool of pi 108 is too small to be considered to play an active role in 
regulating global cellullar levels of PI(3,4,5)P3, it may function in the regulation of 
compartmentalised PI(3,4,5)P3 production. The early lipid kinase activity of pi 108 may 
act to drive pathways activated soon after receptor ligation, which are subject to negative 
regulation at later time points. The transient re-distribution of PKB to the membrane, 
that has been observed following BCR ligation (Astoul et al 1999) but is described to 
rapidly re-localise back to the cytosol and nucleus at time points when global PI(3,4,5)P3 
production is still high, could be regulated by compartmentalised pockets of PI(3,4,5)P3 
production mediated by a distinctly regulated isoform of PI3K. The down regulation of 
pi 108 lipid kinase activity may have important implications in vivo, for example by 
supressing the anti-apoptotic action of PI3Ks in cancer cells (Franke et al 1997).
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This study has also shown that the treatment of Jurkat T cells with the PP1 and PP2a 
family phosphatase inhibitor, okadaic acid, enhances levels o f pi 106 in vitro 
phosphorylation in resting cells, suggesting that pi 106 may be a target for serine 
phosphatase activity. This observation is in accordance with prior data derived from the 
immunoblot analysis of okadiac acid treated Jurkat T cells with anti-phospho serine1039 
pi 105 antibodies (Vanhaesebroeck et al 1999). It could be proposed that the actions of 
such serine phosphatases negatively regulate levels of serine phosphorylated pi 105 and 
thus allow the accumulation of a pool of non-phosphorylated pi 108 which can 
contribute to the accumulation of D-3 phosphoinositides in a resting cell, and upon 
initial receptor ligation, whilst receptor induced autophosphorylation of pi 108 inhibits 
lipid kinase activity at later time points. The transient accumulation of [32-P] labelled 
phosphoinositides, observed via the assay of in vitro lipid kinase activity of pi 105 
immunoprecipitates, supports this model.
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SECTION 3.1- CONCLUSIONS
The recruitment of different catalytic isoforms of PI3K to CD28 upon ligation by its 
physiological ligand B7.1, adds further support to the previously identified role of PI3K 
in CD28 mediated signalling pathways. Furthermore the differential regulation of the in 
vitro lipid kinase activity attributable to each of these isoforms, upon B7.1 stimulation, 
suggested that the recruitment of different PI3K heterodimers to CD28 may be of 
functional importance. Also of particular interest is the activation of pi 1 Ob’s auto 
serine phosphorylation capacity by CD28, and the possibility of the existence of 
additional protein kinase substrates that this raises.
Through the existence of multiple catalytic isoforms, PI3K may be considered to gain 
biochemical access to the diverse array of functional outcomes mediated by CD28 
regulated PI3K dependent signalling cascades (see diagram 15). Equally, the differential 
regulation of these isoforms, as demonstrated in this study, upon receipt of a single 
extra-cellular stimulus, may facilitate the CD28 mediated control of multiple 
intracellular pathways. Thus, the bifurcation of PI3K*s biochemical impact through 















Diagram 15: Schematic representation of pll06/p85 and pll0p/p85 heterodimers 
co-association with CD28.
Following CD28 stimulation by B7.1 in Jurkats the co-association of p lio p  and pi 105 has been 
observed to occur with CD28. The potential functional outcomes of these co-associations are depicted 
above. (1.) This study has indicated that the predominant production of PI(3,4,5)P3 may occur following 
pllOp/p85 heterodimer co-association with CD28. Therefore, pllOP may be responsible for the 
recruitment of PH domain containing proteins, such as PKB, to the membrane, for subsequent activation 
by membrane proximal protein kinases. (2.) pi 105, meanwhile, may undergo an autophosphorylation 
event upon CD28 ligation through its intrinsic protein kinase activity, which down regulates its lipid 
kinase activity leading to the abrogation of PI(3,4,5)P3 production. Whether additional protein kinase 
substrates for pi 105 exist in T cells is not clear at present, but if such proteins exist they may represent 
further targets for CD28 mediated biochemical signals.
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3.2 SHIP
3.2.1 SHIP AND CD28
The 145 kDa SH2 containing 5-polyphosphatase, SHIP has been implicated in the 
degradation of the PI3K product, PI(3,4,5)P3, and hence regulation of PI(3,4,5)P3 
driven effector pathways, via conversion to PI(3,4)P2 (Damen et al 1996). Given that 
CD28 ligation results in the major accumulation of PI(3,4,5)P3 (Ward et al 1995) this 
study aimed to determine whether SHIP is coupled to and/or regulated by CD28.
The murine T cell hybridoma DC27.1 clone DWT6.11, which is a human CD28 
(hCD28) stable transfectant (Pages et al 1996), has been previously demonstrated to 
express considerable levels of 145 kDa SHIP (Edmunds et al 1999). This cell line was 
therefore chosen as a model in which to study the effects of CD28 ligation on SHIP 
tyrosine phosphorylation. Ligation of CD28 in this cell line was achieved with the anti- 
CD28 mAb, 9.3, which recognises human CD28. The physiological ligand for CD28, 
B7.1, was not the tool of choice in this model since one might expect murine expressed 
CD28 to contribute to the biochemical cascade. However cytometric analysis of hCD28 
versus mCD28 expression has demonstrated approximately 50 fold higher levels of 
hCD28 (personal communication, Steven Burgess).
CD28 SPECIFICALLY MEDIATES TYROSINE PHOSPHORYLATION OF 
SHIP.
In unstimulated DC27.1 cells, there is no apparent basal phosphorylaton of SHIP 
detectable in anti-SHIP immunoprecipitates (figure 9). Ligation of hCD28 in this cell 
line, with the anti-human CD28 monoclonal antibody 9.3, results in the rapid tyrosine 
phosphorylation of 145 kDa SHIP after 1 minute of stimulation, and this is sustained for 
up to 10 minutes following ligation (figure 9).
Several groups have reported the tyrosine phosphorylation of SHIP in response to 
FCyRIIB engagement in B cells (Chacko et al 1996). It was therefore important to 
establish that the observed tyrosine phosphorylation of SHIP after CD28 ligation was 
not due to any FCyRIIB association with the FC region of the 9.3 mAb. Several lines of 
evidence indicate that FCyRIIB ligation does not occur. Firstly, the control isotype 
matched (figure 9) IgG2a did not induce tyrosine phosphorylation of SHIP in anti-SHIP 
immunoprecipitates. Secondly, it was established that SHIP tyrosine phosphorylation 
was not mediated through FCyRIIB binding using the FCyRII/III blocking antibody,
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Figure 9: Tyrosine phosphorylation of SHIP following CD28 
ligation with anti-CD28 antibody 9.3.
2 x l07 DC27.1 hCD28+ T cell hybridoma cells were either left unstimulated as 
a control (C), or stimulated with 5 jig either anti CD28 antibody, 9.3, or with 
an isotype matched mouse IgG 2a antibody. Cells were lysed and subject to 
immunoprecipitation with l|ig  anti-SHIP polyclonal antibody. Precipitated 
proteins were separated via 7.5% SDS-PAGE and transferred onto nitro­
cellulose for immunoblotting with anti-phospho tyrosine antibody, 4G10, at a 
concentration of Ipg per ml in 0.05% marvel/PBS. Blots were subsequently 
stripped and re-probed with anti-SHIPAb at lpg per ml in 0.05% marvel/PBS, 
to verify equal loading of immunoprecipitated protein. Proteins were 
visualised via chemiluminescence. These data are from a single experiment and 
are representative of three other experiments.
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2.4G2. This antibody blocks non-antigen specific binding of immunoglobulins to the 
mouse FCyRII and FCyRin. Pre-treating cells with this antibody had no effect on the 
levels of SHIP tyrosine phosphorylation observed following hCD28 stimulation via 
mAb 9.3 in anti-SHIP immunoprecipitates (figure 10). Finally the ligation of CD28 via 
specific ligand B7.1, on CHO-B7.1+ cells, also stimulated the strong tyrosine 
phosphorylation of SHIP (Figure 11). It should be noted that under these conditions, 
tyrosine phosphorylation may result from the interaction of B7.1 with both the 
transfected hCD28 and naturally expressed murine CD28, although levels of murine 
CD28 are approximately 50 fold lower than that of transfected hCD28. The CHO cells 
on which B7.1 is presented to the hybridoma T cell line do not express detectable levels 
of SHIP, so it is unlikely that CHO cells contribute any of the tyrosine phosphorylated 
SHIP that is detected following CD28 ligation via B7.1 (figure 11). Each immunoblot 
was stripped and re-probed with polyclonal SHIP anti-serum, to confirm efficiency of 
immunoprecipitation and transfer onto nitro-cellulose membranes (figures 9, 10, and 
11).
CO-STIMULATORY SIGNALS FURTHER ENHANCE PHOSPHORYLATION 
OF SHIP.
Ligation of the TCR has been reported to stimulate the tyrosine phosphorylation of 
SHIP (Lamkin et al 1997). Given the regulatory role of CD28 on TCR-mediated T cell 
activation, it was important to compare the phosphorylation/activation of SHIP in 
response to ligation of CD28 and TCR either alone or in combination. Hence, ligation of 
hCD28 with mAb 9.3 or naturally expressed murine CD3 with the 2C11 Ab, both 
stimulated the strong tyrosine phosphorylation of SHIP to similar degrees, although the 
CD3 response was initilally stronger and appeared to be more transient in nature (Figure
12). Together these mAb were seen to stimulate an additive effect on enhanced levels of 
SHIP tyrosine phosphorylataion when compared to the levels observed in response to 
individual mAb stimulation (figure 12).
TYROSINE PHOSPHORYLATION AND ACTIVATION OF SHIP 
CORRELATE WITH SUB-CELLULAR RE-DISTRIBUTION UPON CD28 
LIGATION.
The tyrosine phosphorylation and increased activity of SHIP in response to CD28 














r 5’ v V 5’
pl45 ■







.  200 kDa
.  97 kDa
Figure 10: Tyrosine phosphorylation of SHIP in response to 
CD28 stimulation, in the presence of FCyRIII/II blocking 
antibody, 2.4G2.
2x l07 DC27.1 hCD28+ T cell hybridoma cells were either left 
unstimulated as a control (C), stimulated with 5 jug anti-hCD28 
monoclonal antibody, 9.3, or treated with 5 fig anti FCyRIII/II antibody, 
2.4G2 alone or with 9.3 antibody. Cells were lysed and immuno­
precipitated with 1 fig anti-SHIP polyclonal anti-serum. Precipitated 
proteins were separated by SDS-PAGE and transferred onto nitro-cellulose 
for immunoblotting with anti-phosphotyrosine antibody 4G10, at a 
concentration of 1 pg per ml in 0.05% marvel/PBS. Blots were 
subsequently stripped and re-probed with anti-SHIP polyclonal anti-serum 
at a concentration of 1 pg per ml 0.05% marvel/PBS, to verify equal 
loading of immunoprecipitated proteins. Proteins were visualised by 
chemiluminescence. These data are from a single experiment and are 
representative of three separate experiments.
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Figure 11: B7.1 ligation of CD28 stimulates 145 kDa
SHIP phosphorylation.
2x 107 DC27.1, CD28 transfectant T cell hybridoma cells, were either left 
unstimulated as a control (C), or stimulated with CHO-B7.1+ at a ratio of 
3:1 cells per point. Cells were lysed and immunoprecipitated with 1 pg 
anti SHIP polyclonal antiserum. As a control for SHIP expression 2x10 
CHO- B7.1+ cells were lysed and proteins either acetone precipitated 
(A.P.) or immunoprecipitated with 1 pg anti SHIP antiserum. All 
proteins were separated by 7.5 % SDS-PAGE and transferred onto nitro­
cellulose for immunoblotting with anti-phospho-tyrosine antibody 4G10 
at a concentration of 1 pg per ml in 0.05 % marvel/PBS. Blots were 
subsequently stripped and re-probed with anti-SHIP polyclonal anti­
serum to verify equal loading of SHIP proteins. Proteins were visualised 
via chemiluminescence. These data are from a single experiment and are 






Figure 12: Tyrosine phosphorylation of SHIP in response to 
CD28 ligation, CD3 ligation, and co-ligation of CD3 and 
CD28.
2xl07 DC27.1, CD28 transfected T cell hybridoma cells were either left 
unstimulated (C) or stimulated with 5 jig anti-CD28 antibody, 9.3, 5 fj.g anti- 
CD3 antibody, 2C11, or co-stimulated with 5 jig  each of 9.3 and CD28. 
2x l07 cells were lysed per point and immunoprecipitated with 1 pg anti- 
SHIP polyclonal antiserum. Precipitated proteins were separated via 7.5 % 
SDS-PAGE and transferred onto nitro-cellulose for immunoblotting with 
anti-phospho tyrosine antibody 4G10 at a concentration of 1 pg in 0.05% 
marvel/PBS. Blots were subsequently stripped and re-probed with anti-SHIP 
to verify equal loading of immunoprecipitated protein. Proteins were 
visualised via chemiluminescence. These data are from a single experiment 
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analysed by sub cellular fractionation and immuno-fluorescence microscopy (A figure
13). Subcellular fractionation of resting and stimulated DC27.1 cells was carried out in 
order to investigate the effects of CD28 ligation on the cellular redistribution of 145 kDa 
SHIP protein. Fractionation of unstimulated cells demonstrated that the predominant 
proportion of SHIP protein resided in the cytoplasmic fraction of resting cells. However 
upon CD28 ligation by CHO-B7.1+ cells, a redistribution of SHIP protein from 
cytoplasmic fractions into membrane fractions was observed. Visualisation of SHIP 
distribution by confocal microscopy confirmed that CD28 ligation did indeed induce the 
cellular redistribution of SHIP. Under resting conditions, immunofluorescent staining of 
cells, with anti-SHIP polyclonal anti-serum, revealed a punctate distribution of SHIP 
protein throughout the cytoplasm (B figure 13). However there was a marked re­
distribution of SHIP upon CD28 ligation, such that very little SHIP protein remained in 
the cytoplasm, and that SHIP protein in CD28 stimulated cells was predominantly 
localised at the membrane (B figure 13). Control experiments, using pre-immune rabbit 
anti serum in place of the primary antibody, revealed no significant staining, 
demonstrating the specificity of the anti- SHIP polyclonal anti-serum and secondary 
antibody staining (B figure 13).
CD28 COUPLING TO PI3K IS NOT REQUIRED FOR SHIP TYROSINE 
PHOSPHORYLATION.
Previous work by this group has shown that CD28 and SHIP do not co-precipitate 
(Edmunds et al 1999), however the inablity to detect an association of SHIP with CD28, 
may suggest that the coupling of these proteins requires the involvement of intermediate 
molecules. Earlier work also demonstrated that no co-precipitaton could be detected 
between p85 and PI3K and therefore the p85 subunit of PI3K is unlikely to physically 
couple SHIP to CD28 (Edmunds et al 1999). An alternative hypothesis is that PI3K 
may influence the coupling of SHIP to CD28, through the binding of the D3 
phosphoinositide lipid products of PI3K to PH domains of adaptor proteins or to the 
SH2 domain of SHIP (Han et al 1998, Rameh et al 1995). Thus it could be predicted 
that D-3 phosphoinositides, formed in response to CD28 ligation, could interact with the 
SH2 domain of SHIP and recruit SHIP to the membrane where it would be tyrosine 
phosphorylated by CD28 activated PTKs. Alternatively D-3 phosphoinositides might 
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Figure 13: Cellular re-distribution of SHIP in response to a-CD28 
ligation
20xl06 cells DC27.1 CD28+ T cell hybridoma cells were stimulated with 5 pg anti 
CD28 mAb 9.3, or left unstimulated as a control. Cytoplasmic and membrane 
fraction were purified as detailed in Materials and Methods, and separated by 7.5% 
SDS-PAGE, prior to transfer onto nitrocellulose for immunoblotting with anti-SHIP 
Ab (1 pg pre ml in 0.05% Marvel PBS). Proteins were visualised using ECL (Panel 
A).
lxlO6 DC27.1 CD28+ T cell hybridoma cells were either stimulated with 5 pg anti- 
CD28 antibody 9.3, or left unstimulated as a control, and cytospun at 1,000RPM onto 
a microscope slide. The slide was then fixed for 10’ with 1% paraformaldehyde and 
permeabilised with acetone and then stained with either, anti-SHIP polyclonal 
antiserum, or anti rabbit polyclonal anti serum. Slides were washed thoroughly with 
PBS/Tween and coated with anti-Rabbit FITC antibody. Cells were then visualised 
by confocal microscopy (Panel B).
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and/or protein tyrosine kinases, which may then be responsible for the observed 
recruitment to the plasma membrane, and/or tyrosine phosphorylation of SHIP.
To investigate the possibility of the PDK dependency of CD28 mediated tyrosine 
phosphorylation of SHIP, the ability of CD28 to mediate tyrosine phosphorylation was 
compared in DC27.1 cells expressing either wild type CD28 or site-specific CD28 
mutants in which the PDK binding motif around Y l173 as well as around Y 200 (which 
has also been implicated in the recruitment of PDK (Pages et al 1996)) were mutated to 
Phe (AYF173/200). It has been previously demonstrated using this mutant that 
disruption of Y173 and Y200 prevents CD28 coupling to PDK and D-3 phosphoinositide 
accumulation following CD28 ligation (Pages et al 1996). However use of the 
YF173/200 mutant revealed that such mutagenesis of CD28 had little effect on CD28 
stimulated tyrosine phosphorylation of SHIP compared to that observed in wild type 
CD28-expressing DC27.1 cells (Top panel, Figure 14). Efficiency of 
immunoprecipitation was confirmed by stripping an re-probing blots with anti-SHIP 
polyclonal antiserum (Bottom panel, Figure 14).
SUMMARY
1. 9.3 mAb ligation of CD28 results in the tyrosine phosphorylation of the 145 kDa 
SHIP in the DC27.1 T cell hybridoma.
2. FCyRIIB stimulation does not contribute to SHIP tyrosine phosphorylation by
9.3 mAb stimulation.
3. Co-stimulation of CD3 and CD28 receptors stimulates tyrosine phosphorylation 
of SHIP in an additive fashion.
4. CD28 stimulated tyrosine phosphorylation of SHIP correlates with the 
redistribution of SHIP from the cytosol, to the plasma membrane.
5. CD28 stimulated tyrosine phosphorylation of SHIP is independent of CD28 
coupling to PDK.
3.2.2 SHIP AND CTLA4
As described in the introduction to this study the CD28 relative, CTLA4, has been 
described to play a negative regulatory role in T cell activation. The signal transduction 
pathways by which CTLA4 achieves this role are not yet fully understood. CTLA4 is
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Figure 14: Tyrosine phosphorylation of 145 KDa SHIP
following CD28 ligation, in DC27.1 wild type CD28+ and 
the mutant CD28+ T cell hybridoma.
DC27.1 hCD28 transfected, and DC27.1 hCD28 AYF173/200, T cell 
hybridoma cells were either left unstimulated as a control or stimulated 
with 5 pg anti hCD28 antibody, 9.3. 20x106 cells were lysed and proteins 
immunoprecipitated using lpg anti-SHIP polyclonal antiserum. The 
resultant proteins were separated by SDS-PAGE and transferred onto 
nitro-cellulose for immunoblotting with anti-phosphotyrosine antibody, 
4G10 (lpg  per ml in 0.05% Marvel). Blots were subsequently stripped and 
re-probed with anti-SHIP polyclonal antiserum at (lpg  per ml in 0.05% 
Marvel) to verify equal loading of immunoprecipitated proteins. These 
data are from a single experiment and are representative of three separate 
experiments.
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transiently expressed on the T cell surface 2-3 days after T cell activation. It has been 
demonstrated to associate with PI3K via a YXXM motif in its cytoplasmic tail. In an 
attempt to elucidate the nature of these signalling cascades this study describes the 
effects of CTLA4 triggering, by a panel of antibodies, on the production of the PI3K 
metabolic product PI(3,4,5)P3, and also describes a role for SHIP in mediating the 
CTLA4 signal. As CTLA4 is known to play a negative regulatory role in T cell function, 
and CTLA4 ligation had been demonstrated by data presented below to result in a 
decrease in cellular PIP(3,4,5)P3 levels and a concomitant rise in PI(3,4)P2, it seemed 
plausible that the lipid 5’-phosphatase SHIP might be regulated by CTLA4 triggered 
signalling cascades.
INTRACELLULAR AND SURFACE STAINING OF CTLA4.
The study of CTLA4 signalling pathways is hindered by the fact that surface expression 
of this protein is negligible due to constitutive internalisation via AP-1 mediated 
endocytosis (Bradshaw et al 1997). Comparison of CTLA4 surface versus intracellular 
expression demonstrated by the DC27.1 CTLA4+ cell line (kind gift from Chris Rudd) 
using the anti CTLA4 mAb 11D4, identified that although the majority of protein was 
internalised, moderate CTLA4 surface expression was apparent in this cell line (Figure 
15).
PROLIFERATION IN RESPONSE TO ANTI CTLA4 MABs.
To characterise the in vitro effects of CTLA4 ligation, induced by CTLA4 antibodies, 
3D6 and CT29 (generously provided by Carl June), the ability of these antibodies to 
impair CD3/CD28 induced proliferation of freshly purified primary T cells was 
measured. CTLA4 mAbs had been previously coupled Dynal™ beads, at a ratio of 
8:1:1 with anti CD3 and anti CD28 abs respectively.
In vitro proliferative responses, measured via 3H incorporation, show that 3D6 and CT29 
anti CTLA4 antibodies are able to inhibit CD3 and CD28 mAb stimulated proliferation 
(Figure 16). It appeared that these antibodies were able to mimic the proliferative 
effects of CTLA4 stimulation in vitro (Krummel et al 1995, Walanus et al 1996) that 
had previously been described, and that they were suitable for further molecular 
characterisation of the CTLA4 mediated inhibitory signal.
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Figure 15: Intracellular and surface FACS staining for 
CTLA4 expression
5xl05 CTLA4 expressing hybridoma cells were either fixed with 
paraformaldehyde and permeabilised with saponin, for intracellular 
staining, or left unfixed for surface staining, and incubated for 1 hr at 4 
°C with I pgrnf1 either anti-CTLA4 antibody, 11D4 (grey histogram), or 
an isotype matched murine IgG2a as a negative control (black 
histogram). After washing cells were incubated with anti-mouse FITC 
for 30 minutes at 4 °C, then washed and analysed for CTLA4 expression 
















Figure 16: Proliferation of primary T cells in response to 
CTLA4 CD3 and CD28 stimulation.
Freshly purified T cells were incubated with anti-CD3 anti-CD28 and either 
anti CTLA4 antibody 3D6, or anti CTLA4 antibodyCT29. Plates were 
pulsed at 48hrs with [3H] thymidine, and harvested 24 hrs later. 
Proliferation was measured via the incorporation of [3H] thymidine, in 
response to each set of stimuli. These data represent the mean ± SEM from 
three separate experiments.
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ACCUMULATION OF D3 INOSITOL LIPIDS IN RESPONSE TO CTLA4 
STIMULATION.
Having verified the functional consequences of CTLA4 ligation via anti CTLA4 mAbs, 
CT29 and 3D6, their effects on biochemical readouts were ascertained. Using the 
CTLA4 expressing murine T cell hybridoma line, cells were stimulated with anti 
CTLA4 mAb 3D6 and CT29. PI(3,4,5)P3 levels measured in resting cells demonstrated 
moderate levels of basal PI3K activity (Figure 17), which, upon ligation with either 
3D6 or CT29 decreased considerably (Figure 17). Conversely measuring cellular levels 
of PI(3,4)P2 demonstrated a clear increase in levels of this phosphoinositide following 
CT29 and 3D6 treatment, suggesting that ligation of CTLA4 promotes the 
dephosphorylation of PI(3,4,5)P3 resulting in a steady increase in PI(3,4)P2,
ACTIVATION OF SHIP IN RESPONSE TO STIMULATION THROUGH 
CTLA4
To investigate whether SHIP is implicated in signalling pathways initiated by CTLA4, 
the CTLA4+ T cell hybridoma was used. CTLA4 was either ligated by its natural ligand 
B7.1, or by anti-CTLA4 antibodies 3D6 and CT29, whilst anti mouse CD3 mAb, 2C11, 
was used to stimulate cells as a positive control and anti-human CD28 and anti hCD3 
mAb (UCHT1) were used as negative controls. It must be noted that B7.1 can stimulate 
mCTLA4 and mCD28 in addition to the hCTLA4 receptor expressed by this cell line. 
Stimulated and resting cells were lysed, immunoprecipitated with anti-SHIP polyclonal 
antiserum, and immunoblotted with anti-phosphotyrosine mAb 4G10. The presence of a 
145-150kDa band, which increased in intensity upon stimulation with B7.1, 3D6 and 
was particularly prominent following stimulation with CT29, suggested that SHIP 
activation might be a downstream effect of CTLA4 stimulation (figure 18). Similarly, 
stimulation through mCD3 with 2C11 mAb produced tyrosine phosphorylation of this 
protein (Figure 18). Finally stimulation with anti hCD28 mAb 9.3, and anti hCD3 mAb 
UCHT1 for 5 minutes did not induce the tyrosine phosphorylation of 145 kDa SHIP. 
Immunoblotting with anti-SHIP polyclonal antiserum confirmed the identity of the 145 
kDa phospho-protein as SHIP, and demonstrated equal loading, and transfer, of 
immunoprecipitated proteins (Figure 18).































Figure 17: D-3 phosphoinositide lipids accumulation of 
response to anti-CTLA4 stimulation.
20xl06 DC CTLA4+ T hybridoma cells were labelled per point with 
[32P]Pi for 3 hrs at 37°C in phosphate free medium supplemented with 
10% dialysed FCS and HEPES. Cells were then stimulated with anti- 
CTLA4 antibodies, 3D6 and CT29 for 5 minutes. Reactions were 
quenched with chloro-form:methanol, and the phosohatidylinositol 
lipids were extracted from each sample as described in materials and 
methods. Finally samples were de-acylated prior to analysis via HPLC. 
Results are plotted as actual peak area. Actual counts = PI(3,4,5)P:*: 
Control: 587; 3D6: 348; CT29:123cpm; PI(3,4)P2: Control: 150; 3D6: 
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Figure 18: Tyrosine phosphorylation of SHIP in response to 
CTLA4 ligation.
2x l07 CTLA4 expressing T cell hybridoma cells, DC 27.1, were either left 
unstimulated as a control (C), or stimulated with either CHO-B7.1+ cells (at 
a ratio of 3:1 respectively), 5 pg anti-CTLA4 mAbs, 3D6 and CT29, anti- 
mCD3 mAb, 2C11 or, as negative controls, 5 pg anti-hCD28 antibody 9.3, 
or anti-hCD3 antibody UCHT1. Cells were lysed and subject to immuno- 
precipitation with 1 pg anti- SHIP polyclonal anti-serum. Precipitated prot­
eins were separated by 7.5 % SDS-PAGE and transferred onto nitro­
cellulose membranes for immunoblotting with anti-phosphotyrosine 
antibody, 4G10 at 1 pg per ml in 0.05 % marvel/PBS. Blots were stripped 
and re-probed with anti-SHIP polyclonal anti-serumat 1 pg per ml in 0.05 
% to verify equal loading of immunoprecipitated proteins. These data are 
from a single experiment which is representtive of two other experiments.
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TYROSINE PHOSPHORYLATION OF SHIP IS A SPECIFIC CTLA4 
MEDIATED EVENT
As described earlier (section SHIP 3.2) and by Chacko et al (1996), FCyRIIB ligation 
strongly induces the tyrosine phosphorylation of SHIP in B lymphocytes. To rule out the 
possibility that FCyRIIB receptor binding, by FC regions of the anti- CTLA4 mAbs used 
in this study, can contribute to the SHIP tyrosine phosphorylation observed following 
CTLA4 stimulation, a F(ab’)2 fragment of anti CTLA4 mAb, CT29 was utilised. F(ab’)2 
fragments of antibodies lack FC regions and so would not be able to bind non 
specifically to FCyRIIB receptors.
CTLA4+ hybridoma T cells were stimulated with anti-CTLA4 CT29 (F(ab’)2 and 
immunoprecipitated with anti-SHIP polyclonal antiserum. Immunoblotting with anti 
phosphotyrosine antibody 4G10 revealed that a 145-150 kDa band was heavily tyrosine 
phosphorylated in response to CTLA4 ligation by CT29 F(ab’)2 (Figure 19). 
Immunoblotting with anti-SHIP polyclonal antiserum identified this protein as SHIP and 
verified equal loading of immunoprecipitated protein (Figure 19). Therefore tyrosine 
phosphorylation of SHIP following treatment with anti-CTLA4 mAbs is not attributable 
to FC receptor triggered PTK activity and must therefore be a direct consequence of 
CTLA4 ligation.
SUMMARY
1) Anti-CTLA4 mAbs, CT29 and 3D6 inhibit CD28 / CD3 mediated proliferation 
of primary T cells in vitro.
2) Stimulation of the CTLA4 expressing T cell hybridoma DC27.1via anti-CTLA4 
mAbs, CT29 and 3D6 mediates the reduction of cellular PI(3,4,5)P3 levels, 
which correlates with an increase in levels of PI(3,4)P2-
3) Stimulation of DC27.1 with either anti-CTLA4 mAbs, CT29 and 3D6, anti­
murine CD3 mAb, 2C11 or CHO-B7.1+ cells induces rapid tyrosine 
phosphorylation of the inositol 5’-polyphosphatase SHIP.
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Figure 19: F(ab’)2 CT29 induced tyrosine phospho­
rylation of SHIP in the CTLA-4 expressing T cell 
hybridoma DC.
DC27.1 Cells were either left un-stimulated as a control or stimulated 
using 5 pg anti- CTLA-4 F(ab’) CT29. 20xl06 cells per point were 
lysed and immunoprecipitated with 1 pg anti- SHIP. Precipitates were 
separated by 7.5 % SDS-PAGE and transferred to nitro-cellulose for 
immunoblotting with anti-phosphotyrosine antibody 4G10 at 1 pg per 
ml in 0.05% Marvel in PBS. Blots were stripped and reprobed with 
anti- SHIP to verify equal loading of immuno-precipitated proteins. 
Proteins were visualised via chemiluminescence.
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3.2.3 REGULATION OF BASAL LEVELS OF 3’PHOSPHOINOSITIDES
This study has described the identification of 145 kDa SHIP as a target for CTLA4 and 
CD28 mediated signals in T lymphocytes. SHIP’S role in the regulation of PI3K 
dependent signalling cascades in T lymphocytes, via the enzymatic degradation of the 
phosphoinositide lipid product PI(3,4,5)P3, has therefore been discussed. The lack of 
detectable levels of SHIP expression in the Jurkat T cell line has been previously 
demonstrated, and recently the lack of expression of the tumour suppressor PTEN has 
also been reported (Shan et al 2000). As such, the study of the Jurkat T cell line as a 
SHIP and PTEN ‘null model’ may provide useful insight into the role of inositol 
polyphosphatases in the regulation of PI(3,4,5)P3 levels in T cells. We sought to 
investigate the effect of SHIP and PTEN deficiency on constitutive levels of D-3 lipids 
and PKB activation in J6 versus A20 cells.
3’-PHOSPHOINOSITIDE IN RESTING JURKAT T CELLS VERSUS A20 B 
CELLS.
Firstly, it was considered whether the absence of SHIP expression in Jurkats influences 
basal levels of 3-phosphoinositides in this cell line. Metabolic labelling experiments, in 
which phosphoinositide lipids were labelled with [32P]- orthophosphate, were carried out 
and 3-phosphoinositide levels in Jurkat T cells were compared to those in unstimulated 
A20 BALB/c mouse B lymphoma cells. It was observed (table 5) that unstimulated 
Jurkats exhibit basal levels of PI(3,4,5)P3 levels which are approximately five fold 
greater than basal levels of PI(3,4)P2- Upon ligation of the CD28 receptor complex 
(TCR), there was a two fold increase in the PI(3,4,5)/)3 levels above basal. In contrast, 
in the A20 cell line, basal levels of PI(3,4,5)P3 were low and basal levels of the 3’- 
phosphoinositide PI(3,4)P2 were more prominent. Triggering of the B cell antigen 
receptor (BCR) induced a 10-12 fold increase in detectable levels of PI(3,4,5)P3 (table 5) 
and just over a two fold increase in PI(3,4)P2.
DETECTION OF SHIP IN VARIOUS T CELL LINES
In order to demonstrate the absence of SHIP expression in Jurkat T cells in comparison 
to primary T lymphoblasts and A20 B cells, whole cell lysates were prepared from each 
of these cell types and blotted with anti-SHIP polyclonal antiserum.
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Treatment PI(3,4)P2 (cpm) PI(3,4^)P3 (cpm)
A20 Cells:
Basal 2008 ±  381 777 ±  293
F(ab’)2 5499 ±  665 9863 ± 2345
Jurkat Cells:
Basal 565 ±  335 3431 ±  1021
9.3 836 ±  350 6373 ±  1638
Table 5: Basal and stimulated levels of 3’-phosphoinositide lipids in 
Jurkat and A20 Cells.
2xl07 [32P]-labeled Jurkat cells or A20 cells were left unstimulated or stimulated at 37 
°C with 10 mg/ml anti-CD28 mAb 9.3 for 10 minutes or with 12pg F(ab’)2 fragments of 
rabbit anti-mouse IgG (RAMIG) for 5 minutes respectively. The 3’-phosphoinositide 
lipids were extracted, deacylated and the glycerophosphorylinositol derivatives of
PI(3,4)P2 and PI(3,4 ,5)P3 analysed by HPLC separation. Data is mean cpm values ±  
standard errors from at least five experiments.
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This demonstrated that, in accordance with earlier data by this group and others, SHIP 
expression cannot be detected in Jurkat T cells (figure 20), whilst it was readily 
detectable in whole cell lysate derived from A20 B cells and T lymphoblasts (figure 
20). ( NB: only a single SHIP isoform could be detected, which represented 145 kDa 
SHIP. This was most likely due to the use of a different anti-SHIP antibody for this 
experiment, than had been used in the prior sections of this study).
DETECTION OF PTEN PROTEIN IN A20 CELLS AND CTLA4 EXPRESSING 
HYBRIDOMA CELL LINE DC27.1.
Previous work has shown that PTEN is not expressed in J6 (Shan et al 2000). To 
investigate whether PTEN was expressed in the cell models used in this study whole cell 
lysates derived from the A20 B cell line and the DC27.1 hybridoma cell line were 
immunoblotted with anti PTEN mAbs. PTEN is a more recently described lipid 
phosphatase which dephosphorylates PI(3,4,5)P3 at the D-3 position and could thus 
contribute to the abrogation of accumulation of D-3 phosphoinositides observed in 
response to FCyRIIB co-ligation. It was therefore considered whether PTEN could be a 
potential regulator of PI3K lipid products in A20 cells, and moreover in lipid 
signalling pathways in T cells.
To establish whether A20 cells express the lipid phosphatase PTEN cell lysates were 
titrated from 20x106 to 2xl06 cell equivalents (figure 21). In addition lysates of the T 
cell hybridoma, DC27.1, were titrated in a similar manner. Immunoblotting with anti- 
PTEN antibody revealed a band of approximately 50 kD which was visible down to 
2xl06 cell equivalents in the DC27.1 cell line but was only faintly visible at 20 and 
lOxlO6 cell equivalents in A20 cells (Figure 21).
CELLULAR LOCALISATION OF GFP-PKB-PH IN JURKAT T CELLS
Having identified basally high levels of 3’-phosphoinositides exhibited by Jurkat T cells, 
a construct expressing the green fluorescent protein-tagged pleckstrin homology domain 
of the serine threonine kinase, protein kinase B (PKB), GFP- PKB PH (kindly provided 
by Julian Downward ICRF, London) was transfected into Jurkats. The binding of 
phosphoinositides to the PH domain of this construct determines the membrane 
localisation of GFP in cells. The GFP-PH-PKB construct has been used previously in 
B cells (Astoul et al 1999) to visualise the membrane re-localisation of PKB upon
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Figure 20: Expression of 145 kDa SHIP in A20 B cells, Jurkat T cells, 
and cultured T lymphoblasts.
2xl06 A20 B cells, Jurkat T cells, and cultured T lymphoblasts were lysed and acetone 
precipitated woth 0.7 volumes of ice cold acetone. Following centrifugation, proteins were 
separated via 7.5 % SDS PAGE and transferred onto nitro-cellulose for immunoblotting 
with anti-SHIP polyclonal antiserum (Santa Cruz) at a concentration of 1 pg per ml in 0.05 
% marvel/PBS. These data are from a single experiment and are representative of three 
other experiments.
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Figure 21: Differential expression of PTEN in CTLA4 hybridoma and 
A20 cells.
DC27.1 CTLA4+ and A20 cells were lysed at the cell densities shown. Pro­
teins were acetone precipitated and separated via 7.5 % SDS-PAGE, 
transferred onto nitro-cellulose, and immunoblotted with anti-PTEN mAb at a 
concentration of lpg per ml in 0.05 % marvel/PBS. Proteins were visualised 
by chemiluminescence. These data are from a single experiment ahich was 
representative of two others.
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antigen receptor ligation: In resting A20 cells, GFP-PH-PKB was cytoplasmically 
localised and BCR ligation triggered re-localisation to the membrane. This correlated 
with the phosphorylation of endogenous PKB. Overexpression of active PI3K (CD2- 
pl 10) by this study (Astoul et al 1999) elicited the constitutive membrane recruitment of 
GFP-PH-PKB.
Localisation of GFP-PH-PKB at the membrane in Jurkat T cells (figure 22, top left 
panel) correlated with the basally high levels of 3’-phosphoinositides measured in this 
cell line. As a negative control transfection of Jurkats with a non 3’ phosphoinositide 
binding PKB-PH domain mutant (GFP- PKB-PH-R25C). (Rameh et al 1997), and 
immunofluorescent staining, demonstrated the predominant localisation of GFP 
throughout the cytosol in a diffuse manner, with non fluorescing areas indicating 
exclusion of the GFP from the nucleus (figure 22 top right panel).
LY249002 INHIBITION OF PI-3K INDUCES CELLULAR REDISTRIBUTION 
OF GFP-PKB-PH
To gauge the dependency of membrane localisation of GFP-PKB-PH on D-3 lipids, the 
PI3K inhibitor LY249002 was used. The re-localisation of transfected GFP-PKB-PH 
was visualised via immuno-fluorescent-microscopy. GFP-PH-PKB was predominantly 
detected at the membrane until 30 minutes post LY249002 treatment (figure 23), after 
which a significant re-localisation to the cytoplasm could be observed. At 1 hour post 
LY94002 treatment, the majority of GFP-PKB-PH could be visualised in the cytosol 
(figure 23).
CHARACTERISATION AND EXPRESSION OF CD2-SHIP CONSTRUCTS
To investigate the effects of overexpressing catalytically active and mutant SHIP against 
a null SHIP background, Jurkat T cell were transiently transfected with rCD2-SHIP and 
rCD2-SHIP-C671A which were generously provided by Doreen Cantrell, ICRF London. 
These constructs comprised the minimum catalytic core (aa 364-825) of SHIP, or C671A 
mutants of this sequence fused to the intra-cytoplasmic domain of CD2, thus localising 
active or dominant negative to the plasma membrane (figure 24 A.).
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CD2-SHIP CD2-SHIP-C70i/A
Figure 22: Cellular re-localisation of GFP-PH-PKB by co­
expression of rCD2-SHIP and rCD2-SHIP-C701/A.
Jurkat T cells were transiently transfected at 1.5xl07 cells per ml by 
electroporation with green fluorescent protein tagged PKB-pleckstrin homology 
domain cDNA, GFP-PH-PKB, or a non-lipid binding PH mutant GFP-R2 C 
PH-PKB, using 10 pg of plasmid per 1.5xl07 cells. In addition cells were 
transiently co-transfected with 30 pg of cDNA representing the catalytic 
domain of SHIP fused to the CD2 transmembrane domain, CD2-SHIP, or a 
catalytically dead SHIP enzymatic domain fused to the CD2 transmembrane 
domain CD2-SHIP-C70I/A. Following electroporation cells were re-suspended 
in RPMI, 10% FCS and layered onto cover slips in 24 well plates. Cells were 
incubated at 37°C for five hours, and then washed in PBS and fixed for 10’ 
with 1 % paraformaldehyde and then visualised by confocal microscopy.
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+ 30pg L Y 15’
GFP-PH(PKB) GFP-PH(PKB)
+ 30pg L Y 249002 lhr
Diagram 23: Inhibition of GFP-PH (PKB) membrane localisation 
by Ly249002
Jurkat T cells were transiently transfected at 1.5xl07 cells per ml by electroporation 
with green fluorescent protein tagged PKB-pleckstrin homology domain cDNA, 
GFP-PH-PKB, using 10 pg of plasmid per 1.5xl07 cells. Following electroporation 
cells were re-suspended in RPMI, 10% FCS and layered onto cover slips in 24 well 
plates. Cells were treated at the times indicated with 30pM LY249002 prior to 
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M UTANT ACTIVE SHIP IP
Figure 24: Analysis of 5 ’-polyphosphatase activity of CD2'(enz)SHIP 
and CD2- (enz)ASHIP constructs.
15x 106 Jurkat T cells per ml were electroporated with 30 pg rCD2-SHIP or rCD2- 
SHIP-C67IA (A.). Following electroporation cells were resuspended in RPMI 10% 
FCS, and allowed to express overnight. 2x l07 cells were lysed and 
immunoprecipitated with 1 pg anti-CD2 antibody 0X34. As a control 2x l07 
DC27.1 cells were lysed and 100 pi of lysate was removed, and acetone precipitated 
as a control and precipitated with 1 pg anti-SHIP polyclonal anti-serum 
Precipitated proteins were equally split and either separated via 7.5% SDS/PAGE 
and immunoblottted with anti CD2 mAb 0x34 at a concentration of 1 pg per ml in 
0.05 % Marvel/PBS (B.); alternatively IPs assayed for 5’ phosphatase activity by 
measurement of in vitro hydrolysis of [3H]-ins(l,3,4,5)P4 to [3H]-ins(l,3,4)P3. Data 
are from a single experiment (C.).
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To determine the in vitro phosphatase activity of rCD2-SHIP and rCD2-SHIP-C671A , 
anti-rCD2 immunoprecipitates, derived from Jurkat cells which had been transfected 
with these constructs, were assayed for their ability to catalyse the degradation of [ H]- 
Ins (1,3,4,5)P4 to [3H]-Ins (1,3,4)P3 (Figure 24 C.). The rCD2-SHIP construct catalysed 
the degradation of 98.9 % [3H]-Ins (1,3,4 ,5)P4. Whilst the anti-CD2 immunoprecipitates 
from the rCD2-SHIP-C671A transfected cells were able to catalyse the degradation of 28 
% of the [3H]-Ins (1,3,4,5)P4. Meanwhile the anti SHIP immunoprecipitate from the 
resting DC27.1 cell lysate catalysed the degradation of 90% of the [3H]-Ins (1,3,4,5)P4. 
Comparative expression of constructs was established by immunoblotting samples of 
acetone precipitated lysates and anti-rCD2 immunoprecipitated protein from transfected 
samples, with anti-CD2 mAbs (figure 24B.).
CELLULAR RE-LOCALISATION OF GFP-PKB-PH IN JURKAT T CELLS 
VIA THE CO-EXPRESSION OF CD2-SHIP
The in vitro assays proved to be inconsistent thus an alternative method was therefore 
sought by which to assess the activity of rat CD2-SHIP constructs. Hence, given that this 
study had previously shown that J6 do not express either PTEN or SHIP and that they 
express elevated levels of PI(3,4,5)Pj, (which correlate with constitutive membrane 
localisation of GFP-PKB-PH domains) it was reasoned that co-expression of rCD2- 
SHIP mutants with GFP-PKB-PH would assess the effect of rCD2-SHEP constructs on 
the localisation of the GFP- tagged PH domains.
Cells were co-transfected with GFP- PKB PH and either rCD2-SHIP or rCD2-SHIP- 
C A and subject to immunofluorescence microscopy. As a negative control 
transfection of Jurkats with PKB-PH domain mutant (GFP- PKB-PH-R25C) (Rameh et 
al JBC 1997) and immunoflourescent staining demonstrated the predominant 
localisation of GFP in these cells throughout the cytosol in a diffuse manner, with non 
fluorescing areas indicating exclusion of the GFP from the nucleus.
Confocal imaging of GFP-PKB-PH and CD2-SHIP co-transfected cells revealed a 
marked re-distribution of the GFP-PKB-PH protein from the plasma membrane to the 
cytoplasm of the cell (figure 22, bottom left hand panel), when compared with cells 
transfected with GFP-PKB-PH alone. The diffuse localisation of fluorescence across the
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cytoplasm outlined the lobular nucleus as a non fluorescing area, indicating the 
exclusion of GFP protein from this structure. Meanwhile co-expression of CD2-SHIP 
with GFP-PKB-PH, had no effect on the distribution of GFP-PKB-PH, which retained a 
strict plasma membrane co-localisation (figure 22, bottom right hand panel).
SUMMARY
1) Jurkat T cells exhibited high basal levels of PI(3,4,5)P3 and PI(3,4)P2- These 
basal levels of 3’-phosphoinositide are demonstrated here to mediate the 
retention of GFP-PKB-PH at the plasma membrane.
2) Inhibition of constitutive PI3K activity via LY249002 treatment of Jurkat cells, 
mediated the re-localisation of GFP-PKB-PH from the plasma membrane into 
the cytosol which occurred after 30 minutes and was complete at 1 hour.
3) Overexpression of rCD2-SHIP in Jurkats, which has been demonstrated here to 
convey in vitro 5’ phosphatase activity on [3H]- Ins (1,3,4,5)P4, mediates a 
marked cytosolic re-localisation of GFP-PKB-PH away from the membrane.
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3.2 DISCUSSION
3.2.1 CD28 AND SHIP
145 kDa SHIP is classified as a type III member of the family of inositol-5’-poly 
phopshatases which are outlined in the introduction to this study. SHIP specifically 
degrades the D-3 phosphoinositide PI(3,4,5)P3 to PI(3,4)P2 and has been heavily 
implicated by this study in the signalling cascades regulated by the TCR/CD3 
complex and CD28. Data provided by this study indicate that SHIP is a 
biochemical target for CD28 mediated signals and may play a role in regulating T 
cell activation in response to costimulatory signals. Interestingly, 145 kDa SHIP is 
not expressed in Jurkat T cells and thus this study employed the use of the CD28+ T- 
cell hybridoma, DC27.1, which has been previously demonstrated by this group to 
express high levels of the 145 kDa isoform of SHIP, Previous reports in other cell 
lines have described an array of SHIP related proteins, and in the DC27.1 cell line 
additional SHIP related proteins of 155, 135 and 130 were reported to be 
immunoprecipitated with the 145 kDa isoform by the SHIP polyclonal antiserum 
used in this study (Edmunds et al 1999). Furthermore the existence of SHIP species 
of varying molecular weight could account for the multiple SHIP proteins seen by 
this study when re-probing anti-SHIP immunoprecipitates with anti-SHIP antibody.
Although the 145 kDa isoform is generally the largest form of SHIP consistently 
detected, additional 160 and 150 kDa SHIP related proteins have also been described 
(Ono et al 1996, Lioubin et al 1996), and these could represent the 155 kDa SHIP 
related band seen in whole cell lysates from the DC27.1 hybridoma (Edmunds et al 
1999). Additional reports suggest that this band might be SHIP2, which could be 
putatively detected via antibody cross reactivity. A further 135 kDa band in DC27.1 
is likely to be either the 135 kDa splice product, which lacks a 183 nucleotide region 
downstream of the first NPXPY motif that may alter the specificity of SH2 domains 
binding this motif. Alternatively this band could represent a 135 kDa catalytic 
degradation product of the 145 kDa protein which has also been reported (Lucas and 
Rohrschneider et al 1999).
Detection of these proteins may be cell type specific, as demonstrated here by the 
differential expression of SHIP proteins observed between Jurkat and T lymphoblast 
cells. Further, the varying estimates of molecular weight of these bands and their 
differential recognition by a variety of SHIP specific antibodies has added to the
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heterogeneity of SHIP proteins that have been detected, and this has been 
demonstrated here by the differential detection of SHIP isoforms by antibodies used 
in this study. An interesting observation, that SHIP proteins of increasing molecular 
weight can be detected in bone marrow and immature haematopoietic cell lines as 
differentiation proceeds, suggests that the existence of a variety of SHIP proteins 
may be of functional significance (Geier et al 1997). It would appear that some of 
these isoforms are attributable to the specific proteolytic degradation of full length 
SHIP, which occurs progressively from the C-terminus and may be mediated by a 
member of the calpain family (Damen et al 1998). Furthermore the existence of the 
SHIP related SIP-110 (Lucas et al 1999), which lacks the SH2 domain of SHIP and 
is not phosphorylated in response to growth factor receptor signalling, is derived 
from alternatively spliced full length SHIP and demonstrates that different SHIP 
proteins may be regulated by distinct mechanisms.
This study demonstrates that ligation of CD28 via anti CD28 mAbs induces the 
tyrosine phosphorylation of SHIP. Interestingly, SHIP displays low basal tyrosine 
phosphorylation in the DC27.1 cell line, which contrasts with reports of high basal 
SHIP tyrosine phosphorylation in IL-3 dependent (Damen et al 1996) and IL-2 
dependent (Lamkin et al 1997) cell lines, whilst reflecting observations made in 
other T cell lines (Lamkin et al 1997). CD28 ligation via B7.1, the CD28 
physiological ligand, stimulates tyrosine phosphorylation of SHIP in a manner 
consistent with that produced via anti-CD28mAb ligation. Whilst supporting the 
physiological relevance of CD28 mediated phosphorylation of SHIP, this finding 
clearly demonstrates the CD28 specificity of this response. Furthermore, it is shown 
that FCyREB/RIIIB ligation via mAb FC regions, which has been described to lead 
to SHIP phosphorylation in B cells (Chacko et al 1997), has no influence on the 
tyrosine phosphorylation of SHIP induced in response to CD28 mAbs.
Previous studies have demonstrated that the enhanced phosphorylation of SHIP can 
be achieved through the simultaneous ligation of the CD3 and CD4 receptors of a T 
cell hybridoma cell line (Lamkin et al 1997). Similarly, this study has shown that an 
additive effect on SHIP tyrosine phosphorylation is observed when co-stimulation 
through the CD3 and CD28 receptors on the DC27.1 hybridoma is administered. It 
is well established that CD28 can activate PTKs such as pSb1^ *, p59Fyn and Itk (Lu et 
al 1998, Marengere et al 1997, Ward et al 1996), hence it is possible that one or more
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of these kinases may be involved in mediating tyrosine phosphorylation of either 
intermediate proteins or SHIP in response to CD28 ligation.
Although previous work by this group (Edmunds et al 1999) has shown that the 
CD28 stimulated increase in 5-phosphatase activity present in SHIP 
immunoprecipitates correlates with tyrosine phosphorylation of SHIP, a 
requirement for tyrosine phosphorylation for the enhancement of SHIPs enzymatic 
activity remains to be demonstrated. Findings described in this study appear to be 
contradictory to previous observations made which have described that the 
phosphatase activity of SHIP is negatively regulated by tyrosine phosphorylation, in 
the context of the IgE receptor mediated signalling pathways (Osborne et al 1996). 
Furthermore studies have described SHIP immunoprecipitates derived from resting 
and growth factor stimulated cells (Lioubin et al 1996) display comparative levels of 
5- phosphatase activity whilst SHIP’S recruitment to She or tyrosine phosphorylated 
complexes following growth factor stimulation is increased. This suggests that 
neither tyrosine phosphorylation nor coupling to She correlate with up-regulation of 
5-phosphatase activity (Lioubin at el 1996). Data presented in this study, by 
previous work (Edmunds et al 1999), therefore indicate that signalling pathways, 
mediated by CD3 and CD28 in T cells, possess a distinct pattern of events leading to 
the enzymatic activation of SHIP to those which regulate SHIP in growth factor 
mediated signalling pathways. At present, however, the function that tyrosine 
phosphorylation of SHIP plays in the regulation of 5-phosphatase activity is still 
unclear.
A further possibility exists in that the tyrosine phosphorylation of SHIP could be 
required for the adaptor protein mediated re-localisation of SHIP to the plasma 
membrane. The tyrosine residues located within the C terminal NPXPY motif of 
SHIP have been previously demonstrated to interact with She phosphotyrosine 
binding domain (Lamkin et al 1997) and, more recently, the N-terminal 
phosphotyrosine binding domain of p62 Dok-1 has been demonstrated to associate 
with the same SHIP motif (Tamir et al 2000). Furthermore, as the SHIP SH2 domain 
does not participate in these interactions it may be free to bind additional proteins 
which might influence its function. Thus SHIPs relocalisation with the plasma 
membrane through the interaction of its phosphotyrosine residues with the PTB 
domains of other signalling proteins may mediate its approximation with its lipid 
substrates in the membrane, and thus up-regulate its enzymatic function. In
SECTION 3.2-DISCUSSION 128
accordance with this model, data described by this study have demonstrated the 
effects of CD28 ligation on the cellular re-distribution of SHIP to the membrane.
SHIP has previously been reported to associate directly with a phosphorylated 
immunoreceptor tyrosine-based inhibition motif (ITIM) present in the cytoplasmic 
domain o f FCyRIIB, I/LxYxxL (Tridandapani et al 1997, Tridandapani et al 1997b). 
Furthermore, interactions between the TCR/CD3 complex phosphorylated 
immunoreceptor tyrosine based activation motifs (ITAMS) and SHIP have also been 
described (Osborne et al 1996). However whilst CD28 contains four potential sites 
for tyrosine phosphorylation (Y173, Y 188, Y 191, and Y200), none of these lie within any 
reognised ITAM or ITIM motif. Furthermore, in previous work published by this 
group it was not possible to demonstrate a physical association between SHIP and 
CD28. Given the lack of a recognised SHIP binding motif within the CD28 
cytoplasmic tail, it is possible that CD28 couples to SHIP via intermediate adaptor 
molecules. Although an association between PI3K and a 5-phosphatase has been 
described in other systems (Liu et al 1996, Gupta et al 1999), it seems unlikely that 
PI3K is involved in the recruitment and activation of SHIP by CD28, since 
mutagenesis of the PI3K binding sites within the CD28 cytoplasmic tail had no effect 
on the ligation stimulated tyrosine phosphorylation of SHIP. Nevertheless the 
presence of proline rich and PTB domains within SHIP gives it potential for diverse 
biochemical interactions with a plethora of other proteins. In this respect there are at 
least two candidate adaptor proteins, namely Grb-2 and p62 Dok-1 which have been 
reported to co-associate with CD28 (Nunes et al 1996 and Schneider et al 1995) and 
which may therefore mediate an interaction between CD28 and SHIP.
Although the phosphorylation of SHIP, observed in response to CD28 and CD3 
ligation indicates SHIP as a target for PTKs regulated by these signalling pathways, 
the significance of SHIP’S function in CD28 and CD3 mediated signalling pathways 
has not yet been elucidated. Previous studies with SHIP'7' Rag'7' mice have reported 
normal TCR and CD28 -driven proliferation and IL-2 production (Liu et al 1998). 
The existence of alternative phosphatases may be able to substitute for SHIP in the 
SHIP-/- Rag'7' mice since SHIP is unlikely to be the only 5 -phosphatase with 
specificity for PI(3,4,5)P3. For example the identification of the 5-phosphatase 
SHIP2 may explain the lack of severe defects in SHIP-/- mice, (Pesesse et al 1997). 
SHIP2 is the closest relative of SHIP, exhibiting around 38% overall identity, with
SECTION 3.2-DISCUSSION 129
SHIP2 may explain the lack o f severe defects in SHIP-/- mice, (Pesesse et al 1997). 
SHIP2 is the closest relative o f SHIP, exhibiting around 38% overall identity, with 
64% identity within the 5- phosphatase domain, and contains all the major structural 
features which have been described to be present in SHIP (Wisniewski et al 1999). 
SHIP2 has been described as a 155 kDa protein, and potentially antibody cross 
reactivity may mean that SHIP2 represents the 160 kDa band seen in whole cell 
SHIP immunoblots. SHIP and SHIP2 are not entirely redundant phosphatases 
however as, in contrast to SHIP, which can mediate the degradation o f  PI(3,4,5)/?3 
and Ins(l,3,4,5)P4, SHIP2s’ substrate specificity is limited to PI(3,4,5)7*3 
(Wisniewski et al 1999). In addition, whilst expression o f SHIP is limited to 
haematopoietic and spermatogenic tissues, the wider expression pattern o f SHIP2 
protein may implicate it in the regulation o f alternative phosphoinositide metabolism 
pathways to SHIP.
Furthermore the enzymatic action o f the tumour suppressor PTEN has been 
described to mediate degradation o f the PI3K product PI(3,4,5)/*3 through a 3- 
phosphatase activity (PTEN). Interestingly the phenotype o f PTEN _/" mice is more 
severe than that o f SHIP-/- mice, resulting in embryonic lethality (Di Cristofano et al 
1998). In addition, the existence o f 5- phosphatases which may regulate PI(3,4,5)jP3 
accumulation and the accumulation o f the lipid product o f SHIP PI(3,4)7*2 in T cells 
have been described (Woscholski et al 1997). These 5-phosphatases share homology 
to PTEN through the amino acid sequence C(X)sR at the active site (Zhang et al 
1994).
Therefore the activation o f SHIP by CD28 may act, in concert with other 5’ poly 
phosphatases, and polyphosphatases outside o f this family such as PTEN and 4- 
phosphatases as a negative feedback control on the CD28- activated PI3K dependent 
signalling cascade (Diagram 2). SHIP would facilitate the controlled removal o f  
PI(3,4,5)i*3 and thus remove a membrane targeting signal for PH domain containing 
signalling molecules such as PKB and Tec kinases which are biochemical targets for 
CD28 (Parry et al 1997, Marengere et al 1997). A similar role for SHIP has been 
reported in the case o f SHIP mediated inhibitory signalling cascades on PI(3,4,5)i*3 
/Btk dependent signalling in B cells following FCyRIIB ligation (Bolland et al 1998 
and Scharenberg et al 1998).
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An alternative interpretation o f the role o f SHIP mediated degradation o f PI(3,4,5)P3 
in CD28 driven signalling pathways can be given in which SHIP operates to shunt 
signalling away from PI(3,4,5)7*3 dependent effectors, towards effectors that are 
driven by PI(3,4)P2, thus achieving diversity within the PI3K dependent signalling 
cascade (Diagram 2). This suggestion could explain the findings o f one study which 
demonstrated that the catalytic activity o f SHIP can play a positive role in IL-4 
mediated signalling pathways (Giallourakis et al 2000). The notion that PI(3,4,5)P3 
and PI(3,4)P2 exert different functional outcomes is contentious. For instance, while 
in vitro studies reveal that both these phosphoinositides exert similar potency for the 
binding o f certain PH domains (Han et al 1998), other studies have revealed major 
differences in their effect on PKB activation (Alessi et al 1998, Franke et al 1997, 
Freeh et al 1997, Klippel et al 1997). Thus it is unclear from in vitro studies 
whether distinct PI(3,4)P2 driven pathways actually exist, although the situation in 
vivo may be quite different. However, in platelets, integrin ligation leads to an 
elevation in cellular levels o f PI(3,4)7*2 and which correlates with the stimulation o f  
PKB, without any increase in PI(3,4,5)P3, and this supports the existence o f  
pathways which are differentially regulated by these phosphoinositides (Banfic et al 
1998). The notion that SHIP may facilitate the shunting o f the PI3K dependent 
signalling pathways to downstream effectors differentially driven by D-3 
phosphoinositides fits well with the array o f functional responses attributable to 
PI3K. Such variance within a single signalling pathway may facilitate the numerous 
functional outcomes attributed to CD28, which include the regulation o f T cell 
proliferation, IL-2 production, regulation o f other cytokines/chemokines and their 
receptors as well as promotion of cell survival. Moreover, the growing repertoire o f  
PH domain containing signalling molecules, that have been identified to mediate 
enzymatic or adaptor roles within the cell, implicate SHIP as a key regulator o f  
CD28 driven functional events via the degradation o f PI(3,4 ,5)P3.
3.2.2 CTLA4 AND SHIP
CTLA4 has been previously demonstrated to associate with the p85 adaptor subunit 
o f PI3K via the YVKM motif situated within the cytoplasmic tail o f CTLA4 
(Schneider et al 1995). Prior studies have demonstrated that ligation o f CTLA4 with 
anti-CTLA4 antibodies resulted in an elevation o f in vitro lipid kinase activity 
associated with anti- CTLA4 imunoprecipitates (Schneider et al 1995). Data 
presented here has demonstrated a marked decrease in cellular levels o f PI(3,4,5)7*3,
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in response to anti-CTLA4 ligation. Furthermore an elevation o f PI(3,4)P2 levels 
can be observed, which is roughly equal in magnitude to the decrease in PI(3,4,5)P3. 
Initial comparison suggests that these data are in conflict with data presented by 
previous studies (Schneider et al 1995). However, fundamental differences in the 
techniques used by this study and those used by previous studies could explain the 
discrepancy in their findings.
Whilst the in vitro approach employed by Schneider et al allows the assignment o f  
lipid kinase activity to specific protein complexes, the modulation o f this activity 
observed in response to receptor ligation may be non-physiological. Differences 
between the data presented by this study and by Schneider may therefore be 
attributable to the following: Firstly, immunoprecipitation o f proteins from whole 
cell lysates may exclude other proteins which in an intact cell would elicit receptor 
mediated regulation o f lipid kinase activity. Secondly, the contamination o f  
immunoprecipitates, by lipid kinases other than PI3K, may contribute to the lipid 
kinase activity measured. Thirdly, whilst the analysis o f [ P]- labelled 
phosphoinositide profiles from intact cells, as conducted by this study, can 
demonstrate more physiological patterns o f receptor stimulated 3 ,-phosphoinositide 
accumulation, the extent o f the contributory role played by particular lipid kinases or 
regulatory proteins can only be estimated and must therefore be further examined in 
vitro. Thus, whilst Schneider et al demonstrated that CTLA4 ligation, enhances 
PI3K activity measured in vitro, data described by this study suggests that the 
products o f CTLA4 stimulated PI3K activity may be subject to negative regulation 
by lipid phosphatases. However, an alternative interpretation o f these data would be 
that following ligation o f CTLA4 PI3K activity leads to a dis-proportionate elevation 
ofPI(3,4)P2 as compared to levels o f PI(3,4,5)P3.
The analysis o f anti-SHIP immunoprecipitates by this study, demonstrated that 145 
kDa SHIP is a target for CTLA4 stimulated PTK activity. These data implicate SHIP 
in the regulation o f D3-phosphoinositide levels following CTLA4 ligation. Previous 
studies have shown (Chacko et al 1996, Edmunds et al 1999) that the 
phosphorylation o f SHIP correlates with elevated degradation o f 5’-inositol poly­
phosphatase activity. However, there is no evidence o f a direct link between SHIP 
phosphorylation and upregulated phosphatase activity, as already discussed, and it 
may be that membrane localisation o f SHIP may dictate activation. Furthermore 
the finding that SHIP may be activated in response to CTLA4 ligation may explain 
why this study failed to demonstrate any evidence for the CTLA4 mediated elevation
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o f PI(3,4,5)P3 accumulation, despite the finding o f previous studies which had 
shown that CTLA4 ligation could enhance PI3K activity in vitro. Taken together 
the data presented here indicate that upon CTLA4 ligation, SHIP becomes tyrosine 
phosphorylated which may mediate association with other proteins, facilitating 
membrane localisation and activation, and thus leading to the degradation o f  
PI(3,4,5)P3. Alternatively membrane localisation o f SHIP, via a non 
phosphotyrosine dependent mechanism may precede tyrosine phosphorylation by 
membrane localised, CTLA4 activated, PTKs.
The coupling o f SHIP to cellular proteins has been described within various 
signalling contexts including cytokine receptor signalling (Damen et al 1996) and 
TCR mediated signalling (Lamkin et al 1996) and may be considered to mediate its 
membrane approximation in the context o f CTLA4 signalling. The cellular 
redistribution o f SHIP may occur in a phosphotyrosine dependent manner through 
interaction with SH2 domain or PTB domain containing proteins. The association o f  
SHIP with the PTB domain o f She has been demonstrated in T cells (Lamkin et al 
199) and is proposed to contribute to negative signalling in B cells through mediating 
the sequestration o f She away from Grb2/Sos complexes (Tridandapani 1997c). 
SHIP may contribute to the CTLA4 inhibitory signal by mediating the recruitment o f  
She away from Grb2.
Moreover, an interaction between CTLA 4 and the protein tyrosine phosphatase 
SHP2 has been described (Zhang et al 1997) which occurs via the association o f the 
SH2 domain o f SHP2 with the tyrosine phosphorylated cytoplasmic tail o f CTLA4. 
It is thought that SHP2 can couple to SHIP via the SHIP SH2 domain (Sattler et al
1997). Hence upon recruitment o f SHIP to the membrane by She or another PTB 
domain mediated interaction, SHIP may associate with SHP2 and directly couple to 
CTLA4. However this interaction would be dependent on the tyrosine 
phosphorylation o f the intracytoplasmic domain o f CTLA4. Interestingly recent 
studies have demonstrated that mutating the two sites o f tyrosine phosphorylation 
(Y165 and Y 182) within the intracytoplamic tail o f CTLA4 does not affect the 
inhibition o f IL-2 secretion (Cinek et al 2000). Further work has demonstrated that 
although CTLA4 is known to associate with Src related kinases (Chuang et al 1999), 
the inhibition o f ERK phosphorylation and IL-2 secretion are still able to occur in 
cell lines deficient in Zap-70 and lek (Baroja et al 2000) and thus inhibitory 
signalling is not dependent on the tyrosine phosphorylation o f the CTLA4 tail by 
these PTKs. Thus the mechanism by which SHIP achieves membrane localisation
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and activation following CTLA4 ligation is unlikely to be dependent on the tyrosine 
phosphorylation o f CTLA4 by lck or Zap 70. Meanwhile tyrosine phosphorylation 
o f CTLA4 at Y 165 has been shown to be necessary for cell surface retention (Zhang 
et al 1997) and cell surface retention alone has been shown to be sufficient for 
CTLA4 to elicit an inhibitory effect, through the sequestration o f B7.1 away from 
CD28, and thus the inhibition o f stimulatory signalling pathways leading to IL-2 
production (Baroja et al 2000)........................
CTLA4 functional models implicate this receptor in the control o f T cell activation in 
resting cells and in previously activated CD8+ T cells. A model which has been 
proposed to describe CTLA4 mediated inhibition o f naive T cell activation suggest 
that, in the absence o f T cell costimulation o f sufficient magnitude, CTLA4’s 
inhibitory effect predominates and inhibits downstream signalling pathways. 
Meanwhile in the presence o f sufficient costimulatory signals, CD28 and/TCR/CD3 
driven pathways are able to overcome CTLA4 inhibition and can lead to full scale T 
cell activation (Chambers et al 1999). The role o f SHIP in such a model could be 
explained by the SHIP mediated degradation o f PI(3,4,5)P3 which has been described 
by the current study: insufficient co-stimulation could lead to the accumulation o f a 
limited pool o f PI(3,4,5)P3 which would be rapidly removed through CTLA4 
mediated enzymatic activation o f SHIP. Meanwhile, in the presence o f stronger 
costimulatory signals, SHIP may be unable to neutralise the larger pool o f  
PI(3,4,5)P3 generated by TCR/CD28 stimulation, thus allowing T cell activation to 
proceed.
SHIP has been implicated by this study in CD28 and CTLA4 signalling pathways, 
which have opposing downstream physiological effects. The earlier interpretation o f  
the role o f SHIP in the context o f CD28 driven pathways considered that SHIP may 
provide a route for the negative feedback regulation o f the CD28 signal. The 
suggestion that SHIP may also direct CD28 mediated signalling cascades towards 
PI(3,4)P2 driven pathways, was also considered. In the absence o f sufficient 
costimulatory signals, however, SHIP’S predominant role in T cells may be 
downstream of CTLA4, where it is likely to act as a negative regulator o f 3’- 
phosphoinositide accumulation, via PI3K, providing a natural braking mechanism for 
T lymphocyte costimulatory pathways.
3.2.3 3’-PHOSPHOINOSITIDE REGULATION IN THE LEUKAEMIC 
CELL LINE-JURKAT
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Measurement o f 3’ -phosphoinositides in Jurkat T cells by this study has indicated 
high basal levels o f PI(3,4,5)P3 and PI(3,4)P2, in comparison to the levels o f these 
lipids that are detectable in the A20 B cell lymphoma cell line. The causative factors 
that may contribute to the basal 3’-phosphoinositide levels in different cell lines are 
considered here:
Firstly, the absence o f metabolic breakdown o f 3’-phosphoinositides by lipid 
phosphatases may be responsible for the basal levels o f these lipids in a particular 
cell line. Secondly, the basal levels o f P 1(3,4,5)^3 measured in a cell line may be a 
direct result o f the constitutive activity o f PI3K in those cells. Thirdly, the combined 
levels o f lipid phosphatase expression and basal PI3K activity, may each contribute 
to the resting 3’phosphoinositide levels in a given cell line.
In an attempt to determine which o f these scenarios may apply in Jurkats and A20 
cells, this study has demonstrated that the acute lymphoblastic leukaemic T cell line 
Jurkat lacks two major routes for degradation o f PI(3,4,5)P3, via the 3’-phosphatase 
PTEN (Shan et al 2000) and the inositol (poly)phosphate 3’-phosphatase SHIP. Thus 
the lack o f degradative pathways for 3’phosphoinositides may be responsible for 
their high basal levels in Jurkats. In support o f this hypothesis, this study has 
described data which demonstrates the constitutive membrane recruitment o f GFP- 
PH-PKB which results due to the high basal levels o f PI(3,4,5)/>3 in Jurkats. 
Interestingly the overexpression o f catalytically active SHIP can mediate the 
redistribution o f GFP-PKB-PH to the cytosol. These constructs expressed amino 
acids 364-825 o f 145kDa SHIP. The minimal catalytic core o f SHIP has recently 
been described as amino acids 400-866, and constructs which lacked amino acids 
450-466 were insufficient to mediate 5’ phosphatase activity in vitro (Aman et al 
2000). Data described in results section 3.2 o f this study describes the in vitro lipid 
phosphatase activity mediated by rCD2 SHIP and thus proposes that the minimal 
catalytic core o f SHIP is smaller than that proposed by Aman and co-workers. 
Indeed, the redistribution o f GFP-PKB-PH from the membrane, elicited by rCD2- 
SHIP also indicates, although does not unequivocally prove, that this region o f the 
SHIP protein is sufficient to mediate 5’ -phosphoinositide activity in vivo. This data 
further suggests that the absence o f pathways for the enzymatic degradation o f  
PI(3,4,5)P3 in Jurkats may be responsible for the high basal levels o f this lipid.
In contrast to J6 the A20 B cell lymphoma cell line expresses readily detectable 
levels o f SHIP and lower levels o f PTEN. Thus, the existence o f degradative
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pathways for PI(3,4,5)7*3 metabolism may reduce basal levels o f this lipid in A20s. 
Alternatively low levels o f 3’-phosphoinositides in A20 cells may correlate with 
nominal basal levels o f PI3K activity. Interestingly, the basal level o f PI(3,4)7*2 
measured in A20 cells is twice that o f PI(3,4,5)7*3, which may indicate that PI3K is 
basally active, but that its products are subject to negative regulation through 5’- 
phosphatase activity, leading to a disproportionate accumulation o f this lipid. Basally 
active PTEN 3’-phosphatase activity would also lower PI(3,4,5)7*3 levels, however it 
is difficult to detect the accumulation o f PI(4,5)7*2, the product o f PI(3,4 ,5)7*3 
metabolism by PTEN, as cellular levels o f this phosphoinositide are constitutively 
high in all cell types. Thus any accumulation of PI(4,5)7*2 may make an undetectable 
change to the overall cellular pool. Alternatively basally active PI3K, in A20 cells 
may preferentially phosphorylate PI(3)7* over PI(4,5)7*2, leading to the accumulation 
o f a larger cellular pool o f PI(3,4)7*2 than o f PI(3,4,5)7*3.
Work carried out more recently by this laboratory has also demonstrated that the 
basal activation o f the PI3K effector PKB, and phosphorylation o f the PKB target 
GSK-3, in resting Jurkats (personal communication Steven Burgess), correlate 
closely with 3’-phosphoinositide levels detected by this study. Previous studies have 
demonstrated that the in vitro kinase capacity o f epitope tagged PKB could be 
upregulated following antigen receptor or CD28 stimulation (Parry et al 1997) o f  
Jurkat cells. However more recent work has indicated that endogenous PKB is 
constitutively activated and that endogenous levels o f PI(3,4,5)7*3 are sufficient to 
saturate the PI3K/PKB pathway and thus uncouple it from antigen receptor 
regulation (Steven Burgess, personal communication). In accordance with these 
findings work by other groups has examined the basal states o f other targets for PI3 
K produced 3’-phosphoinositides in Jurkat T cells. It has been shown that Tec 
kinase ITK is constitutively active in Jurkats (Shan et al 2000) and that the actin 
binding cytoskeletal protein cofilin, which is regulated by costimulatory signals in 
peripheral blood lymphocytes, is constitutively dephosphorylated, and is basally 
associated with actin in resting Jurkat cells (Lee et al 2000).
Taken together these data suggest that constitutively high levels o f PI3K activity are 
displayed by Jurkat T cells, and this coupled to the lack o f lipid phosphatase 
expression by this cell line would contribute to 3’-phosphoinositide levels in these 
cells.
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Data presented in this study demonstrate that the inhibition o f PI3K in Jurkat T cells, 
by treatment o f cells with LY249002, can elicit the re-distribution o f GFP- PKB - PH 
from the membrane into the cytosol. However the kinetics o f this redistribution are 
extremely slow, with full cytoplasmic re-distribution occurring after 1 hour. 
Furthermore LY249002 treatment o f Jurkats results in the de-phosphorylation o f  
endogenous PKB and its downstream target, GSK-3, which occurs with similarly 
delayed kinetics (personal communication Steven Burgess). Thus it may be 
concluded from this data that the high basal level o f 3’phosphoinositides in the Jurkat 
cell line may not be solely dictated by basally elevated PI-3K activity, but may also 
be related to rates o f lipid degradation.
Previous studies in the A20 cell line (Astoul et al 1999) have shown that LY249002 
treatment o f cells expressing constitutively active PI3K causes the redistribution o f  
GFP-PKB-PH from the membrane to the cytosol within 30 seconds. Further analysis 
of events downstream o f PI3K, demonstrated that PKB activation and GSK-3 
phosphorylation are also rapidly attenuated, following LY249002 treatment 
administered 5 minutes after F(ab)2 treatment (personal communication, Emmanuelle 
Astoul). It may be considered that the basal activities o f SHIP and PTEN in the A20 
cell line may facilitate the rapid turnover o f PI(3,4,5)P3 produced by basally active 
endogenous PI3K activity, and thus following the inhibition o f constitutively 
expressed PI3K, 3’- phosphoinositides produced prior to PI3K inhibition are rapidly 
depleted by the basal activities o f SHIP and PTEN.
It appears that in the cell lines considered by this study both constitutively active 
PI3K and the presence or absence o f lipid phosphatases, act in concert to positively 
and negatively regulate basal levels o f 3’phosphoinositides repectively. This 
conclusion may have important connotations for the interpretation o f previous data 
which has described the failure o f PI3K inhibitors to block T cell costimulatory 
responses in Jurkat T cells (Lu et al 1995). The findings o f this study indicate that as 
Jurkat cells lack two important inositol(poly)phosphate phosphatases and require 
prolonged treatment with PI3K inhibitors to suppress PI3K responses and create 
lower cellular pools o f 3’-phosphoinositides. This means that prior studies which 
have employed the use o f PI3K inhibitors in the Jurkat T cell line may have 
underestimated the role o f PI3K in CD28 mediated signalling. Furthermore, it 
would be interesting to assess primary T cell leukaemias which may possess 
similarly elevated levels o f PI3K effectors and elevated pools o f 3’-
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phosphoinositides. In this respect, loss o f function mutations o f the PTEN gene 
locus have been identified in many human cancers (Cantley et al 2000), and 
a link between this 3’-phosphatase and the PI3K/PKB pathway is now widely 
accepted (Wu et al 1998, Myers et al 1998).
3.2.4 - CONCLUSIONS
This study has demonstrated that the tyrosine phosphorylation o f SHIP is elicited in 
response to physiological stimulation o f the CD28 receptor by its ligand B7.1. This 
finding implicates SHIP in the regulation o f PI(3,4,5)P3 accumulation in T cells in 
response to costimulatory signals. Furthermore, simultaneous ligation o f CD3 and 
CD28 induces additive tyrosine phosphorylation o f SHIP which suggests that SHIP 
may mediate PI(3,4,5)P3 accumulation downstream of both o f these receptors. It is 
proposed that SHIP may control a negative feedback pathway which acts to dampen 
signals leading to T cell activation, or that it shunts signalling towards PI(3,4)P2 
driven pathways (see diagram 14). The physical relationship between SHIP and 
CD28 is unclear, but does not appear to be dependent on PI3K association with 
CD28, or the activity o f PI3K.
CTLA4 ligation elicits a reduction in the basal levels o f 3’-phosphoinositides present 
in unstimulated T cells. This study has shown that the tyrosine phosphorylation o f  
SHIP is also induced in response to CTLA4 stimulation, and thus SHIP’S catalytic 
activity may contribute to the inhibitory signal mediated by this receptor.
The leukaemic T cell Jurkat exhibits high basal levels o f PI(3,4,5)P3 and PI(3,4)P2, 
which is considered to be due to high basal levels o f PI3K activity in this cell line 
and the lack o f inositol phosphatase expression. Furthermore this study has shown 
that the turnover o f PI(3,4,5)P3, following inhibition o f PI3K with LY249002, occurs 
with delayed kinetics, and it is therefore proposed that previous studies which have 
used PI3K inhibitors in this cell line may have misrepresented the role o f PI3K in 


















= D-3 lipid kinase domain 
= PTB domain
/ " )  =5’lipid phosphatase 
^  domain
=PH domain
Diagram 16: Schematic depiction of CD28 mediated tyrosine phosphorlyation of 
SHIP.
Tyrosine phosphorylationof SHIP is mediated by CD28 in response to ligation 
by B7.1.Tyrosine phosphorylation of SHIP is thought to mediate association of 
SHIP with She via the SHIP NPXPY binding to the PTB domain of She. The 
SHIP mediated enzymatic degradation of the PI-3 K metabolic PI(3,4,5)P3 may 
act as a negative feedback loop to attenuate PI-3 K mediated CD28 regulated 
signalling (1). Alternatively, the product of SHIPs’ enzymatic activity PI(3,4,)P2 
may act to shunt signalling towards as yet unidentified proteins whos PH 
domains bind PI(3,4)P2 (2).
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3.3 REGULATION OF PI3K DEPENDENT SIGNALLING CASCADES IN B 
LYMPHOCYTES
3.3.1 FCyRIIB MODULATION OF BCR MEDIATED SIGNALLING 
CASCADES IN A20 CELLS.
The following section of this study describes work carried out in the Balb/c B 
lymphoma cell line A20. This work was undertaken due to the existence of well 
characterised pathways, regulated by the BCR and dependent on PI3K, in this cell 
line. These pathways lead to calcium mobilisation, cell survival, antibody 
production, and proliferation (see Introduction), and are subject to negative 
regulation following co-ligation of the FCyRIIB with the BCR. The inositol-(poly) 
5’-phosphatase SHIP, which already described by this study to play a role in T 
lymphocyte signalling (see results), has been demonstrated by Scharenberg and 
others to be a pivotal effector of the FCyRIIB mediated signal (Scharenberg et al 
1998, Nakamura et al 2000). Thus the following section describes research which has 
examined the regulation of PI3K dependent signalling pathways in the B cell line 
A20.
Crosslinking the BCR in the A20 cell line is achieved using a F(ab’)2 fragment of 
rabbit anti-mouse IgG, hereafter referred to as (Fab’)2 of RAMIG. Meanwhile, BCR 
co-ligation with the FCyRIIB is accomplished using intact rabbit anti-mouse IgG 
(RAMIG). Used in equimolar amounts, comparison of the effects of F(ab’)2 and 
intact RAMIG treatment of A20 cells facilitates the dissection of stimulatory and 
inhibitory signalling cascades in this B cell model.
FCyRIIB MODULATION OF BCR INDUCED CALCIUM FLUX.
Many studies have shown that FCyRIIB co-ligation with the BCR inhib BCR 
mediated calcium flux, in a PI3K dependent manner (Ono et al 1998, Bolland et al
1998). To examine the effects of BCR ligation or BCR/FCyRIIB co-ligation on 
calcium mobilisation in A20 cells, cells were loaded with Fura-2AM and stimulated 
as described in figure 25. Calcium responses were measured by fluorimetry (Figure 
25) using the fluorescent probe fura-2AM. This experiment served to demonstrate 
that activating and inhibitory stimulation of signalling pathways, leading to calcium 
mobilisation, could be achieved in this cell line.
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Figure 25: FCyRIIB 1 and wortmannin mediated
impairment of BCR elicited calcium responses in FURA 2- 
AM loaded A20 cells.
A20 cells were loaded with Fura-2AM for 30 mins at 37°C. After 
washing in Ca 2+ Mg 2+ free HBSS, cells were resuspended in same at 
lxlO 6 cells m l'1. 1ml aliquots of the labelled cell suspension were either 
stimulated at 37°C with, 24 pg F(ab’)2 fragments of RAMIG or 40 pg 
RAMIG; alternatively cells were pre-treated at 37°C with wortmannin and 
then stimulated with F(ab’)2 of RAMIG. Calcium mobilisation was 
measured via fluorimetric analysis. These data are from a single 
experiment and are representative of six separate experiments.
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BCR ligation mediated a rapid initial phase calcium elevation followed by a gradual 
return to basal. FCyRIIB co-ligation with the BCR suppressed the initial phase 
calcium spike, and almost completely abrogated the late phase response (figure 25). 
Interestingly, the PI3K inhibitor wortmannin was able to inhibit BCR mediated 
calcium mobilisation, in a manner similar to FCyRIIB mediated inhibition of this 
response (figure 25).
FCyRIIB MODULATION OF BCR INDUCED ERK1/2 
PHOSPHORYLATION
FCyRIIB inhibition of BCR mediated Ras activation (Sarmay et al 1996), and Rafl 
(Moodie et al 1996) and ERK phosphorylation (Campbell et al 1995) has been 
reported. To confirm that BCR and FCyRIIB co-ligation in the A20 cell line either 
optimally stimulated or inhibited respectively, pathways leading to ERK 
phosphorylation, cells were treated with F(ab’)2 and RAMIG. Whole cell lysates 
were prepared for immunoblot analysis using anti-phospho ERK 1/2 antibodies.
BCR ligation with F(ab’)2 fragments, stimulated the rapid phosphorylation p44/42 
kDa proteins (figure 26) which was diminished following BCR/FCyRUB co-ligation 
when cells were treated with RAMIG (figure 26). Re-probing with anti-pan ERK1/2 
confirmed that the p44/42 kDa proteins were ERK1/2 and demonstrated equal 
loading and transfer of proteins (figure 26).
FCylHIB MEDIATED MODULATION OF PI3K ACTIVITY.
ASSOCIATION OF p85 WITH CD19
Previous studies have demonstrated that BCR ligation results in the CD 19 mediated 
recruitment of PI3K (Tuveson et al 1993), and that this can be inhibited by FcyRIIB 
co-ligation with the BCR (Kiener et al 1996). In order to verify that F(ab’)2 and 
RAMIG stimulation of the A20 cell line couples the BCR and FCyRIIB efficiently to 
the regulation of PDK recruitment, anti-p85a immunoblot analysis of anti-CD 19 
immunoprecipitates was performed. This demonstrated the rapid recruitment o f p85 
to CD 19 which was sustained for 10 minutes following ligation (figure 27). This co­
association diminished to sub basal levels following co-ligation of the FCyRJQB with 
the BCR. Re-probing with anti-CD19 demonstrated equal loading of anti CD19 
immunoprecipitated protein (figure 27).
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Figure 26: FCyRIIB modulation of BCR induced ERK1/2 
phosphorylation in A20 cells.
2 x l0 6 A20 cells per point were either left unstimulated as a control or 
stimulated via the BCR, with 12 pg F(ab’)2 fragments of RAMIG, or via 
FCyRIIB co-ligation with the BCR via 20pg RAMIG. Cells were lysed 
and subject to acetone presipitation on ice for 1 hour. After centrifugation 
proteins were boiled in SDS-Laemmli sample buffer and separated via 
SDS-PAGE. Proteins were then transferred onto nitro-cellulose for 
immunoblotting with anti-phospho-ERKl/2 at 1 pg per ml in 0.05% 
marvel/PBS. Blots were subsequently stripped and re-probed with anti- 
PAN ERK 1/2 to verify equal loading of protein and transfer. These data 
are from a single experiment and are representative of four separate 
experiments.
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Figure 27: BCR ligation versus BCR/FCyRIIBl co-ligation 
induced co-association of p85 with CD19.
2xl07 A20 cells were either left unstimulated as a control or stimulated with 
20 pg RAMIG or 12 pg F(ab’)2 fragments of RAMIG. Cells were lysed and 
immunoprecipitated with 1 pg anti-CD 19. Precipitates were separated by 7.5 % 
SDS-PAGE and transferred onto nitro-cellulose for immunoblotting with anti- 
p85 (top panel) at a concentration of 1 pg per ml in 0.05 % marvel/PBS. Blots 
were then stripped and re-probed with anti- CD 19 (1 pg per ml 0.05 % 
marvel/PBS) to verify equal loading of immunoprecipitated protein (bottom 
panel). These data are from a single experiment which are representative of four 
experiments.
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ACCUMULATION OF 3’-PHOSPHOINOSITIDE LIPIDS IN RESPONSE TO 
BCR LIGATION AND BCR/FCyRIIB CO-LIGATION.
Data described so far, in this section, has demonstrated that efficient activation or 
inhibition of pathways leading to ERK activation, calcium mobilisation and the 
recruitment of PI3K to CD 19 in A20 cells can be elicited by ligation of the BCR and 
coligation of the FCyRDB. In addition it was important to demonstrate that the BCR 
mediated association of PI3K with CD 19 was accompanied by the accumulation of 
D-3 lipids which could be inhibited by coligation of the FCyRIIB, the accumulation 
of PI(3,4 ,5)P3 following F (ab’)2 of RAMIG or RAMIG stimulation was measured. 
Cells were labelled with [32]P- orthophosphoric acid and changes in cellular 3’- 
phosphoinositide levels were measured following extraction and deacylation of lipids 
via HPLC separation.
As can be seen in figure 28, F(ab’)2 mediated stimulation of the BCR resulted in a 
gradual accumulation of PI(3,4,5)P3 at one minute post stimulation which had risen 
by over 7- fold from 421 cpm to 3004 cpm at 15 minutes. In contrast BCR/FcyRIIB 1 
co-ligation, produced a slight increase in PI(3,4,5)P3 levels which peaked at 694cpm, 
a 1.6 fold rise at 10 minutes. Stimulation of the BCR resulted in the initial 
accumulation of PI(3,4)P2 which peaked at 5 minutes at 1279 cpm and which 
represented a 3 fold increase above basal levels (figure 28). RAMIG stimulation of 
the BCR/FCyRIIB resulted in the initial accumulation of PI(3,4)P2 which peaked 
after 5 minutes at 814 cpm (figure 28).
The activation of SHIP following FCyRIIB co-ligation has been previously 
described to regulate levels of PI(3,4 ,5)P3 (Scharenberg et al 1998), leading to the 
production of the enzymatic product of SHIP PI(3,4)P2. However, although RAMIG 
stimulation of the BCR/FCyRIIB, lead to the marked inhibition of PI(3,4,5)P3 
accumulation, there was no concomittant increase in PI(3,4)P2 at later time points 
(figure 28). It therefore appeared that BCR ligation in the A20 cell line rapidly 
stimulated PI3K activation, leading to the accumulation of PI(3,4 ,5)P3 and PI(3,4)P2, 
and that whilst the accumulation of PI(3,4,5)P3 could be abolished by 
BCR/FCyRDB co-ligation the evidence of SHIP mediated degradation of this lipid to 
PI(3,4)P2not be seen.
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Figure 28: FCyRIIB modulation of BCR mediated PIP3 
production.
A20 cells were labelled with [32 PI- phosphoric acid for five hours at 37 0 C 
and then either pretreated with lOOnm wortmannin or left untreated. 20x106 
cells per point were either left un-stimulated as a control or stimulated with 20 
pg RAMIG or 12 pg F(ab’)2 fragments of RAMIG. Cells were then lysed and 
lipids were extracted, lipids were deacylated and analysed by HPLC using a 
parti sphere Sax column.
Total counts: PI(3,4,5)P*=l,537,000cpm. PI(3,4)P2= 9997,567 cpm.These 
data are from a single experiment and are representative of three separate 
experiments.
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TYROSINE PHOSPHORYLATION OF SHIP IN RESPONSE TO BCR 
LIGATION AND BCR FCyRHB CO-LIGATION.
SHIP has been described as a major component of the FCyRIIB inhibitory signal 
(Scharenberg et al 1998, Nakamura et al 2000). To examine the effects of BCR 
ligation and BCR/ FCyRIIB 1 co-ligation on SHIP, tyrosine phosphorylation in 
response to F(ab’)2 and RAMIG treatment was examined. SHIP proteins were 
immunoprecipitated from resting and stimulated cell lysates and blotted with 4G10 
(Figure 29). Multiple tyrosine phosphorylated bands could be seen in SHIP 
immuno-precipitates (figure 29). The most heavily phosphorylated of which was 145 
kDa band which was most prominent at 1 minute post stimulation, and upon re­
probing (figure 29) was confirmed to be 145 kDa SHIP. However at 1 minute the 
tyrosine phosphorylation of a lower band could be seen. The identity of the 
additional bands was not known, however it is possible that these are SHIP related 
proteins or different isoforms of SHIP which could be co-precipitated by the anti- 
SHIP polyclonal antiserum (see discussion section 3.2).
SUMMARY
1) FCyRHB co-ligation with the BCR, through the treatment of A20 cells with 
intact RAMIG was demonstrated to inhibit F(ab’)2 stimulation of BCR 
mediated calcium mobilisation.
2) Wortmannin treatment of cells prior to BCR ligation with F(ab’)2 fragments, 
abrogated calcium mobilisation and demonstrated the major role of PI3K in 
pathways leading to calcium mobilisation.
3) BCR ligation stimulates the gradual production of PI(3,4 ,5)P3 peaks at 15 
minutes, and is inhibited following FCyRIIB co-ligation with the BCR.
4) BCR ligation leads to the accumulation of PI(3,4)P2 which peaks at 5 minutes 
and diminishes thereafter. PI(3,4)P2 accumulation is partially inhibited 
following FCyRHB co-ligation.
5) Tyrosine phosphorylation of SHIP occurs rapidly upon co-ligation of the 
BCR and FCyRHB receptors, and is sustained for up to ten minutes. Ligation 
of the BCR alone mediates the moderate, yet reduced tyrosine 
phosphorylation of SHIP.
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Figure 29: BCR ligation versus BCR/FCyRIIBl co-ligation 
stimulated tyrosine phosphorylation of anti-SHIP 
immunoprecipitates.
2xl07 A20 cells were either left unstimulated as a control or stimulated 
with either 20 pg RAMIG or 12 jag F(ab’)2 fragments of RAMIG. Cells 
were lysed and precipitated with 1 pg anti-SHIP. Precipitates were 
separated by 7.5 % SDS-PAGE and transferred onto nitro-cellulose for 
immunoblotting with anti-phosphotyrosine antibody 4G10 (top panel) at a 
concentration of 1 pg per ml in 0.05% marvel/PBS. Blots were stripped 
and re-probed with anti SHIP to verify equal loading of immuno­
precipitated protein. These data are from a single experiment and are 
representative of more than six others.
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3.3.2 FCyRHB MODULATION OF PI3K RECRUITMENT TO TYROSINE 
PHOSPHORYLATED PROTEIN COMPLEXES
It was postulated that in addition to upregulating the enzymatic activity of SHIP, 
FCyRDB co-ligation may negatively regulate the accumulation of PI3K lipid 
products in A20 cells by controlling the sub-cellular localisation of PI3K proteins. 
Inhibitory signalling cascades, initiated by FCyRDB co-ligation with the BCR, may 
mediate the molecular interaction of PI3K, via the SH2 domains of the p85 adaptor 
subunit, with a distinct array of tyrosine phosphorylated complexes within the cell. 
Recruitment of PI3K to such complexes might be less conducive to PI3K activation, 
or may localise PI3K activity away from PI(3,4,5)P3 dependent signalling pathways 
and into the proximity of SHIP. The working hypothesis for these experiments was 
that PI3K is differentially recruited to tyrosine phosphorylated protein complexes in 
response to BCR and FCyRDB stimulation. To address this possibility comparative 
levels of lipid kinase activity, associated with anti-phospho tyrosine 
immunoprecipitated proteins following BCR and BCR FCyRDB co-ligation, was 
examined.
A20 cells were either left unstimulated or stimulated with F(ab’)2 and RAMIG, and 
subject to immunoprecipitation with anti-phoshotyrosine antibody, 4G10. 
Immunoprecipitates were then assayed in vitro for lipid kinase activity. Enhanced 
levels of lipid kinase activity were immunoprecipitated with tyrosine phosphorylated 
complexes following co-ligation of the FCyRDB with the BCR than following 
ligation of the BCR alone (figure 30).
TYROSINE PHOSPHORYLATION OF WHOLE CELL EXTRACTS FOLL­
OWING BCR LIGATION AND BCR/FCyRIIB COLIGATION
To further define the nature of the FCyRDB mediated inhibitory signal in B cells this 
study has examined the protein targets of BCR and FCyRDB mediated protein 
tyrosine kinase activity. Previously it has been observed that co-crosslinking the 
FCyRDB with the BCR does not markedly reduce tyrosine phosphorylation of 
cellular proteins (Sarkar et al 1995). Several proteins, namely the FCyRDB and 
SHIP (Kiener et al 1997) have been shown to exhibit higher levels of tyrosine 
phosphorylation upon FCyRIIB coligation with the BCR. Meanwhile the 
phosphorylation of other proteins is decreased e.g.: PLCy2 (Sarkar et al 1996), and 
CD 19 (Tuveson et al 1996). Interestingly, the PTK’s Lyn and Syk are activated
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Figure 30: F(ab’)2 and RAMIG induced in vitro lipid kinase 
activity associated with anti-phospho tyrosine immuno­
precipitates.
2 xlO7 A20 cells were either left unstimulated as a control or stimulated 
with either 20 pg RAMIG or 12 pg F(ab’)2 fragments of RAMIG. Cells 
were lysed and precipitated with 1 pg anti-phosphotyrosine antibody 4G10. 
As a positive control 2 x 107 cells were lysed and immunoprecipitated 1 pg 
with anti-p85. Precipitates were incubated in vitro with phosphatidyl- 
inositol and [32P]- ATP to assay lipid kinase activity. Nascent phospho­
lipids were separated by thin layer chromatography and detected via 
autoradiography. These data are from a single experiment and are 
representative of three experiments.
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following both BCR ligation and BCR/FCyRIIB co-ligation and reports have 
described Lyn in direct association with the FCyRIIB ITIM (Sarkar et al 1996). In 
the first instance this study sought to illustrate the tyrosine phosphorylation triggered 
following either BCR ligation or BCR FCyRHB co- ligation via anti- 
phosphotyrosine immunoblot analysis of whole cell lysates stimulated with F(ab’)2 
fragments of RAMIG or RAMIG respectively.
Tyrosine phosphorylation of proteins which migrated at 145 kDa, 100 kDa, 70 kDa 
and 62 kDa protein were identified following BCR ligation (figure 31). 
Phosphorylation of pl45, and plOO was elevated in response to BCR FCyRHB 
coligation, as compared to BCR ligation alone. In contrast tyrosine phosphorylation 
of p70 was higher in response to BCR ligation alone, and was induced at only low 
levels in response to BCR/FCyRHB co-ligation (figure 31). The tyrosine 
phosphorylation of all proteins, in response to BCR ligation and BCR/FCyRIIB co­
ligation, was rapid with maximal phosphorylation being detected after one minute 
(figure 31). The putative identification of these proteins is addressed in subsequent 
sections.
DIFFERENTIAL TYROSINE PHOSPHORYLATION OF GAB 2 
FOLLOWING LIGATION OF THE BCR OR COLIGATION OF THE 
BCR/FCyRHB.
One possible identity of the 100 kDa protein in A20 whole cell lysates, which was 
subject to tyrosine phosphorylation in response to BCR ligation or co-ligation of the 
BCR/FCyRHB, was putatively identified as the adaptor protein Gab2. Studies in 
haemopoietic cells (Craddock and Welham 1997) and T cells (Nishida et al 1999), 
have examined the receptor triggered phosphorylation of a 100 kDa band which 
reportedly co-precipitates with SHP2, PI3K, Grb-2. Multiple tyrosine 
phosphorylation sites exist within the amino acid sequence of this protein which in 
phosphorylated state can be seen as an electrophoretic band shift. More recently this 
protein has been cloned and named Gab2 (Nishida et al 1999).
To investigate whether the 100 kDa phospho-protein seen in stimulated A20 cell 
lysates was in fact Gab 2, immunoprecipitates were prepared using Gab 2 antibodies 
from resting and RAMIG or F(ab’)2 of RAMIG stimulated A20 cell lysates (Figure 
32). Immunoblotting with anti-phosphotyrosine antibody 4G10 is shown in the top 
panel and revealed the tyrosine phosphorylation of a 100 kDa protein. Re-probing
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Figure 31: Modulation of BCR induced tyrosine phos­
phorylation of cellular proteins, following 
BCR/FCyRIIB co-ligation.
2xl06 A20 cells were either left unstimulated as a control or stimulated with 
20 pg RAMIG or 12 jig F(ab’)2 fragments of RAMIG. Cells were lysed and 
proteins were acetone precipitated and boiled in SDS-laemmli sample buffer. 
Proteins were then separated by SDS-PAGE and transferred onto nitro­
cellulose for immunoblotting with anti phosphotyrosine antibody 4G10 at a 
concentration of 1 pg per ml in 0.05% marvel/PBS. Approximate sizes of 
phospho-tyrosyl proteins are indicated on the left of the figure. These data are 
from a single experiment representative of three others representative of three 
others.
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Figure 32: RAMIG and F(ab’)2 induced tyrosine phospho­
rylation of Gab2 immunoprecipitates.
2x 107 A20 cells were either left unstimulated, as a control or stimulated with 
20 pg RAMIG or 12 pg F(ab’)2 fragments of RAMIG. Cell lysates were 
immuno-precipitated with 1 pg anti-Gab2 and proteins were separated by 7- 
17 % SDS-PAGE and transferred to nitro-cellulose for immunoblotting with 
anti-phosphotyrosine antibody 4G10 (upper panel) at a concentration of 1 
jj.g per ml in 0.05 % marvel/PBS.
Blots were stripped and re-probed with anti- Gab2, at 1 pg per ml, to verify 
equal loading of immunoprecipitated protein (lower panel). These data are 
from a single experiment representative of three others.
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with anti-Gab2 {lower panel, Figure 32) confirmed that this protein was Gab 2 and 
illustrated that a band shift occurs upon stimulation induced tyrosine 
phosphorylation of Gab 2. Moreover it appeared that Gab 2 was more strongly 
tyrosine phosphorylated following co-ligation of BCR/FCyRIIB than by ligation of 
the BCR alone (Figure 32). The identification of the differential phosphorylation of 
Gab 2 by BCR and BCR/FcyRIIB mediated signalling pathways, further 
characterises the early biochemical events which mediate the inhibitory signalling 
cascade.
BCR LIGATION AND BCR/FCyRIIB CO-LIGATION STIMULATES THE 
PRESENCE OF GAB2 IN ANTI p85 PRECIPITATES.
This study has demonstrated that the p85 adaptor sub-unit of PI3K can associate 
strongly with CD19 following BCR ligation, and that this interaction leads to the 
activation of PI3K and the production of PI(3,4,5)P3 (Tuveson et al 1993, Gold et al 
1994). This event plays a pivotal role in the triggering of the upstream events in B 
cell activation. In addition to CD 19, the docking protein Gab2 also contains p85 
SH2 binding motifs (Nishida et al 1999). The presence of these motifs within the 
Gab2 protein led to the hypothesis that Gab2 and p85 may associate in A20 cells, as 
they have been described to do in numerous previous studies in haemopoietic cells 
(Craddock and Welham 1997, Carlberg et al 1997, Nishida et al 1999). Initially it 
was important to identify whether a co-association between p85 and Gab2 following 
BCR ligation or FCyRDB co-ligation in A20 cells. p85 immunoprecipitates were 
prepared from resting and F(ab’)2 or RAMIG treated cells and immunoblotted with 
anti-phosphotyrosine and anti-Gab2 antibodies.
Anti-p85 precipitates were first immunoblotted with anti-phosphotyrosine antibody 
4G10. A 1 minute exposure of this blot (Figure 33) showed the rapid tyrosine 
phosphorylation of a 100 kDa protein, following BCR/FCyRDB co-ligation, which 
diminishes gradually and is barely detectable at 15 minutes. This protein was visible 
at reduced levels after 1 minute following BCR ligation and had almost completely 
diminished after ten minutes. Examination of a 1 hour exposure of this blot revealed 
the enhanced tyrosine phosphorylation of a 70kDa band following ligation of the 
BCR (figure 33). This protein, which was suspected to be SHP2, may represent the 
phosphorylated p70 protein detected in antiphosphotyrosine blotting of whole cell 
lysates (figure 31). Additionally, a heavily phosphorylated 62 kDa protein can be 
seen, and this protein which may represent the p62 protein seen in figure 31. Re-
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Figure 33: Tyrosine phosphorylation of anti-p85 immuno- 
precipitates following BCR ligation or BCR/FCyRIIB 1 
co-ligation.
2xl07 A20 cells were either left unstimulated as a control or stimulated 
with 20 pg RAMIG or 12 jig F(ab’)2 fragments of RAMIG. Cells were 
lysed and precipitated with 1 pg anti-p85 antibody. Proteins were 
separated by 7.5 % SDS-PAGE and transferred onto nitro-cellulose. 
Immunoblotting was carried out with anti phospho-tyrosine antibody 
4G10 (top and second panel)at a concentration of 1 pg per ml in 0.05% 
marvel/PBS, anti-Gab2 (third panel) at 1 pg per ml, and finally with anti- 
p85 at a concentration of 1 pg per ml, to verify equal loading of immuno­
precipitated proteins blots (bottom panel). These data are from a single 
experiment and are representative of three separate experiments.
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probing with anti-Gab2 antibodies (figure 33) readily confirmed that the RAMIG 
induced plOO band was Gab 2. Overexposure (for 1 hour) (figure 33) was required 
to detect the lesser quantities of Gab 2 associated with p85 following BCR ligation. 
Finally re-probing with anti-p85 mAb demonstrated equal loading and transfer of 
immunoprecipitated protein.
THE N AND C TERMINAL SH2 DOMAINS OF p85 CAN ASSOCIATE 
WITH GAB2.
Having demonstrated that Gab2 can co-associate with p85 immunoprecipitated 
complexes in A20 cells, an effort to identify whether this association was based on a 
direct physical interaction between Gab2 phosphotyrosine residues and p85 SH2 N 
and C terminal SH2 domains was made. Previously, studies in haemopoietic cells 
using GST fusion proteins representing the N and C terminal SH2 domains of p85 
have demonstrated that Gab2 and p85 can directly interact in response to IL-3 
stimulation (Craddock and Welham 1997). This study has employed these constructs 
which were a kind gift from Mike Waterfield, Ludwig Institute London.
Using these GST fusion proteins, precipitation of proteins from resting or stimulated 
A20 cells was performed (figure 34). In the first instance, precipitates were 
immunoblotted with anti-phosphotyrosine antibody 4G10 (figure 34). In both sets 
of precipitates tyrosine phosphorylated bands migrated at 100 kDa, 70 kDa, and in 
the GST-p85-NSH2 precipitates alone, at 62 kDa. The 100 kDa protein was the most 
common precipitated species, and as the aminio acid sequence of the Gab2 
suggests, re-probing with anti-Gab2 antibodies demonstrated that this protein was in 
fact Gab2 (figure 34). The kinetics of the association of Gab2 with both GST-p85- 
NSH2 and GST-p85-CSH2 proteins, mirrored those previously observed from 
immunoblotting endogenous p85 immunoprecipitates with 4G10 and Gab2 (figure 
34). In short, a greater amount of tyrosine phosphorylated Gab2 protein was seen to 
co-precipitate with the GST-p85-SH2 fusion proteins at 1 minute following FCyRIIB 
co-ligation with the BCR, which is decresed at 5 minutes. Meanwhile BCR ligation 
results in moderate accumulation of tyrosine phosphorylated Gab2 protein in NSH2 
immunoprecipitates, which was maximal at 5 minutes.
The association of Gab2 with the GST-p85-CSH2 was reduced in comparison with 
the association of GST-p85-NSH2 and Gab2 (figure 34). FCyRHB co-ligation with 
the BCR induced slightly greater co-association of Gab2 in GST-p85-CSH2
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Figure 34: BCR ligation versus BCR/FCyRIIB co-ligation 
induced tyrosine phosphorylation of N-SH2-p85-GSTor C-SH2- 
p85-GST precipitated proteins.
2x l07 A20 cells were either left unstimulated as a control or stimulated with 20 
jig RAMIG or 12 jag F(ab’)2 fragments of RAMIG. Cells were lysed and 
subject to precipitation with 10 pg N-SH2-p85-GST or 10 pg C-SH2-p85-GST 
fusion protein. Precipitates were separated using 7-17% gradient SDS-PAGE 
and transferred onto nitro-cellulose for immunoblotting with anti- 
phosphotyrosine antibody 4G10 (top panel) at a concentration of 1 pg per ml in 
0.05 % marvel/PBS. Blots were subsequently stripped and re-probed with anti- 
Gab2 (second panel) at 1 pg per ml, and anti-GST at 0.1 pg per ml to verify 
equal loading of fusion protein (bottom panel). These data are from a single 
experiment which is representative of four others.
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precipitates, and Gab2 levels following both BCR and BCR/FCyRDB co-ligation 
peaked at 1 minute and diminished slightly thereafter (figure 34). Furthermore 
tyrosine phosphorylated proteins were also detected at 70 and 62 kDa (Figure 34). 
By virtue of their molecular weight, potential candidates for these tyrosine 
phosphorylated proteins are SHP2 and p62 Dok-1 (figure 34). Re-probing with anti- 
GST antibody verified equal loading of fusion protein (figure 34).
THE C- AND N- TERMINAL SH2 DOMAINS OF p85 DIRECTLY 
INTERACT WITH GAB2 FOLLOWING BCR LIGATION AND 
BCR/FCyRIIB CO-LIGATION IN GAB2IMMUNOPRECIPITATES.
To confirm that the C- and N- terminal SH2 domains of p85 could interact directly 
with Gab2, following stimulation through the BCR and BCR /FcyRUB in A20 cells, 
Gab2 immunoprecipitates were prepared from resting or stimulated cells and far 
western blotted with either GST-p85-NSH2 or GST-p85-CSH2 (figure 35). As 
observed in N-SH2 and C-SH2-p85-GST immunoprecipitates (figure 35), a band of 
lOOkDa was seen (figure 35). Re-probing with anti-Gab2 identified the 100 kDa 
band as Gab2.
Once more the kinetics of the N-terminal SH2 domain association with Gab2 were 
strongest following co-ligation of the BCR/FCyRDB (figure 35) and were maximal 
after 1 minute. This association increased just above basal levels following BCR 
ligation alone at 5 minutes. Far-Western blotting with the C-terminal SH2 domain 
demonstrated similar patterns of co-association, with maximal association between 
Gab2 and C-SH2 p85-GST occurring following FCyRIIB co-ligation with the BCR, 
which was elevated at 1 minute (figure 35). This data confirmed that Gab2 forms a 
direct physical association with p85 via the N and C terminal p85 SH2 domains.
BCR AND BCR/FCyRHB LIGATION INDUCE TYROSINE PHOSPHO­
RYLATION OF SHP2 AND ASSOCIATION WITH MULTIPLE TYROSINE 
PHOSPHORYLATED PROTEINS.
The presence of a 70 kDa tyrosine phosphorylated band in A20 whole cell lysates 
and anti-p85 immunoprecipitates was considered to be SHP2 which has been 
demonstrated to associate with Gab2 and p85 in haemopoietic cells (Craddock and 
Welham 1997). Furthermore, SHP 2 has been reported to play opposing roles, being 
implicated in negative signalling in B cells (D’ambrosio et al 1995, Nakamura et al 
2000) and positive signalling through the MAP kinase pathway in
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Figure 35: BCR ligation and FCyRIIB co-ligation induced 
association of a GST protein representing the p85 N and C 
terminal SH2 domains with a 100 kDa protein Gab2 
immuno-precipitates.
2 x 107 A20 cells were either left unstimulated or stimulated with 20 pg
RAMIG or 12 pg F(ab’)2 fragments of RAMIG. Cell lysates were
precipitated with anti-Gab2 and separated by 7.5 % SDS-PAGE. Proteins 
were transferred onto nitro-cellulose and ‘far-western’ blotted with NSH2
p85-GST (top panel) or CSH2-p85-GST (third panel) at a concentration of 
o.l pg per ml in 0.05% Marvel/PBS. Blots were subsequently stripped and
re-probed with Gab-2 at 1 pg per ml to verify equal loading and 
identification of associating proteins (second and bottom panel). These data 
are from a single experiment and are representative of three separate
experiments.
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other systems (Noguchi et al 1994, Li et al 1994). Thus it was of interest for the 
purposes of this study to positively identify this protein and investigate its interaction 
with Gab2 and p85 in response to FCyRIIB and BCR initiated signals. In the first 
instance anti-SHP2 immunoprecipitates were derived from BCR and BCR FCyRIIB 
stimulated A20 cells. Immunoprecipitates were blotted with anti-phosphotyrosine 
antibody to identify patterns of tyrosine phosphorylation under these conditions. This 
revealed (figure 36), a considerable level of associating tyrosine phosphorylated 
proteins and in particular a constitutively phosphorylated band of approximately 62 
kD. This band was putatively considered to be p62 DOK and further investigations 
to assess this possibility were subsequently carried out.
A heavily tyrosine phosphorylated protein, which migrated at around 70 kDa (figure 
36 top panel) was thought to be SHP2 and re-probing with anti-SHP2 mAb 
confirmed this. This band appeared to be tyrosine phosphorylated in response to 
BCR ligation, which was sustained until 10 minutes post ligation. Meanwhile, 
FCyRIIB induced a much more transient tyrosine phosphorylation of this protein, 
which had diminished to almost basal levels by five minutes post-ligation (figure 36). 
This suggested that SHP2 could be transiently phosphorylated above basal levels by 
stimulation of the inhibitory pathway in A20 cells, whilst BCR ligation induced a 
more sustained level of SHP2 tyrosine phosphorylation.
In addition to the phosphorylation of SHP2 and potentially p62, figure 36 shows the 
tyrosine phosphorylation of a 100 kDa band which re-probing (figure 36) 
demonstrated to be Gab 2. The association of Gab2 with SHP2 immunoprecipitates 
following BCR ligation was maximal at five minutes and diminished thereafter. 
Following FCyRIIB co-ligation with the BCR, a rapid and transient association of 
Gab2 is detected in anti- SHP2 precipitates which is barely detectable at five 
minutes post ligation. Re-probing with anti-SHP2 antibody demonstrated the equal 
loading and transfer of immunoprecipitated protein.
SHP2 GAB2 AND p85 CAN BE DETECTED IN THE SAME COMPLEX IN 
ANTI-SHP2 PRECIPITATES IN RESPONSE TO BCR/FCyRIIB CO­
LIGATION.
SHP2 has been previously described to co-precipitate with p85 (Welham et al 1994), 
via a plOO protein, now identified as Gab2 (Nishida et al 1999, Craddock and 
Welham 1997, Gu et al 1998). Following the detection of a p70 kDa band in p85
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Figure 36: BCR ligation, and FCyRIIB co-ligation, induced 
tyrosine phosphorylation of anti-SHP2 immunoprecipitated 
proteins.
2 xlO 7 A20 cells were either left unstimulated as a control or stimulated with
20 pg RAMIG or 12 pg F(ab’)2 of RAMIG. Cell lysates were immuno­
precipitated with 1 pg anti-SHP2 and proteins separated by 7-17% SDS- 
PAGE. Precipitates were transferred onto nitro-cellulose and probed with
anti-phosphotyrosine antibody 4G10 (top panel) at 1 pg per ml, anti-Gab2 
(second panel) at 1 pg per ml, and finally anti-SHP2 (bottom panel) at 1 pg
per ml to verify equal loading of immunoprecipitated protein. These data are 
from a single experiment and are representative of three separate
experiments.
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immunoprecipitates, and the observation that tyrosine phosphorylated Gab 2 can co­
associate with SHP2 and p85 precipitated proteins, it seemed important to establish 
whether p85, could be associating via Gab2 with SHP2. Consequently, anti-SHP2 
immunoprecipitates were subject to immunoblot analysis with anti-p85 antibodies. 
Rapid and sustained co-association of p85 was detected in SHP2 immunoprecipitates 
following BCR ligation (Figure 37). Similarly following FCyRIIB co-ligation with 
the BCR p85 was detected in SHP2 immunoprecipitates after 1 minute, but this had 
dramatically diminished by 5 minutes. Equal loading of SHP2 protein was verified 
by stripping and re-probing with anti-SHP2 (figure 37).
ASSOCIATION OF GAB 2 WITH GST FUSION PROTEINS 
REPRESENTING N TERMINAL SH2 DOMAIN, C TERMINAL SH2 
DOMAIN AND FULL LENGTH SHP2.
SHP2 and Gab 2 have been reported by this study to co-associate. To define the 
nature of their physical interaction further, GST fusion proteins expressing the N 
and C terminal SH2 domains of SHP2 and full length SHP2, were used to precipitate 
protein from resting or BCR and BCR/FCyRHB stimulated A20 cells. 
Immunoblotting of precipitates with anti-Gab2 identified the kinetics and strength of 
Gab2 association with each SH2 domain and compared each of these to the 
association of Gab2 with full length SHP2.
Immunoblotting of full length GST-SHP2-SH2 precipitates revealed that the 
association between GST-SHP2-SH2 and Gab2 is greatest following co-ligation of 
the BCR/FCyRHB (figure 38). Co-association was greatest at one minute post co­
ligation and rapidly diminished from this point. BCR ligation lead to a gradual 
accumulation of Gab2 which peaked at ten minutes post stimulation. Conversely, C- 
terminal SHP2-SH2 precipitates blotted with Gab2 (figure 38), revealed that the 
greatest association between Gab2 and the C-terminal SH2 domain of SHP2 occurred 
following BCR ligation alone, with the greatest association detected at one minute. 
However, considerable co-association could also be detected at 5 minutes following 
BCR/FCyRHB co-ligation. Finally, the lower panel of figure 38 demonstrates the 
association of Gab 2 with the N- terminal SH2 domain of SHP2. Here, as with the 
full length SHP2-SH2 immunoprecipitates the N terminal SH2 domain can be seen to 
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Figure 37: BCR ligation versus BCR/FCyRIIBl co-ligation 
induced association of Gab2 and p85 with anti-SHP2 
precipitated proteins.
2xl07 A20 cells were either left unstimulated or stimulated with 20 pg 
RAMIG or 12 pg Fab’2 fragments of RAMIG. Cells were lysed and 
proteins were subsequently immunoprecipitated using 1 pg anti-SHP2 rabbit 
polyclonal antibody. Immune-complexes were separated via 7.5% SDS- 
PAGE, transferred onto nitro cellulose and sequentially immunoblotted 
with anti- Gab2 antibody (top panel) at a concentration of 1 pg per ml in 
0.05 % marvel/PBS , anti- p85 (second panel) at 1 pg per ml, and finally 
SHP2 (bottom panel) at 1 pg per ml to confirm equal loading of 
immunoprecipitated proteins. Blots were stripped before each reprobe. 
These data are from a single experiment which was representative of two 
separate experiments.
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Figure 38: BCR ligation versus BCR/FCyRIIB 1 co-ligation 
stimulated association of Gab2 with SHP2 N-terminal SH2 
domain, C-terminal SH2 domain, and full length (FL) GST fusion 
proteins.
A20 cells were either left unstimulated as a control or stimulated with 20 jag 
RAMIG or 12 jag F(ab’)2 RAMIG for the time points indicated. 20x 106 cells per 
point were lysed and proteins were immunoprecipitated with GST fusion proteins 
and glutathione sepharose. Precipitated proteins were separated via 7-17% SDS- 
PAGE, transferred to nitrocellulose membranes and immunoblotted with anti- 
Gab2 at lpg per ml antibody in 0.05% marvel/PBS (all panels). Proteins were 
visualised by chemiluminescence. These data are from a single experiment, the 
C-SH2 and FL-SH2 SHP2 -GST IPS are representative of two experiments, 
whilst the NSH2-SHP2-GSTIPS are representative of four separate experiments.
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SUMMARY
1) Elevated levels of in vitro lipid kinase activity can be detected in association 
with anti- phosphotyrosine immunoprecipitates derived from BCR/FCyRIIB 
co-ligated A20 cells, as compared to immunoprecipitates from cells 
stimulated via the BCR alone.
2) BCR ligation induces the tyrosine phosphorylation of proteins at 145 kDa 
lOOkDa and 70 kDa. The tyrosine phosphorylation of pl45 and plOO is 
enhanced in response to BCR/FCyRIIB co-ligation whilst phosphorylation of 
p70 is reduced.
3) The plOO phospho-protein in A20 whole cell lysates was identified as Gab2 
and is subject to rapid and considerable tyrosine phosphorylation in response 
to BCR/FCyRHB co-ligation. BCR ligation induces more gradual, and 
moderate tyrosine phosphorylation of Gab2.
4) Tyrosine phosphorylated Gab2 co-associates with the regulatory subunit of 
PI3K, p85 and this association is enhanced following BCR/ FCyRIIB co­
ligation.
5) Gab2 directly co-associates most strongly with p85 via the N terminal SH2 
domains of p85 following BCR/ FCyRIIB co-ligation. Weak association with 
the p85 C terminal SH2 domain can also be observed and is also greatest 
under inhibitory signalling conditions.
6) Tyrosine phosphorylation of SHP2 is transiently induced in response to 
BCR/FCyRIIB co-ligation, and diminishes after 1 minute. In contrast BCR 
ligation induces the gradual tyrosine phosphorylation of SHP2 which is 
sustained at ten minutes.
7) SHP2 co-precipitates with Gab2. This co-association is rapid and transient 
following FCyRIIB co-ligation and is undetectable after 1 minute. 
Furthermore this association appears to be mediated predominantly by the N 
terminal SH2 domain of SHP2 under negative signalling conditions, whilst 
following BCR ligation, the C terminal SH2 domain can interact with Gab2.
8) p85 is also detected in SHP2 immunoprecipitates, with kinetics which mirror 
the phosphorylation and co-association of SHP2, and association with Gab2.
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3.3 DISCUSSION
3.3.1 FCyRIIB MODULATION OF THE FUNCTIONAL READOUTS OF BCR 
MEDIATED SIGNALLING CASCADES IN A20 CELLS.
The mobilisation of calcium, observed in this study to occur upon BCR ligation 
correlates with data presented by previous studies, which demonstrated that BCR 
ligation induces a massive calcium influx in B cells (Coggeshall et al 1991, Carter et al 
1991). Studies which have examined the intracellular events that mediate this response 
demonstrate that the BCR stimulates the assembly of PLCy-BTK-BLNK (Takata et al 
1996, Ishai et al 1999) complexes. In this way PLCy activation is induced through 
proximity with the Tec kinase Btk, and the ensuing accumulation of inositol 
polyphosphates initiates the mobilisation of intracellular calcium (Buhl et al 1998, 
Lankester et al 1996, Li et al 1998, Nagai et al 1995). Furthermore, this study has 
described the effective inhibition of calcium mobilisation that can be achieved via 
RAMIG mediated co-ligation of the FCyRIIB with the BCR. This is also in accordance 
with previous studies which have shown that co-ligation of the ITIM bearing inhibitory 
receptor, FCyRIIB, with the BCR leads to the inhibition of calcium mobilisation (Diegel 
et al 1994). The SHIP mediated enzymatic degradation of PIP3 which prevents the 
activation of Btk, and its subsequent phosphorylation of PLCy is proposed to be the 
major determining factor in the abrogation of calcium signalling (Ono et al 1997).
This study also demonstrates that ERK1/2 MAP kinases could be phosphorylated in a 
BCR dependent manner and that this phosphorylation was abrogated by FCyRIIB co­
ligation with the BCR. These observations indicated that positive and negative 
signalling cascades in the A20 B cell line could be optimally stimulated with regard to 
ERK activation. These data are in accordance with previous work by other researchers, 
which has shown that ERK activation can be achieved following BCR ligation. 
BCR/CD 19 proximal events include the association of Vav with CD 19 (Gulbins et al 
1997), the phosphorylation of She the association of She with the Iga chains of the BCR 
(Lankester et al 1996) and the assembly of Shc/Grb 2/SOS complexes (Nagai et al 
1995). The observed association of Vav with CD19 (Gulbins et al 1997), and the 
accumulation of Grb2/SOS complexes in response to BCR triggering (Harmer et al 
1993), mediate phosphorylation of ERK 1 /2/MAP kinases (Li et al 1998). FCyRIIB 
mediated inhibitory signals lead to the depressed activation of the MAP kinase pathway 
(Sarmay et al 1996, Moodie et al 1994, Campbell et al 1995).
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This study has demonstrated that the efficient coupling of BCR mediated pathways, 
which lead to the activation of PI3K, can be achieved by the treatment of A20 cells with 
F(ab’)2, and can be abrogated following co-ligation of the BCR with the FCyRIIB 
receptor, by treatment of cells with RAMIG. In accordance with previous studies 
(Tuveson et al 1997, Gold et al 1994) the recruitment of p85 to the CD19 receptor is 
observed in (Fab’)2 treated A20 cells, and is accompanied by a marked accumulation 
of PI(3,4,5)P3. The BCR mediated upregulation of PI3K is essential for the downstream 
activation of PH domain containing proteins PKB (Gold et al 1999, Astoul et al 1999) 
and Btk (Buhl et al 1999), which, respectively, play important roles in enhancing cell 
survival (Coffer et al 1998) and mediating calcium mobilisation (Fluckiger et al 1997).
3.3.2 REGULATION OF PI(3,4,5)P3 ACCUMULATION BY SHIP
FCyRIIB mediated inhibition of PI(3,4,5)P3 accumulation has been observed by this 
and previous studies (Scharenberg et al 1998), following the treatment of A20 cells 
with RAMIG. The inhibited accumulation of this lipid could be attributable to the 
dephosphorylation of CD 19, that has been previously described (Kiener et al 1997) to 
occur upon FCyRIIB co-ligation, and which prevents the co-association and activation 
of PI3K via CD 19. The absence of p85 protein, detected in this study upon 
immunoblotting of anti-CD 19 immunoprecipitates, reflects the abrogation of p85 
recruitment to CD19, and may explain the observed reduction in PI(3,4,5)P3 
accumulation. Furthermore, the enzymatic activation of the 5’-inositol poly phosphatase 
SHIP by the FCyRIB has been described as a major effector of the inhibitory signal 
through the dephosphorylation of PI(3,4,5)P3 (Ono et al 1996 and Bolland et al 1998). 
This study has demonstrated the FCyRIIB mediated tyrosine phosphorylation of SHIP. 
Tyrosine phosphorylation has been observed to correlate with catalytic activation of 
SHIP in T cells (Edmunds et al 1999), which suggests that the accumulation of 
PI(3,4,5)P3 in A20 cells may be regulated both by the dephosphorylation of CD 19 and 
the enzymatic activation of SHIP.
The enzymatic regulation of PI(3,4,5)P3 levels by SHIP would result in the 
accumulation of SHIP’S metabolic product PI(3,4)P2. However measurement of 
PI(3,4)P2 accumulation by this study demonstrated that reduced levels of this lipid 
accumulate following FCyRIIB co-ligation, as compared to ligation of the BCR alone. 
These data could indicate that SHIP does not mediate a catalytic role in inhibitory
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signalling, which would suggest that the diminished level of PI(3,4,5)P3, observed 
following FCyRIIB coligation, is a result of the non-phosphorylation of CD 19. If this 
were the case then the essential role that has been described for SHIP, in mediating the 
FCyRIIB signal (Scharenberg et al 1996), must be elicited by SHIP’S structural motifs 
which lie outside its phosphatase domain.
The presence of multiple sites for protein-protein interaction within the SHIP protein 
have previously implicated SHIP in mediating an adaptor function in inhibitory 
signalling. Interestingly one study has described the co-precipitation of p85 by tyrosine 
phosphorylated SHIP, via the SH2 domains of p85 (Gupta et al 1998). Thus SHIP may 
prevent the activation of PI3K via the sequestration of p85 away from active signalling 
complexes. However no evidence for this role could be provided here as co-association 
between SHIP and p85 could not be detected by this study. Support for an adaptor 
function for SHIP can be gained from previous work which has examined conserved 
motifs within the SHIP protein. The C terminal region of SHIP contains two key 
tyrosine residues which have been previously described to mediate associations with 
She in T cells (Lamkin et al 1997) and B cells (Tridandapani et al 1997) and p62 Dok in 
B cells (Tamir et al 2000). The SH2 domain of non-phosphorylated SHIP preferentially 
mediates SHIP’S interaction with the FCyRIIB ITIM (Muta et al 1994) whilst the SH2 
domain of tyrosine phosphorylated SHIP SH2 preferentially binds to the Y317 residue of 
She (Tamir et al 2000), competing at this site with the Grb2 SH2 domain, for binding to 
She (Tridandapani et al 1997). Furthermore recent studies have demonstrated that 
truncation of the C terminal 190 amino acids of SHIP impairs SHIP'S ability to inhibit 
calcium mobilisation (Aman et al 2000). The constitutive membrane localisation of 
truncated SHIP can restore SHIP’S inhibitory function, and thus it has been proposed 
that this region may regulate SHIP’S inhibitory function via the membrane localisation 
of SHIP (Aman et al 2000).
There is therefore much evidence to support a role for SHIP in protein-protein 
interactions that contribute to the FCyRIIB inhibitory cascade. However, further studies 
have equally demonstrated a role for SHIP’S phosphatase activity. Membrane 
expression of catalytic mutants of SHIP in B cells inhibited FCyRIIB elicited membrane 
recruitment of Btk (Bolland et al 1998) and calcium mobilisation (Ono et al 1996). 
Furthermore it was recently observed that a 135 kDa isoform of SHIP, which is
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catalytically active but cannot interact C terminally with PI3K and lacks proline rich 
regions that are predicted to interact with SH3 containing molecules, is sufficient to 
mediate inhibitory signalling in B cells (March et al 2000).
Thus the enzymatic activity of SHIP cannot be disregarded when interpreting the 
findings of this current study. It could be considered, therefore that the lack of FCyRIIB 
mediated PI(3,4)P2 accumulation observed here was due to the removal of this lipid, or 
its progenitor PI(3,4,5)P3, by lipid phosphatases with specificity for phosphoinositdes 
phosphorylated at positions other the 5’-OH on the inositol ring. In accordance with 
this possibility, the low level expression of the tumour suppressor 3’ phosphatase, 
PTEN, was detected in A20 cells and was described earlier in this study. The 3’- 
phosphatase activity of PTEN would negatively regulate the accumulation of PI(3,4)P2, 
or PI(3,4,5)Pj and would result in the accumulation of PI(4)P or PI(4,5)P2 respectively. 
Thus the concerted efforts of SHIP and PTEN may regulate 3’-phosphoinositide levels 
following FCyRIIB co-ligation with the BCR, and it would be interesting to assess this 
relationship in future studies.
This study demonstrated the reduced yet moderate phosphorylation of SHIP following 
BCR ligation alone. Although the rapid tyrosine phosphorylation of SHIP, in response 
to FCyRIIB coligation with the BCR is widely accepted, Ship’s tyrosine 
phosphorylation in response to BCR ligation is described in previous studies to occur to 
varying extents (Sarkar et al 1995, Chacko et al 1996). Thus SHIP may be active in 
BCR mediated pathways, which may explain the elevated accumulation of PI(3,4,5)P3, 
and mobilisation of intracellular calcium, that is observed upon BCR ligation of SHIP-/- 
B cells (Bolland et al 1998).
To conclude, It appears that the inhibitory signal mediated by the FCyRIIB receptor in 
A20 cells mediates the abrogation of PI3K dependent signalling pathways either via the 
prevention of PI3K activation, by lack of CD 19 phosphorylation, or through the 
enzymatic activation of SHIP. In addition the actions of other lipid phosphatases e.g. 
PTEN, may be involved in regulating PI3K dependent pathways in B cells. Furthermore 
the abrogation of non-PI3K dependent pathways which contribute to MAPK activation 
may also be brought about by SHIP, through its ability to act as an adaptor protein.
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3.3.3 REGULATION OF PI3K BY ITS RECRUITMENT TO TYROSINE 
PHOSPHORYLATED PROTEIN COMPLEXES
Work presented by this study has examined the hypothesis that BCR and FCyRIIB 
mediated signalling cascades differentially regulate the association of PI-3K activity 
with tyrosine phosphorylated complexes in vitro. Data suggests, that in intact cells, the 
global production of PI(3,4 ,5)P3 is suppressed under inhibitory signalling conditions. 
Hence, these in vitro observations in response to FCyRIIB co-ligation, may represent 
either a) the sequestration of lipid kinase activity in phosphotyrosyl complexes, that 
may direct PI3Ks’ approximation with SHIP; or b) the elevated association of PI-3K 
protein in complexes that prevent its activation by competing for the p85 SH2 domains, 
that under positive signalling conditions mediate PI3K activation through membrane 
localisation via co-association with cell surface receptors.
In addition to a role for SHIP in mediating inhibitory signalling cascades through its’ 
secondary function as an adaptor protein, other adaptor proteins may mediate the 
suppression of PI3K dependent signalling, through the sequestration of the p85 
regulatory sub-unit. Examination of lipid kinase activity associated with anti- 
phosphotyrosine immunoprecipitates suggested that an association of PI3K with 
tyrosine phosphorylated complexes under negative signalling conditions, may exist. It is 
unclear whether the increased lipid kinase activity observed following FCyRIIB 
coligation is a direct result of upregulation of a pool of PI3K that is associated with 
tyrosine phosphorylated proteins, or an enhanced recruitment of basally active PI3K 
protein into phosphotyrosine complexes. If the former is the case then, to achieve the 
overall reduction in PIP3 accumulation observed in response to FCyRIIB co-ligation in 
intact cells, the FCyRIIB enhanced PI3K activity might be redistributed into the vicinity 
of enzymatically active SHIP, via tyrosine phosphorylated complexes. A similar 
analogy was put forward by Gupta et al (1998), in that they observed the sequestration 
of p85 via a direct interaction between the C terminal SH2 domain of p85 and tyrosine 
phosphorylated SHIP. It was postulated that under negative signalling conditions SHIP 
is responsible for the activation of PI3K and the degradation of its’ lipid products to 
PIP2 (Gupta et al 1998). It was proposed that whilst the degradation of PI(3,4,5)Pj by 
SHIP abrogates the activation of Btk, the accompanying production of PI(3,4)P2 could 
be responsible for the residual activation of PKB (Gupta et al 1998). If argument b) 
stated above were the case then the recruitment of PI3K to tyrosine phosphorylated 
protein complexes may serve to sequester inactive PI3K and prevent its activation. The
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identity of alternative phosphotyrosine containing proteins, that could mediate the 
sequestration of p85 and/or direct its approximation with SHIP, has therefore been 
examined by this study.
3.3.4 GAB2 AND SHP2 IN FCyRIIB MEDIATED MODULATION OF PI3K 
AND MAPK ACTIVATION
The demonstration that the 100 kDa scaffold protein, Gab2, was heavily phosphorylated 
upon FCyRIIB co-ligation with the BCR, suggested that this protein may be implicated 
in negative signalling in B cells. Previous work has repeatedly demonstrated the co­
association of a 100 kDa protein with p85 via the p85 SH2 domains (Craddock and 
Welham 1997, Gadina et al 1999) and recent cloning designated this protein as Gab2 
(Nishida et al 1999). Gab2 has been implicated in mediating positive signalling linking 
receptors to ERK activation (Nishida et al 1999). In a more recent study, Gab2’s 
coassociation with p85 has been shown to be essential for activation of PI3K and IL-3 
dependent activation of the AKT pathway (Gu et al 2000). In the same study She was 
implicated in mediating tyrosine phosphorylation of Gab2 and initiating a 
shc/grb2/Gab2/PI3K/AKT pathway in response to IL-2 receptor signalling (Gu et al 
2000). A role for Gab2 in mediating positive signals in T cells has also been described 
by studies which have shown that IL-2 and IL-15 receptor stimulation can couple to 
MAPK activation via Jak3 elicited tyrosine phosphorylation of Gab2 (Gadina et al 
2000). Interestingly, the same study demonstrated that expression of Gab2 protein is 
upregulated upon T cell activation, further implicating this protein in the delivery of 
upstream signals to downstream components of lymphocyte function (Gadina et al 
2000). However, further studies have indicated an inhibitory role for Gab2 in 
uncoupling signals from ERK to transcriptional activation of ELK-1 triggered by a 
dominant active Ras mutant (RasV12) or under IL-3 stimulation (Zhao et al 1999).
This study provides the first demonstration that Gab2 is a substrate for PTK activity 
mediated upon BCR/FCyRIIB co-ligation. Furthermore it has been shown here that 
tyrosine phosphorylation of Gab2 is reduced upon BCR ligation as compared to that 
induced by BCR/FCyRIIB co-ligation. This study also provides novel data concerning 
the enhanced co-association of Gab2 with p85 in response to BCR/FCyRIIB mediated 
signals. Thus, a close correlation between the association of p85 with Gab2, and the 
tyrosine phosphorylation of Gab2, exists. This observation is in accordance with prior 
studies which observed that the co-association of Gab2 and p85 is mediated by the SH2
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domains of p85 upon cytokine receptor stimulation (Craddock and Welham 1997), 
which can interact with tyrosine phosphorylated YXXM motifs in the Gab2 amino acid 
sequence (Nishida et al 1999). This study demonstrated that co-association of Gab2 and 
p85 can occur in A20 cells in response to BCR mediated signals, and that this 
association is elevated following FCyRIIB co-ligation. Furthermore this interaction was 
mediated most strongly via the N terminal SH2 domain of p85. The direct physical 
nature of this interaction was supported by far western blotting with GST p85 N and C 
SH2 fusion proteins.
This study has also examined the role of SHP2 in B cell receptor and FCyRIIB mediated 
signalling cascades. The protein tyrosine phosphatase SHP2 has been previously 
implicated in negative signalling in B cells, through its association, upon 
FCyRHB/BCR coligation, with the phosphorylated ITIM (D’ambrosio et al 1995). 
SHP2 binds the ITIM with the second greatest affinity after SHIP, and before SHP1 
(previous reference). Studies which blocked the association of SHP2 with the ITIM 
have concluded that SHP2 plays a minimal role (Nakamura et al 2000) in suppressing 
ERK activation and calcium mobilisation following FCyRIIB co-ligation. Conversely in 
growth factor mediated signalling cascades SHP2 has been implicated in pathways 
leading to cell cycle progression (Bennet et al 1996), cell survival (Pazdrak et al 1997) 
and mitogenesis (Xiao et al 1994). Thus, the biochemical nature of SHP2’s role 
following FCyRIIB co-ligation with the BCR, in B cells is poorly understood. A single 
study has reported a co- association between SHP2 with a 120-kDa protein which 
occurs upon BCR ligation in RAMOS B cells, and is reduced following FCyRIIB co­
ligation with the BCR (Nakamura et al 1998). This protein was later putatively 
identified as Gabl (Nishida et al 1999), which has been implicated in the activation of 
ERK1/2 MAP kinases (Takahashi Tezuka et al 1998).
This study has presented novel data which demonstrates that tyrosine phosphorylation 
of SHP2 is mediated in response to BCR ligation and BCR/FCyRIIB co-ligation in A20 
cells. Previous studies have linked tyrosine phosphorylation of SHP2 in other cell 
types to MAPK activation (Bennett et al 1994): PDGF receptor mediated signalling 
pathways elicit the phosphorylation of the SHP2 C terminal tyrosine motifs which allow 
the association of SHP2 with the Grb2 SH2 domain. Subsequent association of the Grb2 
SH3 domain with SOS has been shown to link SHP2 to the activation of Ras, and hence 
to the initiation of the pathways leading to MAPK activation (Bennett et al 1994).
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Thus, SHP2 phosphorylation, observed by this study following BCR ligation, could 
implicate SHP2 in coupling the BCR to ERK 1/2 phosphorylation (see Diagram 4). 
BCR ligation has already been described to couple to MAPK signalling pathways via 
Vav (Gulbins et al 1997) and the assembly of Shc/Grb 2 complexes (Nagai et al 1995). 
This study may describe a further route via which SHP2 may couple B cell receptor 
stimulation to MAPK signalling pathways.
Following FCyRIIB co-ligation, the phosphorylation of SHP2 is rapidly attenuated . 
Such de-phosphorylation would abrogate any SHP2 association with Grb2, and remove 
this route to MAPK activation. The mechanism of de-phosphorylation of SHP2 is 
unclear. The reported activation of the PTPase activity of SHP1 under negative 
signalling conditions (D’ambrosio et al 1995) could mediate the de-phosphorylation of 
SHP2. If this were the case SH Pl’s known associations with Grb2 and mSOS in 
haemopoietic cells (Kon-Kozlowski et al 1996), could act to bring SHP1 into proximity 
with SHP2, where it could elicit the de-phosphorylation of SHP2, and abrogate any 
SHP2 phosphotyrosine based molecular interactions.
The assignment of a potential role for SHP2 in BCR/FCyRHB mediated pathways 
leading to ERK1/2 activation/ abrogation may add to our understanding of SHP2’s role 
in B cells. However, the association of SHP2 with the FCyRIIB ITIM, and the role that 
this interaction plays in inhibitory signalling cascades is still not clear. Previously an 
interaction between SHP2 and Gab2 has been demonstrated and Gab2 has been 
described as a potential substrate for SHP2 catalytic activity (Craddock and Welham 
1997, Zhang et al 1998, Yamauchi et al 1995). Further examination of the tyrosine 
phosphorylated proteins immuno-precipitated with SHP2 by this study has led to the 
identification of an association between Gab2 and SHP2. In the context of insulin and 
EGF mediated signalling pathways, the catalytic activity of SHP2 is essential for linking 
receptor stimulation to Rafl (Milarski et al 1994, Bennett et al 1996), and interestingly 
Gab2 has been implicated in coupling the enzymatic activity of SHP2 to ERK, as 
overexpression of Gab2 leads to the enhanced phosphorylation of ERK (Nishida et al 
1999). However inhibition of SHP2 /Gab2 interactions via the mutation of the SHP2- 
SH2 domain binding motifs of Gab2 leads to enhanced MAPK activation. Thus the 
mechanism whereby the Gab2/SHP2 interaction couples to ERK MAPK activation is 
not straightforward. It was therefore considered what role may be played by the Gab2
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SHP2 interaction in A20 cells, and whether the enzymatic activity o f SHP2 was 
involved.
In accordance with previous studies (Craddock and Welham 1997, Gadina et al 1999, 
Zhang et al 1998) Gab2’s association with SHP2, measured in this study is closely 
correlated with the tyrosine phosphorylation of the associated Gab2 protein. This 
suggests that the association is mediated via Gab2 phosphotyrosine interaction with 
SH2 domains of SHP2. Observation of a larger band shift of the Gab2 protein was 
observed following FCyRIIB coligation than following BCR ligation alone (N.B. the 
enhanced resolution of the p 100 band shift seen here was visualised when precipitates 
were run on 7-17% gradient gels). Further examination of Gab2 proteins precipitating 
with GST fusion proteins representing SH2 domains of SHP2 demonstrates that the 
lower levels of Gab2 phosphorylation induced by BCR ligation are sufficient to mediate 
an interaction with the C terminal SHP2 SH2 domain. However upon BCR/FCyRHB 
co-ligation, enhanced levels of Gab2 phosphorylation are sufficient to mediate a 
stronger interaction between Gab2 and both SHP2 SH2 domains.
Data presented here demonstrates that the kinetics that characterise the Gab2 and SHP2 
interaction, following BCR ligation or FCyRIIB co-ligation are distinct. The ligation of 
the BCR induces a steady accumulation of Gab2 in SHP2 immunoprecipitates, which 
diminishes after five minutes. Contrastedly, FCyRIIB co-ligation mediates the rapid 
and transient co-association of Gab2 with SHP2, which is completely abrogated after 1 
minute. The abrogation of the presence of Gab2 in SHP2 immunoprecipitates following 
FCyRIIB/ BCR co-ligation may represent the enzymatic activation of SHP2, following 
the occupancy of both N and C terminal SH2 domains, an event which has been 
proposed to activate SHP2 PTP activity (Pluskey et 1997). Activation of SHP2 PTP 
activity, would lead to a reduction in the tyrosine phosphorylation of its substrates and 
thus abrogate SHP2-SH2 domain/ substrate complexes. The FCyRIIB mediated 
abrogation of Gab2 in SHP2 immunoprecipitated complexes, which is preceded by the 
interaction of the N and C terminal SH2 domains of SHP2 with Gab2, may allude to a 
situation where Gab2 can act as a substrate for PTP activity of SHP2 in B cells.
Previous reports have indicated that p85 and SHP2 may exist in the same complex 
(Welham et al 1994, Craddock and Welham 1997, Zhang et al 1998) and this study
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observed the association of SHP2 with anti-p85 immunoprecipitates. Due to the lack of 
any known p85 binding motifs within SHP2 previous studies have suggested that SHP2 
may couple to p85 via an indirect route, and proposed that the plOO protein seen also in 
association with SHP2, and p85 immunoprecipitates may mediate this interaction 
(Craddock and Welham 1997). The similarity in the kinetics of p85/SHP2 co­
association and SHP2/Gab2 co-association observed by this study in response to BCR 
ligation and FCyRIIB co-ligation, is in accordance with a role for Gab2 in mediating the 
association between p85 and SHP2. Furthermore the presence of a 70 kDa protein in 
GST-NSH2-p85 precipitates at early time points demonstrates that the co-precipitation 
of SHP2 with p85 is mediated via the p85 SH2 domains and this may further indicate a 
trimeric complex in which Gab2 is the intermediate protein.
The following model could be put forward to describe the role of SHP2 and Gab2 in B 
cells: Under positive signalling conditions SHP2, binds, via its C terminal SH2 domain, 
to minimally phosphorylated Gab2. BCR ligation also imparts the tyrosine 
phosphorylation of SHP2 which could facilitate the binding of Grb2 via its SH2 
domain to the C-terminal phosphotyrosine motif of SHP2. SHP2 could thus mediate 
the recruitment of Grb2-SOS complexes and allow the subsequent activation of Ras, 
providing an additional pathway via which the BCR could couple to Map Kinase 
activation. The presence of low levels of Gab2 coupled to SHP2 via the SHP2 C 
terminal SH2 domain could stabilise the SHP2, Grb2 complex, through binding via the 
Gab2 proline rich motif to Grb2’s SH3 domain, in the manner described for She, Grb2, 
SOS complexes (Harmer et al 1999). As Grb2/Gab2 associations do not occupy the N- 
terminal SH3 domain of Grb2 (Zhao et al 1999), through which Grb2 associates with 
SOS, this stabilising interaction would allow association and activation of SOS 
exchange activity. In addition to MAPK activation, BCR induced phosphorylation of 
CD 19 allows the association and activation of PI3K, leading to the accumulation of 
PI(3,4,5)P3, and stimulation of PDK dependent signalling cascades, which lead to PKB 
activation, BTK activation and calcium mobilisation.
Under negative signalling conditions, initiated by FCyRIIB co-ligation, initial 
phosphorylation of SHP2 is rapidly abrogated , which causes its dissociation from Grb2. 
Meanwhile, FCyRIIB activated PTKs elicit the enhanced phosphorylation of Gab2 
which then binds both SH2 domains of SHP2. This event mediates the activation of 
SHP2 PTPase activity, and its subsequent dissociation from Gab2 complexes. Under
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negative signalling conditions, therefore, SHP2 is un-coupled from both Gab2 and 
Grb2, the binding partners through which it has been described to couple to Ras, and 
Map Kinase activation. FCyRIIB co-ligation also induces the hyper- tyrosine 
phosphorylation of Gab2, which enhances the association of the N- and C- terminal SH2 
domains of p85 with the Gab2 protein. The enhanced association of p85 with Gab2 
correlates with the BCR/FCyRIIB co-ligation mediated reduction in p85 association 
with CD 19. A working model is therefore proposed whereby the marked increase in 
association of Gab2 with the SH2 domains of p85, observed under inhibitory signalling 
conditions, may represent the sequestration of p85 away from residually phosphorylated 
CD19.
With regard to the above hypothesis, a very recent paper has described a negative 
regulatory role for Gab 2 in T cells which leads to inhibition of 11-2 transcription and is 
dependent on an association between p85 an Gab2 (Pratt et al 2000). The inhibitory 
relationship observed between Gab2 and p85 by Pratt et al was dependent on PI3K 
activity, and it was suggested that PI3K products binding to the PH domain of Gab2 
may mediate the localisation of Gab2 /PI3K complexes to a subcellular site where they 
can mediate the observed negative effect. The PH domain of Gab2 has not been 
considered by the current study however the initial observation made here that 
considerable in vitro lipid kinase activity can be immunoprecipitated with tyrosine 
phosphorylated complexes under negative signalling conditions, may reflect the 
enhanced Gab2 co-association with active PI3K under these conditions.
Finally, SHP2’s association with the FCyRIIB ITIM under negative signalling 
conditions may mediate the approximation of Gab2 with FCyRIIB activated PTKs, and 
elicit hyper-phosphorylation of Gab2. Gab2 can then bind both SHP2 SH2 domains, 
abrogating the association of SHP2 with the ITIM, and activating its PTPase activity. 
The consequent dissociation of SHP2 from Gab2, would cause the release of SHP2 
from signalling complexes at the membrane. The PH domain of Gab2 may allow it to 
remain in the vicinity of the FCyRIIB where it could sequester Grb2 and bring p85 into 
the vicinity of SHIP. Thus the enzymatic activity of SHP2, which has been described to 
be essential for ERK activation downstream of positive signalling pathways, may act 
under negative signalling conditions in B cells to release Gab2 and p85 into the 
‘inhibitory signalling environment* of the FCyRIIB.
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3.3.5 - CONCLUSIONS
This study has examined the mechanisms which regulate PI3K activity in B cells, t has 
shown that FCyRIIB co-ligation with the BCR stimulates the hyper-phosphorylation of 
the adaptor molecule Gab2 which correlates with the enhanced association of the p85 
regulatory subunit of PI3K, via its N and C terminal SH2 domains, with Gab2. It is 
proposed that this interaction may reflect the sequestration of PI3K by Gab2 under 
inhibitory signalling conditions (diagram 17).
Furthermore, the PTPase SHP2 is subject to sustained tyrosine phosphorylation 
following BCR ligation and can co-associate mainly via its C-terminal SH2 domain 
with Gab2. It is proposed that this may mediate SHP2 association with Grb2, which has 
been reported previously to enhance pathways leading to MAPK activation.
FCyRIIB coligation with the BCR mediates the transient tyrosine phosphorylation of 
SHP2, and elicits the association of N and C terminal SH2 domains of SHP2 with 
Gab2. It is proposed that this interaction activates SHP2 catalytic activity, which targets 
Gab2 and releases SHP2 and from the Gab2/p85 protein complex, which serve to 











Diagram 17: Schematic representation of differential recruitment of p85 to CD19 and Gab2 following BCR and BCR FCyRIIB co-ligation.
BCR ligation results in activation of BCR regulated PTKs, which mediate the phosphorylation of CD 19 tandem p85 interacting motifs (YXXM) allowing 
p85 coassociation with CD 19 whereupon it becomes active and leads to the accumulation of D-3 phosphoinositides. BCR/FCyRIIB co-ligation results in 
the phosphorylation of the FCyRIIB ITIM, by FCyRIIB regulated PTKs. SHIP subsequently associates with the ITIM, and becomes phosphorylated, an 
event which correlates with a reduction in phosphoinositide production. Gab2 becomes hyperphosphorylated under these conditions and recruits p85, 
away from CD 19, and towards the enzymatic activity of SHIP.
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Diagram 18: Schematic representation of the BCR and FCyRIIB induced coassociations between SHP2, p85 and Gab2.
BCR ligation induces SHP2 phosphorylation, which may enhance association with Grb2, and formation of Grb2 SOS complexes.. Gab2 may act to 
stabilise this interaction. Hyperophosphorylation of Gab2 following BCR/FCyRIIIB co-ligation may activate SHP2 PTPase activity through dual SH2 
domain occupancy. This would release the non- phosphorylated SHP2, preventing both its’ coassociation with Gab2 and Grb2, via which SHP2 has 
been reported to couple to activation of MAPK signalling cascades. Meanwhile p85 and Gab3 remain in association, which may lead to the 


















FUTURE D IRECTIO N S
PI3K- R ECRU ITM EN T O F 110 CATALYTIC ISO FO RM S TO  CD28 
The differential recruitment of p i 10 catalytic isoforms to CD28, following B7.1 
ligation, has demonstrated by this study. Previous studies have demonstrated that 
PI3K can be immunoprecipitated by phosphopeptides corresponding to the £ chain 
IT AMS of the TCR (Exley et al 1994), and whilst activation of PI3K in response to 
TCR ligation occurs at 10-5 fold lower levels than that elicited in response to CD28 
ligation (Ward et al 1992, Ward et al 1993). In addition to the recruitment of p i 10 
isoforms to CD28 described by this study, it would be of interest to investigate the 
differential recruitment of p i 10 isoforms to the TCR complex in response to ligation 
by mAb UCHT1. Furthermore, Previous studies have reported the serine/threonine, 
but not tyrosine, phosphorylation of the regulatory PI3K subunit, p85 in response to 
TCR ligation (Reif et al 1993). Furthermore this study has demonstrated that serine 
phosphorylation of p i 105 occurs in response to CD28 ligation. It would therefore be 
of interest to examine the receptor regulated tyrosine, serine and threonine 
phosphorylation of different p i 10 isoforms mediated by CD28.
This study has discussed the possibility of the existence of p i 105 protein targets, and 
efforts to identify these would be an interesting line of future research. Firstly it 
would be important to identify the extra bands which were detected by the IVK assay 
of p i 105 imunoprecipitated proteins described in this study.
Data presented by the latter part of this study examined the regulatory mechanisms 
which govern PI3K activation in B lymphocytes. In light of data which has 
demonstrated that PI3K deficient B cells exhibit severely impaired signalling, whilst 
PI3K deficient T cells retain normal responsiveness, it would be of interest to fully 
examine whether the relationships described by this study between Gab2 SHP2 and 
PI3K are similar in T cells. Initial studies have examined relationships between these 
molecules induced in response to TCR ligation (Frearson et al 1998), and the 
analysis of the CD28 mediated co-association of these proteins would be of interest, 
particularly as CD28 is uncoupled from the Ras pathway to which SHP2 and Gab2 
have been linked.
TY ROSINE PH O SPH O RY LA TIO N  O F SH IP  M EDIATED BY CTLA4
Data presented by this study disputes previous reports which have shown the in vitro 
activation of PI3K by CTLA4 stimulation (Schneider et al 1995). Analysis of the in
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vitro lipid phosphatase activity of SHIP in CTLA4 stimulated cells would further 
support the role of SHIP in mediating the degradation of PI(3,4,5)P3 observed 
following CTLA4 ligation. Additionally the analysis of differential recruitment of 
p i 108 and p i 10(3 to CTLA4 would be of interest.
FCyRIIB M ODULATION O F BCR M EDIATED SIGNALS 
This study has examined BCR and FCyRIIB mediated signalling pathways in the B 
cell lymphoma cell line A20. This work revealed several avenues which would 
provide a useful start point for further enquiry, and the suggestions which follow 
would back up the conclusions reached by this study. Firstly the validation of the 
observed effects of FCyRIIB co-ligation could be achieved using the FCyRIIB 
blocking antibody 2.4G2. It would also be useful to examine the enzymatic activity 
of SHIP in vitro in response to BCR and FCyRIIB mediated signalling pathways, as 
tyrosine phosphorylation of SHIP does not necessarily correlate with its activation. 
Thirdly, to further investigate the role of PTEN in FCyRIIB mediated signalling 
pathways it would be of interest to measure the accumulation of PI(4,5)P2> and 
PI(4)P upon FCyRIIB co-ligation. Furthermore, the analysis of the accumulation of 
these lipids, and the degradation of PI(3,4,5)/\3 and Pl(3,4)Pi, induced in response to 
FCyRIIB ligation in SHIP deficient cells would allow clearer visualisation of what 
role PTEN plays in the regulation of 3’-phosphoinositides in A20 cells.
With reference to the data presented here regarding SHP2, future investigations are 
necessary to examine the potential role of this protein in coupling the BCR to ERK 
activation. In order to examine whether the tyrosine phosphorylation of SHP2 allows 
it to recruit Grb2 as has been described previously (Bennett et al 1994). This could 
be verified by immuno-precipitation of SHP2 and immunoblot analysis using anti- 
Grb2 antibodies. Also, to identify whether SHP2’s catalytic activity targets Gab2 in 
response to FCyRIIB/BCR co-ligation cells could be pervanadate treated, to block 
PTPase activity, and comparison of levels of Gab2 protein that could be 
immunoprecipitated with SHP2 in treated versus untreated cells carried out. Further 
the analysis of the effects of blocking SHP2 activity with pervanadate on the 
downstream consequences of FCyRIIB co-ligation could be analysed through the 
measurement of ERK phosphorylation and phosphoinositide accumulation. 
Similarly, the overexpression of enzymatically dead SHP2 in A20 cells and the 
immunoblot analysis of SHP2 immunoprecipitates with Gab2 and p85 antibodies
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would support/refute the role of SHP2’s enzymatic activity in mediating the de­
phosphorylation and release of Gab2 from SHP2/Gab2/PI3K protein complexes.
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